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Abstract 
Patients with germline mutations in the tumour suppressor gene CYLD develop 
multiple cutaneous tumours on the head and neck; historically this has been 
termed “turban tumour” syndrome. Cylindromas and spiradenomas, hair follicle 
related tumours seen in this syndrome, cause significant clinical morbidity. Here 
we characterise the clinical phenotype of these patients, utilising tumour 
mapping to determine the location of tumours in mutation carriers from two 
large pedigrees. We demonstrate the disease often affects sites outwith the 
head and neck, and that androgen stimulated hair follicles are particularly 
vulnerable to tumour formation. The impact of this disease is severe, with 1 in 4 
carriers of this gene undergoing complete scalp removal. To improve this 
outcome, we performed whole genome profiling of CYLD defective tumours, 
characterising genomic and transcriptomic changes to determine targetable 
signalling pathways. High resolution analysis using whole genome array based 
comparative genomic hybridisation and single nucleotide polymorphism 
analysis suggest that loss of heterozygosity at the CYLD locus may be the only 
change required for tumour phenotype. Gene expression profiling highlighted 
transcriptomic similarity between cylindromas and spiradenomas. Three-
dimensional reconstruction in silico from serial sections of tumours 
demonstrated contiguous growth between cylindromas and spiradenomas, in  
support of this finding. In both tumour types, dysregulated tropomyosin receptor 
kinase (TRK) signalling was found. Consistent with this, was the finding that 
TRKB and TRKC protein was overexpressed selectively in the tumour samples, 
demonstrated on a tissue microarray. Therapeutic utility of targeting this 
pathway was demonstrated by reduced viability of CYLD defective primary cell 
cultures in the presence of TRK inhibitors. These preliminary data support the 
use of TRK inhibitors as a therapeutic strategy in severely affected CYLD 
mutation carriers. 
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Cylindroma tumours represent an intriguing model to explore cutaneous 
tumour biology. Patients who inherit a tendency to develop multiple 
cylindroma tumours have been described since 1842 by Ancell and are 
termed to have familial cylindromatosis (FC- OMIM 132700) (Welch, Wells et 
al. 1968). These tumours have a predisposition to the face and scalp, and 
surgery often leaves disfiguring scars. In some patients, when the tumours 
form a confluent mass termed a “turban tumour” the entire scalp must be 
removed (O'Blenes, Lee et al. 2010). 
 
Figure 1 Multiple cylindromas form a confluent mass on the scalp. 
The locus of the gene that is mutated in patients with FC was identified by 
classical linkage analysis to chromosome 16q (Biggs, Wooster et al. 1995). 
Five years later, the gene, termed CYLD, was found by positional cloning and 
sequenced (Bignell, Warren et al. 2000).  
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CYLD was subsequently shown to encode an ubiquitin hydrolase enzyme that 
negatively regulated the NF!B pathway (Trompouki, Hatzivassiliou et al. 
2003). It was postulated that constitutively activated NF!B signalling, 
recognised to be important in proliferation and apoptosis resistance, was likely 
to confer the tumour phenotype seen in CYLD defective tumours 
(Brummelkamp, Nijman et al. 2003; Kovalenko, Chable-Bessia et al. 2003; 
Trompouki, Hatzivassiliou et al. 2003). Non-surgical treatments became a 
possibility when CYLD was found to negatively regulate TRAF2 and TRAF6, 
members of the NF!B signalling pathway that were upstream of aspirin’s point 
of action at IKK (Yin, Yamamoto et al. 1998). Such medical treatments are an 
attractive, unexplored avenue, particularly as the tumours are easily 
accessible, allowing for topical or intralesional delivery of these agents with 
potentially fewer systemic side-effects. However, a clinical trial with topical 
salicylic acid only demonstrated a modest result in a small number of tumours 
(Oosterkamp, Neering et al. 2006), prompting a search for alternative 
therapeutic agents.  
 
Inspired by the prospect of non-surgical treatments, an unbiased whole 
genome approach was adopted for this work, characterising the genomic and 
transcriptomic changes seen in “CYLD defective” tumours. This was feasible 
as I had access to fresh tumour tissue, collected from CYLD mutation carriers 
undergoing routine surgery to control tumour burden. Here, we describe the 
results of a detailed molecular dissection of this intriguing tumour syndrome, 
highlighting novel targetable pathways and insights into non-melanoma skin 
cancer.  
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Patients with FC develop tumours at hair bearing sites, and the hair follicle 
and its related structures are thought to contain the cell of origin of these 
tumours (Massoumi, Podda et al. 2006). The hair follicle and its associated 
structures represent a mini organ within the skin (Figure 2). 
 
Figure 2 The hair follicle and related structures.  
Key: SC – stratum corneum, GL – granular layer, SL, spinous layer, BL – basal layer. The hair follicle, 
originating from the epidermis, consists of several layers, as indicated in the diagram. At the bottom of 
the follicle is the hair bulb, made from proliferating matrix cells. The dermal component of the hair follicle 
is the dermal papilla, which consists of specialized mesenchymal cellssurrounded by hair matrix cells. 
Adapted from Fuchs et al.(Fuchs and Raghavan 2002) 
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The components of this organ include: the hair follicle, the sebaceous gland 
(responsible for sebum production) and the apocrine gland (responsible for 
scent, found at particular body sites such as the axilla). The eccrine gland is 
distinct but found closely associated with hairs, and is important for 
thermoregulation. Aspects of hair biology pertinent to the study of CYLD 
defective tumours include hair development, the cyclic nature of hair follicle 
growth and the maintenance of this structure by stem cell compartments.  
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Murine hair biology parallels human hair biology and has been useful for 
understanding the contributory effects of different structures and genes 
towards hair development (Schmidt-Ullrich and Paus 2005). Hair structures 
are formed following interaction of ectodermal (epidermis) and mesenchymal  
(dermis) layers. The first sign of embryonic hair formation is the development 
of a placode at the interface of these two layers. The epidermis at this site is 
then committed to the formation of a hair follicle. Using transgenic mice, the 
details of the interplay of complex signalling networks between dermis and 
epidermis that commit these cells towards a hair follicle fate have begun to be 
understood (Figure 3). Central to the formation of a placode is Wnt signalling, 
highlighted by the lack of hairs demonstrated in a mouse overexpressing Wnt 
inhibitor DKK1 (Andl, Reddy et al. 2002). Another key pathway, NF!B 
signalling, is thought to influence the type of mouse hair seen. Mice that have 
mutations in Eda, Edar and Edaradd, important in NF!B signalling, have been 
shown to develop a reduced number of hairs, and only one type of hair, awl 
hair, is seen (Schmidt-Ullrich, Aebischer et al. 2001). 
 
Figure 3  Hair follicle specification of epidermal fate. Epidermal cells that are responsive to Wnt 
signalling in the embryonic epidermis respond to dermal BMP inhibitory signals to form a hair placode. 
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Additional dermal messages further instruct the placode to form the hair follicle. Adapted from Fuchs et 
al. (Fuchs 2007). 
Following the development of the placode, the mesenchymal dermal papilla is 
then encapsulated by ectodermal hair follicle. This structure, termed a peg, 
grows to invade the dermis, a process dependent on SHH signalling. The hair 
subsequently matures and different components including layers of the hair 
shaft, sebaceous glands and innervation are then seen to form.  
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After the follicle is formed, the hair cycles through phases of growth (anagen), 
rest (catagen), shedding (telogen) and renewal, mimicking some of the 
processes that occur during embryogenesis (Figure 4). In humans, hairs from 
different body sites have intrinsic mechanisms that influence the length of 
each phase of this cycle, with the regulation of duration of anagen being key 
for hair length. These mechanisms have been shown to be maintained 
independent of site by respective hair follicles following hair transplantation 
experiments in humans (Orentreich 1959).  
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Figure 4 The hair cycle. The hair follicle is a cycling structure in adult life, undergoing phases of growth 
(anagen), rest (catagen) and shedding (telogen). Adapted from Fuchs et al  (Fuchs 2007). 
Recent data has highlighted the role of genes (CLOCK and BMAL1) that are 
influenced by diurnal variation may influence the length of these cycles, and 
hence account for seasonal variations in hair growth (Lin, Kumar et al. 2009).  
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In adult life, compartments of stem cells maintain the hair follicle. Stem cell 
compartments of slow cycling cells that both self renew and give rise to transit 
amplifying cells are of interest in skin cancer as they are a prime site for 
accumulating mutations that may be responsible for tumour formation (Perez-
Losada and Balmain 2003). Cells from the hair follicle bulge in mice are 
thought to be the reservoir of stem cells that contribute to the new transit 
amplifying cells needed for hair growth. These cells interact with the dermal 
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papilla to form a new hair follicle. In mouse whiskers, migration of stem cells 
along the outer root sheath to the papilla are thought to facilitate the formation 
of a new hair, and hence stem cells can also be demonstrated at this site 
(Oshima, Rochat et al. 2001). The bulge is likely to contain a mixture of 
multipotent cell types, with for example, cells of neural crest origin 
demonstrated at this site (Hu, Zhang et al. 2006). Recent wound healing 
experiments using LGR6 transgenic mice for fate mapping, demonstrate the 
formation of labelled new hairs and all the structures in the skin from a region 
above the hair bulge, highlighting this as the niche for the most primitive stem 
cells (Snippert, Haegebarth et al. 2010). Stem cell compartments are thought 
to also exist in sebaceous glands, following retroviral mediated lacz labelling 
and lineage tracing experiments in mice (Ghazizadeh and Taichman 2001).  
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In humans, hairs at different body sites demonstrate a growth response 
following puberty. Humans are thought to be, in an ontological sense, nude 
apes, and are distinct in the acquisition of secondary sexual hair at this time. 
The change from fine vellus hair to coarse hair as well as increased length is 
thought to be mediated by androgen stimulation, and highlights the 
heterogeneity of hair types seen in humans (Randall 2008). Furthermore, 
there is the paradoxical observation that androgen stimulation is important in 
hair loss, as seen in male pattern balding, highlighting the differential effect of 
androgen stimulation (Randall, Hibberts et al. 2000). Apart from hair growth, 
hair follicles at some body sites become inflamed at puberty, with the 
development of acne. This can include the chest and back in addition to the 
face. Acne and the sites of development of secondary sexual hair are hence 
markers of androgen sensitive hair follicles  
 
In summary, human hair formation and growth is complex. Perturbation of the 
homeostatic mechanisms that maintain normal growth may result in tumour 
formation. CYLD defective tumours represent an interesting model to gain 
insight into molecular changes seen in the putative context of hair follicle cells. 
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FC is an autosomal dominant predisposition to multiple tumours thought to 
derive from the hair follicle (Massoumi, Podda et al. 2006). Cylindromas are 
not exclusively seen in FC however (Figure 5). Brooke and Fordyce described 
a distinct, inherited disfiguring disease, predominantly resulting in nasolabial 
and facial hair follicle tumours – multiple familial trichoepitheliomas, with 
which cylindromas are sometimes seen (MFT- OMIM 601606) (Welch, Wells 
et al. 1968) . An overlap between FC, where cylindromas predominate and 
MFT, where trichoepitheliomas are the main tumour, occurs in Brooke-
Spiegler syndrome (BSS- OMIM 605041). Patients with BSS may also 
develop other hair follicle related tumors such as eccrine spiradenomas, 
syringomas and milia. The common finding of cylindroma tumours in all three 
syndromes was recently corroborated by detection of germ-line mutations in 
CYLD in all three conditions (Young, Kellermayer et al. 2006). These data 
suggest that the three recognised inherited tumour syndromes in which 
cylindromas are seen may represent a phenotypic spectrum (Figure 5). 
 
The majority of tumours in seen in CYLD mutation carriers are on the head 
and neck, however some are seen on the back and the pubic region (Rajan, 
Langtry et al. 2009). The tumours vary in size, the smallest being 
approximately a centimeter in diameter, and the largest between 10-15 
centimeters in diameter. The three commonest CYLD defective tumours seen 
are cylindromas, spiradenomas and trichoepitheliomas. Cylindromas are 
typically pink nodules often found in the scalp. They may have telangiectatic 
vessels overlying them and are often slow growing tumours. 
Trichoepitheliomas are small skin coloured (usually 2-5mm) papules 
commonly seen on the nose or upper lip. Eccrine spiradenomas have a dusky 
blue appearance, particularly if the overlying skin is atrophic. It is intriguing 
that all three tumour phenotypes can arise in the same patient, as are the 
processes that may influence the presentation of the different tumour 
phenotypes. 
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Figure 5 Clinical and histological features in CYLD mutation carriers.  
Exemplary cases of (a) familial cylindromatosis, (b) Brooke-Spiegler syndrome and (c) multiple familial 
trichoepitheliomas. (d) Cylindroma tumour, (e) Spiradenoma at surgery and (f) trichoepitheliomas 
(arrowed). Haematoxylin and eosin staining of (g) cylindroma tumour displaying classical “cylinder 
shaped” islands of cells, separated by abnormal basement membranes. (h) Diffuse sheet of basophilic 
cells as seen in spiradenoma. (i) Two islands of trichoepithelioma tumour, with early abortive hair cysts 
(arrowed ) 
 
 Apart from the disfiguring appearance these tumours have, they can be 
highly symptomatic. Larger tumours, tumours at pressure sites, and tumours 
that are subject to repeated trauma can ulcerate and bleed. Eccrine 
spiradenomas are typically painful tumours, and the pain associated with this 
is not well reported in the literature (Kazakov, Soukup et al. 2005). Occlusion 
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of the external auditory canal by tumours can cause conductive hearing loss, 
a favoured site for trichoepitheliomas and cylindromas (Wolf, Gluckman et al. 
1985).  
Beyond the skin, there is an association between patients with inherited 
cylindromas and salivary gland adenocarcinoma, which shares remarkable 
histological similarity (Jungehülsing, Wagner et al. 1999). Isolated reports 
exist of breast carcinoma (Sandbank and Bashan 1978) and lung cylindroma 
(Vernon, Olsen et al. 1988) in patients with MFT and BSS respectively. It 
would appear that the patients are not otherwise predisposed to developing 
common cancers, suggesting that the expression of CYLD as a tumour 
suppressor gene is crucial at the hair follicle. Malignant change of cylindromas 
and eccrine spiradenomas are reported and metastasis described, but is 
unusual despite the profuse number of lesions, suggesting genomic stability in 
these tumours (Gerretsen, van der Putte et al. 1993; Volter, Baier et al. 2002). 
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Cylindromas, spiradenomas and trichoepitheliomas are histologically distinct 
(Figure 5 g-i). Cylindromas are so called, as the histological arrangement of 
the tumour cells is reminiscent of multiple stacked cylinders seen in cross 
section. Peripheral cells are basophillic and are arranged in a palisading 
fashion, whilst central cells in these islands are paler and larger. Each island 
is surrounded by a thick hyaline basal membrane. In between the islands of 
cylindroma, thin bands of stroma are sometimes seen. Occasional, ductal 
structures are seen in the central areas of cylindroma. Immunohistochemical 
analysis has demonstrated the presence of different cytokeratins in these 
distinct areas (Meybehm and Fischer 1997). These features are summarised 
in Figure 6. Cylindromas have been shown to express cytokeratins relating to 
the hair follicle, including cytokeratin 6 and 14. Certain cytokeratins, seen in 
eccrine ducts including cytokeratin 17 and 18 have also been noted. Some 
authors demonstrate malformed eccrine ducts containing foci of cylindroma 
and spiradenoma tumour, suggesting that these structures may contain the 
cell of origin of these tumours (Meybehm and Fischer 1997). The presence of 
keratins associated with these different structures, prompted debate as to the 
true structure of origin of cylindromas. Recent data demonstrating CYLD 
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expression in the IRS of the hair follicle, has swayed the debate back to a 
pluripotent cell in the hair follicle (Massoumi, Podda et al. 2006). Apart from 
distinct cytokeratins profiles, collagen deposition is disordered. The thick 
hyaline basal membrane has been shown to be rich in collagen 4, 6 and 7. 
There is also increased laminin 5 adjacent to the peripheral basophilic cells 
(Tunggal, Ravaux et al. 2002).  
 
 
Figure 6 Immunohistochemical characterisation of cylindromas. 
A cartoon representing one island of cylindroma cells, highlighting the patterns of immunohistochemical 
staining typically seen in different regions. Colour key : Magenta -hyaline membrane; Purple – 
peripheral palisading cells, ; Pink – central paler cells; Red – ductal structures; Green – dendritic cells.  
 
Spiradenomas share similar cytokeratin markers as well as differentiation 
markers as cylindroma (Meybehm and Fischer 1997). Spiradenomas appear 
as basophilic nodules that are well circumscribed. Cells are arranged in 
sheets or are sometimes seen in a trabeculated pattern. Darker cells are seen 
in the periphery, with paler cells seen in the centre. Cystic structures are 
sometimes seen. The proliferative marker Ki67 is seen in the central, paler 
cells in both cylindroma and spiradenoma.  
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Cylindroma tumours have been reported to be more severe in women (Rajan, 
Langtry et al. 2009). Hormone receptors such as oestrogen and progesterone 
receptor staining has been performed and shown to be negative in 3 cases of 
cylindroma (Albores-Saavedra, Heard et al. 2005). Another group however 
demonstrated positivity of oestrogen receptor and progesterone receptor in 2 
out of 3 cases of spiradenoma, as well as androgen receptor positivity in 1 out 
of 3 cases examined (Kariya, Moriya et al. 2005). These data are of limited 
use in interpreting the role of hormone stimulation in cylindroma growth due to 
the small numbers. 
Immunohistochemical analysis has also highlighted other cells within the 
tumours. A finding in some spiradenomas is the presence of lymphocytes 
distributed among tumour cells (Kazakov, Thoma-Uszynski et al. 2009). 
Furthermore, dendritic cells have been seen within the tumour mass 
(Tellechea, Reis et al. 1995). The contribution of these cells to tumorigenesis 
remains to be clarified. 
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The discovery of CYLD has allowed for assessment of correlation between 
human CYLD mutation type and clinical phenotype. CYLD maps to 
chromosome 16q21 and has a 56kb genomic footprint. The transcript 
comprises 20 exons of which the first 3 are non-coding, with a resulting cDNA 
transcript of 2.87Kb. Interestingly, the majority of the heterozygous germ-line 
mutations identified in cylindroma families have mapped to the 3’ end of the 
gene. No significant correlation has been seen between mutation type and 
phenotype seen (Saggar, Chernoff et al. 2008). These mutations are typically 
single base changes or deletions, resulting in frameshift mutations, splice site 
mutations, nonsense or missense mutations. The majority of mutations result 
in premature termination codons and predict translated truncated proteins that 
have reduced catalytic activity (Saggar, Chernoff et al. 2008)(Figure 7). 
 CYLD defective tumours adhere to Knudson’s two hit hypothesis (Knudson 
1971) with loss of the wildtype allele of CYLD in 70% of tumours examined, in 
keeping with other tumour suppressor genes (Bignell, Warren et al. 2000; 
Leonard, Chaggar et al. 2001).  
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The consequence of loss of functional CYLD in this scenario may be informed 
by CYLD structure. The CYLD protein is 956 amino acids long and has a 
molecular weight of 107 kDa. A shorter isoform 953 amino acids long exists, 
and is a result of alternative splicing of exon 7. There are 4 identified 
functional motifs which include three cytoskeleton-associated-protein–glycine 
conserved (CAP-GLY) domains, a SH3-binding domain, four finger-like metal 
binding domains and two ubiquitin carboxy-terminal hydrolase (UCH) catalytic 
domains. The longer isoform is expressed ubiquitously, whilst the shorter 
isoform is expressed in all tissues except the kidney. In the hair follicle, CYLD 
is expressed in the inner root sheath (Massoumi, Podda et al. 2006).The 
ubiquitous expression contrasts with the largely restricted development of 
tumours to the skin. The mechanism behind such tissue tropism is intriguing 
and undetermined but has been described in other germline mutations in 
tumour suppressor genes such as BRCA (Monteiro 2003). 
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Figure 7  The mutation spectrum seen in CYLD mutation carriers.  
CYLD encodes an ubiquitin hydrolase containing three CAP-GLY domains and a catalytic ubiquitin hydrolase domain, 
within which the human mutations cluster. Newcastle families are highlighted in red. Key A – Reported CYLD mutations, B 
– Exons, C- CYLD protein domains, D- CYLD ubiquitin hydrolase domain, E- missense mutations highlighted within the 
hydrolase domain. Adapted from Toro et al. (Blake and Toro 2009) 
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CYLD is an ubiquitin hydrolase enzyme. Polyubquitination is a post translation 
modification associated with targeting protein to the proteasome for 
degradation. This is catalysed by three enzymatic steps, involving ubiquitin 
activating enzyme (E1), ubiquitin conjugating enzyme (E2) and finally 
ubiquitin-protein ligase (E3) that links the ubiquitin polypeptide to the target 
protein (Chen 2005). Linkage of ubiquitin polypeptide by the lysine 48 residue 
has been shown to target a protein for proteasome degradation, whilst 
proteins tagged with polyubiquitin chains linked together by lysine 63 are 
involved in DNA repair and signal transduction (Kerscher, Felberbaum et al. 
2006). Recently further work has suggested monoubiquitination to be 
responsible for endocytosis and transcriptional regulation (Chen 2005).  
Hydrolases such as CYLD have the opposite function. CYLD encodes an 
ubiquitin hydrolase that cleaves lysine 63 (K63) linked ubiquitin chains 
(Brummelkamp, Nijman et al. 2003; Kovalenko, Chable-Bessia et al. 2003; 
Trompouki, Hatzivassiliou et al. 2003). K63 tagging of proteins is increasingly 
recognised to have a role in cancer (Yang, Zhang et al. 2010). CYLD contains 
a B-box domain, which confers specificity for K63 linked ubiquitin chains, 
removal of which alters processes such as signal transduction and receptor 
endocytosis (Komander, Lord et al. 2008). Signalling pathways that are 
regulated by K63 ubiquitination are likely to be perturbed by the loss of 
functional CYLD, and are detailed below (Figure 8).  
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Figure 8 CYLD interacting partners and signalling pathways.  
Key: CYLD – dark blue, K63 ubiquitin chains – black spheres, K48 ubiquitin chains – red spheres, 
straight arrows with solid lines – direct effect or interaction, straight arrows with dotted lines -  indirect 
effect or incompletely characterised effect, curved solid arrows – deubiquitination. CYLD removes 
ubiquitin chains from proteins involved in several signalling pathways recognised to be important in 
cancer and immunity, such as NFkB, JNK,  RIG-1/IRF and Cyclin pathways. (Adapted from Toro et 
al.(Blake and Toro 2009) 
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Loss of CYLD was discovered to result in upregulation NF!B in a RNA 
interference screen of ubiquitin hydrolase enzymes (Brummelkamp, Nijman et 
al. 2003). There are five members of the NF!B family, namely p65/RelA, Rel 
B, c-Rel, p52/p100 and p50/105. The importance of this pathway in 
tumourigenesis is highlighted by the discovery that many cancers exhibit 
disturbances in signalling pathways that activate NF!B. This may relate to its 
role in regulating genes that control inflammation, the immune response, or 
cell death (Chen and Goeddel 2002) . 
NF!B is normally found in the cell cytoplasm, where it is kept inactive by 
inhibitor (I!B) proteins. Upon stimulation by proteins such as tumour-necrosis 
factor alpha (TNF-") or interleukins, TNF receptors signal to intracellular 
adapter proteins known as TRAFs. These proteins have a variety of effects, 
one of which is to activate the IkB kinase (IKK) complex. IKK in turn 
phosphorylates I!B, leading to its polyubiquitination and degradation. NF!B is 
then released from its repressor and is free to move into the nucleus, where it 
transcribes a variety of genes that facilitate cell proliferation (Massoumi 2006). 
CYLD binds NEMO (IKK#), a regulatory component of the IKK complex, and 
has been shown to deubiquitinate attached K63 polyubiquitin chains. CYLD 
also deubiquitinates TRAF2 and TRAF6, which is upstream of IKK. IKK 
activation is thus inhibited and NF!B remains in the cytoplasm (Kovalenko, 
Chable-Bessia et al. 2003). These results imply that under normal conditions 
CYLD is involved in downregulating NF!B signalling at a point upstream of 
IKK activation.  
c-Jun NH2 terminal kinase (JNK) is a member of the MAP kinase family, and 
is also activated following upstream activation of members of the TRAF family 
such as TRAF 2 and TRAF 6. The biological functions of JNK are diverse and 
include regulation of immune and inflammatory responses, cell growth, 
apoptosis and tumour formation (Manning and Davis 2003). Reiley et al. 
showed a preferential activation of JNK rather than IKK following knockdown 
by CYLD siRNA knockdown in HeLa cells and HEK293 cells stimulated with 
TNF (Reiley 2004), in contrast with previous overexpression studies 
(Kovalenko, Chable-Bessia et al. 2003). JNK activation is shown to be 
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negatively regulated by CYLD in response to CD40, TNF, IL-1$ and LPS, 
whilst IKK activation is negatively regulated by CYLD only in response to 
specific stimulation with LPS and IL-1$ rather than TNF. These data 
demonstrate the JNK signalling pathway as a downstream target of CYLD and 
suggest a receptor-dependent role of CYLD in regulating the I!B kinase 
pathway. 
TAK1, a ubiquitin dependent kinase in the NF!B pathway, also interacts with 
CYLD. CYLD negatively regulates TAK1 mediated stimulation of IKK and 
hence activation of NF!B (Reiley, Jin et al. 2007). TAK1 also plays a role 
outwith the NF!B pathway, as it phosphorylates and activates MKK6 and 
MKK7, leading to the activation of p38 and JNK kinase pathways which may 
also contribute to pathogenesis (Reiley 2004; Liu, Xie et al. 2006).  
CYLD has been shown to negatively regulate BCL3, preventing its nuclear 
entry where it forms a dimer with p50/p52, resulting in transcription of genes 
involved in proliferation including cyclin D1 (Massoumi 2006). NF!B in its 
active form is usually a heterodimer, with a transactivation and a transcription 
domain. Massoumi et al. demonstrated that a transcriptional co-activator, 
BCL3 could form a heterodimer with p52 (that contains a transactivation 
domain) to transcribe cell proliferation genes such as cyclin D1 (Massoumi 
2006). CYLD was shown to co-localise with and negatively regulate BCL3, by 
retaining it in its inactive form in the cytoplasm. Massoumi et al. postulate that 
the different family members of NF!B modulate different effects, with p50/p65 
being responsible for activation of immune responses and inflammation, whilst 
p52/BCL3 may be responsible for tumourigenesis.   
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CYLD has recently been shown to regulate Dishevelled, a member of the Wnt 
signalling pathway (Tauriello, Haegebarth et al. 2010). CYLD knockdown 
results in upregulation of canonical Wnt signalling, with nuclear beta-catenin 
demonstrated in cylindroma tumour cells. This data is of interest as Wnt 
signalling has been shown to be pathogenic in other hair follicle tumours, such 
as pilomatrixoma (Chan, Gat et al. 1999).  
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Recent data has shown that CYLD plays a role in cells entering mitosis. CYLD 
was found as part of a siRNA screen that was designed to identify genes 
whose downregulation resulted in delayed mitotic entry or defective spindle 
checkpoint function (Stegmeier, Sowa et al. 2007). CYLD RNAi in HeLa 
produced cells that accumulated prior to mitosis and had normal interphase 
nuclear morphology. CYLD’s deubiquitinating activity was shown to be 
important for regulation of cell cycle function, with a catalytically inactive 
CYLD mutant (C601A) failing to cause the premitotic arrest phenotype.  
CYLD protein levels were also shown to vary in the cell cycle using lysate 
from synchronised cells. CYLD levels are low during G1, accumulate during S 
phase and subsequently degrade at the end of mitosis. This is characteristic 
of other substrates of the anaphase promoting complex such as PLK1 and 
Cyclin B. Interestingly, CYLD has been shown to interact with PLK1 , which 
was detected on a proteomics screen using a mass spectrophotometry 
approach. These data suggests CYLD may deubiquitinate a regulator of 
mitotic entry and may function in the same pathway as PLK1. This raises the 
paradox in this model that CYLD is a tumour promoter, rather than a tumour 
suppressor. The authors speculate that CYLD’s role in the cell cycle may vary 
between tissue types and may be less critical in tissues where other 
deubiquitinating enzymes afford redundancy. Alternatively, they suggest the 
benign nature of cylindromas may be due to the cell cycle arrest resulting 
from the loss of CYLD compensating for the antiapoptotic constitutively 
activated NF"B also seen.  
CYLD has been shown to inhibit Aurora-B, an important protein in the cell 
cycle, independently of its deubiquitinase activity. This kinase, which is 
important in cytokinesis and cell proliferation, has elevated activity in human 
cancer (Katayama, Brinkley et al. 2003). The authors speculate that the 
tumour- suppressing function of CYLD might be attributed at least partly to its 
inhibition of Aurora-B activity.  
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Tight regulation of CYLD itself may be important in regulating the innate 
immune response. CYLD degradation has been shown to be mediated by 
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IKK# phosphorylation. Lysates from a Jurkat cell line deficient in IKK# 
(JM4.5.2), demonstrated the presence of a phosphorylated CYLD band, that 
was lost following over expression with IKK#. Using CYLD mutants harbouring 
serial truncations, the site at which CYLD was phosphorylated was narrowed 
to between amino acids 420 and 446. Site-specific mutations of two serine 
pairs inhibited phosphorylation of CYLD within this region. CYLD 
phosphorylation by IKK# inactivates it’s ubiquitin hydrolase activity, which may 
serve as a mechanism that allows accumulation of ubiquitinated TRAF2 and 
hence sustained NF"B and JNK signalling in response to TNF and other 
infective stimuli.  
Conversely in the context of attenuating the innate immune response to 
bacterial infections, CYLD is overexpressed as a consequence of 
peptidoglycan induced TLR2 signalling. An autoregulatory mechanism for the 
tight regulation of TLR stimulation is mediated via deubiquitination of TRAF6 
and TRAF7, which results in negative regulation and attenuation of the 
NF!B/p38 mediated induction of immune and inflammatory responses 
(Yoshida, Jono et al. 2005). CYLD also regulates aspects of the host 
response to viral infections, by inhibition of the interferon regulatory factor 3 
(IRF3) signalling pathway by acting as a negative regulator of retinoic acid-
inducible gene 1 (RIG-1), a cytoplasmic viral RNA sensor (Friedman, 
O'Donnell et al. 2008) The putative mechanism is thought to be via CYLD 
deubiquitination of RIG-I and the IKK-related kinases IKK%/TBK1, kinases that 
phosphorylate IRF3.  
!">"> H13*'(.;1%1&+*(1%'=*18(%0)(7;041&-08(-7(<?@:(
Beyond its role as tumour suppressor, CYLD also has roles in regulating 
immunity, microtubule assembly, spermatogenesis and calcium ion channel 
regulation (Reiley, Zhang et al. 2006; Stokes, Wakano et al. 2006; Stegmeier, 
Sowa et al. 2007; Wright, Reiley et al. 2007; Gao, Huo et al. 2008). CYLD has 
been shown to deubiquitinate K63 linked ubiquitin chains from TRKA, 
modulating TRKA receptor endocytosis and signalling (Geetha, Jiang et al. 
2005).  How perturbation of these pathways by loss of functional CYLD may 
contribute to tumour formation is not yet clear. The signalling pathways CYLD 
are involved with are summarised in Figure 8.In addition to knowledge of 
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CYLD function from in vitro models, transgenic animal models have been 
developed that highlight the tissues in which CYLD defects result in disease 
pathogenesis. 
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To further define the function of this interesting tumour suppressor gene, 
mouse models have been developed, which show markedly different 
phenotypes. Crucially, none of them develop cylindromas, indicative of the 
fact that mouse hair follicle biology is not a perfect model to study human 
disease. Human and murine CYLD share 94% sequence homology at the 
transcript level however, and should elucidate CYLD function in humans.  
CYLD deficient mouse models with complete loss of CYLD expression do not 
develop spontaneous tumours, but show an increased susceptibility to cancer. 
This includes an increased susceptibility to chemical carcinogen induced 
cutaneous tumours (Massoumi 2006) as well as colorectal tumours following 
dextran sulphate induced colitis (Zhang, Stirling et al. 2006). Mice expressing 
truncated CYLD mutations that mimic human mutations in contrast, are not 
viable beyond a few hours after birth (Ermolaeva, Sebban et al. 2006; 
Trompouki, Tsagaratou et al. 2009). This difference in the two phenotypes is 
intriguing and suggests that further work is required to understand genotype-
phenotype correlations. Intriguingly, a null mouse with a conditional deletion of 
exon 7 that abrogates the TRAF2/NEMO binding site is viable, suggesting a 
dominant negative effect mediated by this binding site may account for the 
perinatal lethal phenotype.  
Apart from increased susceptibility to tumour formation, CYLD deficient mice 
(both complete knockouts and exon 7 deletions), demonstrate several 
immunological defects.  These defects include the lack of maturation of T-
cells, hyperproliferative T and B cell responses following stimulation and 
hyperplasia of the lymphoid tissue, summarised in Table 1.  
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Table 1 CYLD transgenic mice phenotypes.  
 
 
CYLD TRANSGENIC MICE PHENOTYPES 
AUTHOR KO GROSS PHENOTYPE CANCER 
SUSCEPTIBILITY 
IMMUNOLOGIC
AL FEATURES 
Massoumi Exon 4 
deletion 
Null normal phenotype.  Mutation increases 
likelihood of squamous 
proliferation (not cancer 
per se),  following DBMA 
and TPA treatment. 
Number of papillomas 
increases from wt, to het 
to null.  
Not described 
Reiley Exon 1 
deletion 
No description of 
abnormalities of mouse 
phenotype. 
Not described Fewer mature 
CD4 and CD8 
thymocytes and 
peripheral T cells. 
Hyperproliferative 
T cell responses, 
and abnormal B 
cell responses. 
Zhang Exon 2-3 
deletion 
Null - normal at birth. 
Changes in the organs of 10-
month-old null mice, include 
marked lymphoid 
hyperplasia of the thymus 
and lymphoid inflammatory 
infiltrates in numerous 
tissues including the liver, 
spleen, lungs, and salivary 
glands.  
Null mice were more 
susceptible to induced 
colonic inflammation and 
showed a dramatic 
increase in the incidence 
of tumors compared with 
controls in a colitis-
associated cancer 
model. 
Normal T cell 
ratios 
Mosialos Exon 9 
deletion 
Nulls die at P1, are smaller 
in size and have a kinked 
tail. Lungs are immature and 
fail to inflate.  
Not described Not described 
Hovelmeyer Exon 7 
deletion 
No gross changes; a short 
splice variant of CYLD is 
excessively expressed, and 
the mice are viable 
Not described A dramatic 
expansion of 
mature B 
lymphocyte 
populations in all 
peripheral 
lymphoid organs 
occurs in this 
strain. 
Ashworth  
(unpublishe
d data) 
Exon 
19 
Nulls die at P1 from 
generalised inflammatory 
changes, are smaller in size 
and have subtle tail 
abnormalities. Increased 
numbers of hair follicles seen 
in nulls.  
Hets develop liver 
tumours after 6 months. 
Not described 
Courtois Truncate
d CYLD 
knockin 
Perinatal lethal Not described Not described 
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Human and Drosophila CYLD share 45% sequence homology. Drosophila 
has an analogous NF!B pathway (IMD –Immune deficiency pathway), in 
which proteins similar to the mammalian counterparts of NF"B are seen. 
Drosophila CYLD has deubiquitinating activity; the conservation of this 
domain may afford further insight into CYLD biology. The key phenotype seen 
in null flies are altered fat body morphology, increased survival against 
starvation and increased susceptibility to bacterial infections (Tsichritzis, 
Gaentzsch et al. 2007). 
 
The lack of cylindromas in CYLD transgenic models has limited the use of 
these models for drug discovery. Intriguingly a GLI1 overexpressing mouse 
has been described, where cylindromas, trichoepitheliomas and basal cell 
carcinomas were seen. Whilst the cylindromas seen in this model have not 
arisen following mutations in CYLD, the model highlights the possibility of 
SHH signalling playing a role in CYLD defective tumours (Nilsson, Undèn et 
al. 2000).  Equally, molecular insights gained from CYLD defective tumours 
may inform the pathogenesis of BCC. 
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Apart from cylindromas, other cancers that lack functioning CYLD or have 
reduced expression of CYLD include hepatocellular and colonic carcinoma 
(Hellerbrand, Bumes et al. 2007), multiple myeloma (Annunziata, Davis et al. 
2007; Jenner, Leone et al. 2007; Keats, Fonseca et al. 2007), lung cancer 
(Zhong, Fields et al. 2007), prostate cancer (Kikuno, Shiina et al. 2008) and 
malignant melanoma (Massoumi, Kuphal et al. 2009). In multiple myeloma, 
loss of heterozygosity (LOH) at 16q, the genomic location of the CYLD gene, 
is an indicator of poor prognosis and is associated with reduced overall 
survival (Jenner, Leone et al. 2007). Both deletions involving the locus of 
CYLD resulting in reduced copy number, as well as biallelic events, 
comprising a 16q deletion with mutations within the coding exons of CYLD in 
the remaining allele have been shown (Demchenko, Glebov et al. 2010). 
Overexpression of NF!B target genes has been demonstrated in myeloma 
consistent with the proposed role of CYLD (Jenner, Leone et al. 2007). Apart 
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from genetic changes resulting in reduced CYLD expression in cancer, 
epigenetics have also been shown to play a role. CYLD expression is reduced 
in non-small cell lung cancer cell lines, a process mediated by histone 
deacetylation (Zhong, Fields et al. 2007). In prostate cancer cell lines (LNCap 
and PC3) CYLD expression is increased following phytoestrogen mediated 
demethylation and acetylation and is associated with reduced NF!B activity, 
suggesting methylation as method of repressing CYLD (Kikuno, Shiina et al. 
2008). The reduced expression of CYLD contributing to tumorigenesis in 
cancers beyond cylindromas is in keeping with its role as a tumour suppressor 
gene.  
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CYLD mutation carriers undergo repeated surgery to control tumour burden. 
These procedures can culminate in complete scalp removal. Taken together 
with the disfiguring and painful nature of these tumours, and the impairment of 
function, the development of non-surgical therapies is indicated. The 
discovery that CYLD negatively regulated the NF!B pathway upstream of 
aspirin’s putative point of action raised the possibility of non-surgical 
treatments. The concept of treating cylindromas with aspirin is an appealing 
one. Aspirin is cheap and has a well-known safety profile. Cylindromas are 
easily accessible and topical application, as well as transcutaneous delivery 
or intralesional injections are feasible to achieve sufficient tissue 
concentrations. Aspirin competitively inhibits ATP binding to IKK-beta and 
hence reduces IKK’s enzymatic activity (Yin, Yamamoto et al. 1998). As a 
CYLD independent weak inhibitor of IKK, aspirin can compensate for the 
activation of IKK seen in CYLD depleted cells. This was shown in HeLa cells 
subjected to siRNA CYLD knockdown, where the resistance to TNF induced 
apoptosis was overcome by the addition of aspirin. However, topical 
application of salicylic acid only had a modest effect in CYLD mutation 
carriers, with complete remission seen in only two tumours after prolonged 
daily treatment (Oosterkamp, Neering et al. 2006).This prompted the 
development of this work, which has an overarching aim to use an unbiased 
approach to discover targetable pathways using rare tumour samples from 
CYLD mutation carriers.  
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The aims of this project are: 
1. Characterisation of the distribution and histological features of CYLD 
defective tumours in germline CYLD mutation carriers 
2. Identification of the key regulatory pathways, abrogation of which are 
associated with formation of CYLD defective tumours. 
3. Functional studies of disrupting such pathways in primary cell culture 
models derived from CYLD defective tumours. 
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Appropriate approval from the local ethical review board was obtained (REC 
06/1059) and written informed consent was obtained from patients.  
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Two large families with known germline mutations (Bignell, Warren et al. 
2000) within the CYLD locus were identified for the assessment using a 
questionnaire and tumour mapping (see below). Family A has a frameshift 
mutation (c.2460delC), resulting in a premature termination codon, whilst 
Family B has a splice site mutation (c.2469+1G>A). In total, twenty-six 
affected individuals as determined by a dermatologist or geneticist were 
surveyed, of which eighteen were clinically examined . Eight unaffected 
relatives, five from family A and three from family B, provided blood samples 
to exclude the presence of a non-penetrant mutation. Patients provided blood 
samples from which genomic DNA was extracted.  
In addition to patients from these pedigrees, further patients who were 
undergoing routine surgery to control tumour burden were identified. Surplus 
tissue from these patients, were used as described. These patients carried 
germline mutations that were c.2460delc, c.2469+1G>A and c.2290del5 
(Accession No. NM_015247). 
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A questionnaire was designed following a search for all publications in 
PubMed for the text: CYLD, cylindroma, Brooke-Spiegler syndrome, familial 
cylindromatosis, and multiple familial trichoepitheliomas. The phenotypes 
seen in CYLD knockout mice models and all clinical phenotypic data were 
collated into a clinical questionnaire. The questionnaire aimed to gather 
clinical data on patient signs and symptoms, disease severity, hormonal 
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therapy exposure in females, associated diseases and response to existing 
aspirin or NSAID therapy.  
Due to the extensive geographical spread of the families, a template was 
designed, and affected members were asked to self-report the exact location 
of tumours. However, as the majority of patients lived in the North East of 
England, detailed examination of eighteen patients was performed to ensure 
corroboration. Tumour mapping done in the clinic corroborated well with the 
template data on the torso and face. Detailed location on the scalp was 
accurate when there were less than approximately ten tumours; accurate 
resolution was not possible when confluent tumours were present.  
Eight affected patients, who were not examined due to geographical reasons, 
were interviewed by telephone. These patients self-reported lesion locations 
on a template and supplemented this subjective description with confirmatory 
digital photographic images. Histological reports were reviewed to confirm the 
nature of the tumours where available.  The distribution of tumours on each 
patient was ultimately marked on a template and a composite image was 
created by overlaying the templates according to gender using Adobe 
Photoshop™.  
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Patients who underwent routine surgery and had consented to the use of 
surplus tumour tissue for surgical procedures were included. Tumour 
locations were recorded at the time of surgery on a diagram used to map the 
location of the collected tissue. Tumour tissue was collected under sterile 
conditions at the time of operation, and depending on the intended use, was 
snap frozen in liquid nitrogen, fixed in PFA or placed in supplemented tissue 
culture medium that contained antibiotics (Transport medium). 
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Tissue used for standard haematoxylin and eosin staining, and 
immunohistochemical detection of proteins from tissue sections were fixed in 
4% PFA for 4-12 hours depending on the dimensions of the tissue block. 
Specimens were then gently agitated and dehydrated in graded alcohols.  
Materials and methods 
 29 
Specimens were then immersed in xylene, before being immersed in wax, 
and then finally placed in wax blocks. 
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A custom made tissue microarray was made from single 2mm cores from 
representative tumour areas and was used to validate protein expression in 
tissue sections. The TMA contained 10 cylindroma samples, 4 spiradenoma 
samples and 2 trichoepithelioma samples. Cylindromas and spiradenomas 
were chosen from both scalp and torso, and trichoepitheliomas were from the 
face. 2mm cores of tumour samples were placed onto a piece of PCR film, 
which was cut to fit into a tissue processing mould. Molten wax was then 
poured into the mould, and allowed to cool. The PCR film was then removed. 
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Tissue sections were cut using a microtome, typically at 5 µm thickness. 
Serial sections were cut and orientated on Superfrost Plus (VWR, UK) glass 
slides, which were sequentially labelled. Sections were floated on distilled 
water, warmed using a hotplate. Missing sections, where applicable, were 
noted. Surplus water was removed and the slides were baked overnight at 
58°C. Slides were then cooled to room temperature.  
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Slides were incubated in a warm oven at 60°C for 30 minutes, prior to being 
dewaxed in fresh xylene twice. Tissue sections were rehydrated in graded 
alcohols, and then finally immersed in distilled water, prior to the applications 
below.  
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Rehydrated sections on glass slides were transferred from distilled water to 
haematoxylin solution for 25 seconds, immersed for 5 seconds in distilled 
water, and then immersed in bluing solution for 10 seconds. After a brief 5 
second immersion in water, slides were then immersed in eosin solution for 
30 seconds. The slides were then dehydrated in graded alcohols, immersed in 
two changes of xylene, and then coverslipped using DPX mounting media.  
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Tissue sections were transferred from distilled water into sodium citrate buffer 
(pH 6.0), and antigen retrieval was performed using a pressure cooker for 7 
mins. This was done to unmask antigenic epitopes that may have been 
masked following the cross linking of proteins following PFA fixation. Slides 
were then cooled to room temperature, and washed once in PBS. Slides were 
marked with a membrane pen (ImmEdge Hydrophobic Barrier pen - H-4000, 
VECTOR Industries) , with care taken not to allow the sections to dry out. 
Sections were then blocked in serum free protein block (X0909, DAKO UK) 
for ten minutes, before incubation with primary antibodies diluted in antibody 
diluent (Background Reducing S3022, DAKO UK), at concentrations specified 
below in Table 2. After an hour incubation, slides were gently washed in PBS 
thrice, before incubation with secondary antibodies at a dilution of 1:200, and 
DAPI (SIGMA, UK) at a dilution of 1:10000 (1mg/ml stock solution). After a 
further hour incubation, slides were washed thrice in PBS, and then mounted 
using Vectashield Hardset Mounting Medium (H-1400, VECTOR Industries). 
Fluorescent staining was visualised using a UV Zeiss Axioimager microscope, 
and images captured using a monochrome digital camera connected to a 
computer running Zeiss Axiovision 4.7 software (Zeiss, UK). 
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Tissue sections were transferred from distilled water into sodium citrate buffer 
(pH 6.0), and antigen retrieval was performed using a pressure cooker for 7 
mins. Slides were then cooled to room temperature, and washed once in 
PBS. Slides were marked with a membrane pen (ImmEdge Hydrophobic 
Barrier pen - H-4000, VECTOR Industries) , with care taken not to allow the 
sections to dry out. Tissue sections were then blocked with peroxidase 
blocking agent (DAKO, UK) and then incubated with primary antibodies as 
indicated in Table 2 Concentration of antibodies used for 
immunohistochemistry for 1 hour at room temperature. Tissue sections were 
then washed in phosphate buffered saline and probed with secondary 
polymer linked HRP-conjugated antibodies for 30 minutes (DAKO, UK), and 
staining was visualized with 3,3'-Diaminobenzidine (DAB). Haematoxylin 
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(SIGMA, UK) was used as a nuclear counterstain. Colour photomicrographs 
were captured using a Zeiss Axioplan microscope, coupled to a colour digital 
camera connected to a computer running Zeiss Axiovision 4.7 software 
(Zeiss, UK). 
Table 2 Concentration of antibodies used for immunohistochemistry. 
Primary Antibody Concentration 
of 1˚Ab 
Secondary 
antibody 
Concentration 
of 2˚Ab 
CK6 (Abcam) 1:200 Anti mouse FITC 
(Jackson) 
1:200 
CK14 (Abcam) 1:200 Anti mouse FITC 
(Jackson) 
1:200 
CK17 (Abcam) 1:200 Anti mouse FITC 
(Jackson) 
1:200 
SMA (Abcam) 1:200 Anti rabbit FITC 
(Jackson) 
1:200 
Beta Catenin (BD) 1:50 DAKO Mouse 
Polymer HRP 
N/A 
BCL2 (Cell Signalling) 1:200 DAKO Rabbit 
Polymer HRP 
N/A 
TRKA (Cell Signalling) 1:200 DAKO Rabbit 
Polymer HRP 
N/A 
TRKB (Cell Signalling) 1:200 DAKO Rabbit 
Polymer HRP 
N/A 
TRKC (Cell Signalling) 1:200 DAKO Rabbit 
Polymer HRP 
N/A 
Phospho ERK (Cell 
Signalling) 
1:200 DAKO Rabbit 
Polymer HRP 
N/A 
LEF1 (Cell Signalling) 1:200 DAKO Rabbit 
Polymer HRP 
N/A 
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Formalin fixed paraffin embedded tissue was serially sectioned at 5 µm 
thickness. Tissue sections were subject to routine haematoxylin and eosin 
staining, and then photographed using Zeiss Axioplan microscope coupled to 
a Nikon D300 camera with a 50mm objective. Images were acquired using a 
5x microscope objective. Alignment was performed manually using Amira 
software (V4.0 – Visage Imaging), allowing accurate overlap of serial 
sections. Artificial colour labels were applied to individual cylinders of tumour 
cells, allowing tracking of cylinders through the tumour block. Surface 
rendering of the ensuing columns of tumour cells and virtual flythrough 
examination was performed within Amira software. 
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Photomicrographs were taken of the tissue sections that encapsulated the 
sections used for transcriptomic profiling. Tissue sections were subject to 
routine haematoxylin and eosin staining, and then photographed using Zeiss 
Axioplan microscope coupled to a Nikon D300 camera with a 50mm objective. 
These images were stitched together in Adobe Photoshop™ CS3. Each 
island of tumour cells was then highlighted by tracing around the periphery on 
a new layer in Adobe Photoshop. This layer, which contained circular shapes 
of different sizes, was then analysed in Image J (v1.64b - NIH) to determine 
the size of each island. A threshold size of 10,000 square pixels was used as 
the threshold at which tumour islands lost a circular pattern of organisation. 
The number of islands that fell on either side of this threshold was then 
determined as a proportion of the total number of islands in that sample. This 
measure of proportion of each sample’s level of organisation was then 
correlated with the 3000 selected transcripts across 25 samples where 
morphometric analysis was technically adequate Spearman’s coefficient was 
used to determine the statistical significance, with a value of p<0.05 taken to 
be significant. 
62> K-;'0/;$()N'0#,1M/'?)
#"6"! KO1'%41&-0(-7(VAR((
Care was taken during the preparation of RNA to keep the working area and 
instruments free of RNAse contamination. This was achieved by wiping work 
surfaces and equipment with Diethylpyrocarbonate (DEPC)-ethanol or RNAse 
Zap (Ambion, UK), wearing disposable gloves wiped with DEPC-ethanol and 
using aerosol resistant tips.  
Total RNA was extracted as per the Trizol (Invitrogen, UK) protocol. Samples 
were incubated at room temperature in 800µl for 5 mins to allow complete 
dissociation of nucleoprotein complexes after which 0.2ml of  chloroform 
(Sigma, UK) per 800µl Trizol was added and the microfuge tubes shaken 
vigorously by hand for 15 secs. Samples were incubated at room temperature 
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for 2 mins and then centrifuged at 12000 rcf for 15 mins at 4˚C. The upper 
colourless aqueous phase containing the total RNA was carefully transferred 
to a fresh tube. Total RNA was then precipitated from the aqueous phase by 
adding 0.5ml isopropyl alcohol combined with 0.5 µl glycogen (Ultra Pure 
Glycogen - Invitrogen, UK). Samples were then incubated at room 
temperature for 10 mins and centrifuged at 12000 rcf for 10 mins at 4˚C. The 
supernatant was removed taking care not to disturb the total RNA pellet which 
was then washed with 1ml of 75% ethanol. The sample was vortexed briefly 
prior to centrifugation at 7500 rcf for 5mins at 4˚C. The supernatant was 
removed and the pellet air-dried on the bench for 5 mins. The total RNA pellet 
was then resuspended in 20µl DEPC-dH2O and stored at -20˚C. 
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Contaminating genomic DNA was removed from the above total RNA 
preparations by the addition of 0.2U DNaseI, RNAse free (Promega) per 20µl 
resuspended total RNA and incubating the mix for 5mins at 37˚C. The 
reaction was stopped by the addition of EDTA, pH 8.0 at a final concentration 
of 20mM. 
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Trizol was used as it was feasible to perform extraction of DNA from the 
microdissected samples after the RNA isolation stage described above was 
complete. Any remaining aqueous phase was aspirated, before 300µl of 
100% ethanol was added. This was mixed and allowed to stand at room 
temperature for 3 minutes. The tube was then centrifuged at 2000 rcf for 5 
minutes at 4˚C, and the supernatant was removed. The remaining DNA pellet 
was washed in a 0.1M sodium citrate with 10% ethanol solution, left at room 
temperature for 30 minutes and then spun down at 2000 rcf at 4˚C for 5 mins. 
This was repeated once, and the pellet was washed in 75% ethanol before 
being spun down again. The ethanol was aspirated, the pellet air dried, and 
then resuspended in 8mM sodium hydroxide. This was titrated with HEPES to 
a final pH of 8. 
Materials and methods 
 34 
#"6"9 Q8-,%1&-0(-7(=*0-/&4(:AR(7'-/(W3-,*(X,--)(
Genomic DNA from peripheral blood was extracted using the QIAGEN whole 
blood kit according to manufacturer’s protocol. In brief, cells are lysed in 
buffers that provide immediate denaturation of proteins such as nucleases, 
histones, and DNA-binding proteins. Under the pH and low-salt conditions 
provided by the buffer, DNA binds to the QIAGEN resin in the column while 
other cell constituents such as proteins, carbohydrates, and metabolites flow 
through. Purified DNA is eluted in high-salt buffer, and precipitated in 
isopropranol, before being resuspended in EB buffer. 
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DNA and RNA was quantified using a Nanodrop UV spectrophotometer 
(Nanodrop, UK). The ratio of the absorbance readings at 260nm and 280 nm 
(A260/A280) were calculated on the NanoDrop to provide an estimate of the 
purity of the DNA and RNA with respect to contaminants. A ratio of >1.8 was 
used as a threshold of a pure sample. Total RNA and DNA concentration was 
determined by measuring the absorbance at 260nm using the NanoDrop 
(Labtech International) spectrophotometer. An A260 reading of 1.0 is 
equivalent to about 40 #g/ml of RNA, and 50 #g/ml of DNA. 
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RNA integrity analysis was performed using a chip based electrophoresis kit 
to confirm preservation of the 18S and 28S ribosomal bands, in accordance 
with the manufacturer's protocol (RNA 6000 Nano and Pico Chip kits; Agilent 
2100 Bioanalyzer).  
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cDNA was synthesized from total RNA using a Superscript III RT Kit 
(Invitrogen, UK) according to the manufacturers instructions. Reverse 
transcription of 100ng-5µg of total RNA was carried out in a 20µl reaction 
volume containing 100ng of random primers, 10mM dNTP mix, sterile distilled 
water, first strand buffer and DTT to a final concentration of 10mM. Reaction 
mixes were incubated at 25˚C for 2 minutes and then Superscript III RT was 
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added. The reaction was then incubated at 25˚C for ten minutes, 42˚C for 50 
minutes and inactivated by heating to 70˚C for 15 minutes.  
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Where primer design was not dictated by the need to incorporate 
endonuclease restriction sites, a Kozak sequence or to amplify the full coding 
sequence of a gene, the Perl primer v1.14 design program was used for both 
PCR and sequencing primers.  
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Sequencing primers were used to verify the sequence of CYLD. These were: 
Table 3 CYLD cDNA sequencing primers. 
Primer Primer sequence (5’-3’) Position 
pLEX MCS FWD CACCAAAATCAACGGGACTT -120 
CYLD 2F CTCCAAATAGACGTGGGC 642 
CYLD 3F GAGTGTGACGCAGGAAAGG 1190 
CYLD 4F GGCTGAAGTTAAGGAGAACC 1691 
CYLD 5F AGGCTGCATCAGGATTTACC 2275 
CYLD 6F CAGTGTCACTTCCCAAAGAC 2776 
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Primers designed with restriction endonuclease sites were used to amplify 
CYLD.  These included SpeI and AgeI restriction sites. CYLD Forward 5’ - 
GGCACTAGTAGCATGAGTTCAGGCTTA - 3ʼ; CYLD Reverse 5ʼ –
GGCACCGGTTTATTTGTACAAACTCATTGT - 3ʼ. (Restriction sites indicated 
in italics; underlined sequences represent the coding sequence of CYLD) 
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These primers were adapted from Saggar et al. (Saggar, Chernoff et al. 
2008).  
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Table 4 CYLD exon amplification primers. 
Forward 
Primer 5’-3’ sequence 
Reverse 
Primer 5’-3’ sequence 
AT 
°C 
CYLD4F GTATGTCTTTTAGCCCTTTT CYLD4R TGCATACAAATACACAGACA 55 
CYLD5F CCTAGAGTGAACCCCTTTTCC CYLD5R TTTGCAAGTAAATTGGTCCTAAAA 62 
CYLD6F TTTTGGAGGATTCTTTATGG CYLD6R AGAAATCACCACGAAAGAAC 60 
CYLD7F AACACATCCCCCTCCTCTTT CYLD7R ACCTTAAAGCCCAGCAATGA 50 
CYLD8F TTCCTTGTTTCTCTTCTATA CYLD8R ACATGTTCAGAAGTAATAGC 50 
CYLD9F CTTTGATGCTATATTGACTT CYLD9R TCTACTTATTCTGTTTCCAA 50 
CYLD10F TTGTGATGCCTATGAGAGTA CYLD10R TCAAAAAGCATATAATAGGG 55 
CYLD11F GGAGTGGTGAGAAAGGGTAT CYLD11R GCGTTGGCAAGAAATATATT 55 
CYLD12F GCATCAAAATACAAAAACAT CYLD12R CACAGTCATCCAGTTTCTCT 50 
CYLD13F CTTTACTTATTTTCCTCTTC CYLD13R ACATGAAGACAAGGTATAAA 55 
CYLD14F GCCTGAGTGATAGAGTGAGA CYLD14R TCATTATTCCACATCATCAA 55 
CYLD15F GAAAACTTGAAAACTGTGCT CYLD15R AGAGCCCTAAACAAATACAA 55 
CYLD16F TCTGTTGTTCTGACTATCCA CYLD16R GTGTTTCAAACTTTTCTCAG 55 
CYLD17F GTGGCTTATTGGTGTCCTCT CYLD17R GCCTTGGGAAATACTGTGTC 55 
CYLD18F GAGAGCTTAAGCAGATGGAA CYLD18R TAAACAGAAAAGGCAAAAGC 55 
CYLD19F ATTTAAATGATTCTCCTGCC CYLD19R TGTTGTCACCAGAATAATCC 55 
CYLD20F ATAAAATCACTGGCAAAAGG CYLD20R TCATCACCACAAAGACATCC 55 
 
The annealing temperature for each primer pair in the reaction is indicated in 
the column “AT”. Amplified PCR products were sequenced using the forward 
primer. 
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All polymerase chain reactions (PCR) were setup in a dedicated laminar flow 
hood. PCR reactions carried out for the purpose of genotyping or amplification 
of the first strand from the reverse transcription of RNA were performed using 
Taq DNA Polymerase (Invitrogen, UK). The PCR reaction was carried out in a 
total volume of 50µl comprising the following: DNA template, 0.4mM dNTPs, 
1µM forward primer, 1µM reverse primer, 10X Taq DNA Polymerase Buffer, 
1.5mM MgCl2, 2U Taq DNA Polymerase and DEPC H20. All components 
were combined in sterile PCR tubes on ice using aerosol resistant tips. 
Amplification was performed in a thermal cycler using the following 
parameters: 95˚C for 3mins; 30-35 cycles of 30secs at 95˚C, 1min at the 
primer annealing temperature and 1min per kilobase of the desired product at 
72˚C; a final 10min extension at 72˚C. Products were analysed on a 1-2.5% 
agarose gel, depending on size of the product. 
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PCR reactions carried out for the purpose of generating a cDNA product 
which incorporated specific restriction endonuclease sites at either end to 
facilitate cloning were performed using high fidelity polymerase. Phusion high-
fidelity DNA polymerase (Finnzymes) with 5’ ! 3’ DNA polymerase activity 
and 3’ ! 5’ proofreading exonuclease activity was used. The PCR reaction 
was carried out in a total volume of 50µl comprising the following: DNA 
template, 0.2mM dNTPs, 0.5µM forward primer, 0.5µM reverse primer, 5X 
Phusion HF Buffer containing 1.5mM MgCl2 and 1U Phu DNA Polymerase. 
Amplification was performed in a thermal cycler using the following 
parameters: 98˚C for 1min; 30 cycles of 10 secs at 98˚C, 30 secs at the 
primer annealing temperature and 15-30 secs per kilobase of the desired 
product at 72˚C; a final 10min extension at 72˚C. Products were analysed on 
a 1% agarose gel prior to excision and purification. 
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Total RNA was extracted from cylindroma primary cell cultures as described 
above, subject to DNAse digestion and then reverse transcribed using a 
Superscript III kit (Invitrogen, UK) according to manufacturers instructions. 
cDNA was then used for quantitative PCR with the following primers (5’-3)’: 
(GAPDH F – ATGGGGAAGGTGAAGGTCG, GAPDH R –
GGGGTCATTGATGGCAACAATA, NTRK2 F – 
TGTTCAGCACATCAAGCGACA, NTRK2 R – 
GCTCAGGACAGAGGTTATAGCAT, NTRK3 F 
TCCGTCAGGGACACAACTG, NTRK3 R – 
GCACACTCCATAGAACTTGACA) with a SYBR green contain Taq 
polymerase master mix (Sigma, UK) , in an ABI 7900HT thermal cycler. Gene 
expression was normalised to GAPDH and comparisons in expression were 
made using the 2-&&CT formula as the PCR reactions had similar efficiencies of 
amplification.  
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PCR products generated for genotyping were visualised on 2% Tris-Acetate-
EDTA (TAE) agarose gels. Gels contained ethidium bromide at a final 
concentration of 2µg/ml. DNA was mixed with 6X loading dye (Promega) to a 
final concentration of 1X prior to loading on an agarose gel. 1kb or 100bp 
ladder (Promega) was loaded alongside DNA samples to provide markers by 
which to ascertain the size of DNA fragments. Samples were run in 1X TAE 
Buffer at 25V until separation of the DNA fragments was achieved. 
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DNA fragments were extracted and purified using a QIAquick Gel Extraction 
Kit (Qiagen) according to the manufacturer’s instructions. Briefly, 0.5-1µg of 
DNA was separated by electrophoresis on a 1% agarose gel. The fragment of 
interest was excised under UV light visualisation and transferred to a 
microfuge tube using a clean scalpel for each fragment. The agarose was 
dissolved by the addition of Buffer QG and heating to 50˚C for 10mins. For 
DNA fragments less than 500bp and greater than 4kb, isopropanol was added 
to the sample to increase the yield. The sample was then applied to a 
QIAquick spin column and centrifuged. The column was washed with Buffer 
QG to remove any trace of agarose, and then incubated for 5 minutes after 
the addition of Buffer PE to remove salts which may interfere with 
downstream ligations. Purified DNA was eluted from the column in 30µl Buffer 
EB.  
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DNA sequencing was performed using the Big Dye terminator sequencing 
method, performed by MWG/Eurofins. Plasmid DNA extracted using the 
QIAGEN Miniprep kit were sent with sequencing primers at the recommended 
concentrations. PCR products were purified using the QIAquick PCR cleanup 
kit according to manufacturer’s instructions, before the sequencing primer 
(forward primer from amplification reaction) was added at the recommended 
concentration. When a novel mutation was detected in a sample from a 
patient, the sequencing reaction was repeated using the reverse primer for 
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the PCR reaction. Sequence data was viewed and aligned in Sequencher 
(v4.9 - http://www.genecodes.com) 
62D ";-,1,5)
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All cells were grown in 2X LB broth. This consisted 20g/L of LB-Broth-Lennox 
10g/L peptone and 5g/l yeast extract. 15g/L agar was added for pouring 
plates. 
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E. coli DH5-alpha (Stratagene, UK) were streaked from a glycerol stock onto 
a LB agar plate and incubated at 37˚C overnight. A starter culture of 10ml LB 
without a selection antibiotic was then inoculated with a single colony and 
incubated overnight at 37˚C with shaking at 220rpm. 100ml of LB media was 
then inoculated with 1ml of starter culture and grown at 37˚C with vigorous 
shaking to an OD600 of 0.6. Cells were harvested by chilling the culture flask 
on ice for 10 mins and then pelleting the cells by centrifugation in a pre-chilled 
rotor at 6000rpm for 10mins. Cells were resuspended in 25mls of ice cold 
sterile 100mM CaCl2 and incubated for 20 mins followed by centrifugation as 
above. The cells were then centrifuged as above and resuspended with 5ml of 
100mM CaCl2. 1ml of cold 100% glycerol was added. 100µl aliquots of 
competent cells were snap frozen in liquid nitrogen and stored at -70˚C. Prior 
to use the cells were tested to ensure a transformation efficiency of 107cfu / 
1µg DNA. 
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A 100µl aliquot of E. coli DH5-alpha cells were defrosted on ice for 15 
minutes. 2µl of the DNA was added and allowed to incubate for 15 minutes on 
ice. The cells were briefly heated to 42˚C for 45 seconds, and then returned to 
ice. The cells were then agitated at 220rpm for 1 hour. The cells were 
pelleted, and spread onto agar plates made with the relevant selective 
antibiotic, and incubated at 37˚C overnight.  
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A single colony of E. coli DH5 Alpha was picked from selective agar plates 
and used to inoculate 5ml of LB media plus the appropriate selective 
antibiotic. The E. coli were cultured overnight at 37˚C, 220rpm. A 1ml aliquot 
of the overnight culture was taken to make glycerol stocks and the remaining 
4ml pelleted by centrifugation at 2100g (RCF) for 15 mins at 21˚C. Plasmid 
DNA was purified from the E.coli based on a modified alkaline lysis protocol 
using QIAprep Spin Miniprep Kits (Qiagen) as per the manufacturer’s 
instructions for high-copy recombinant plasmids.  
In summary, bacteria cells were lysed in Buffer P2 which contains NaOH-
SDS. The cell lysate was then neutralised by the addition of Buffer N3. The 
high salt concentration of Buffer N3 precipitates cellular debris, enabling 
separation of the plasmid DNA which remains in solution by centrifugation. 
The plasmid DNA was then selectively adsorbed to the silica-gel membrane of 
the QIAprep column. The DNA was washed with Buffer PB and then Buffer 
PE to remove endonucleases and salts respectively.  Purified plasmid DNA 
was eluted in 100 µl of Buffer EB and stored at -20˚C. 
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1ml of a 5ml overnight bacterial culture was transferred to a microfuge tube 
and centrifuged at 13000rpm for 1min at room temp. The supernatant was 
discarded and the pellet resuspended in 0.5ml of 30% LB Glycerol. Glycerol 
stocks were stored at -80˚C. 
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Restriction enzymes (Promega, UK) were used with the buffer supplied in 
single digests. The most compatible buffer for all enzymes was selected for 
double digests. 0.2µg of DNA was combined with 2µg Acetylated BSA, 10X 
RE Buffer to a final concentration of 1X and 5U restriction enzyme. 
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Where a restriction digest requiring two enzymes was necessary, and could 
be achieved using the same buffer, 5U of each enzyme were combined in a 
single reaction. 
For all restriction digests, samples were incubated at the specified 
temperature for 3 hours before being resolved on an agarose gel. 
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DNA of vector and insert carrying restriction enzyme sites were subject to 
restriction digestion, and the products subject to agarose gel electrophoresis. 
The bands of interest were cut out from the gel, purified, and ligated in 
different ratios of vector to insert using a T4 DNA ligase (Fermentas). The 
ligation product was then used to transform competent cells, which were 
plated on antibiotic selective agar plates. Colonies were picked after a 16 hour 
incubation at 37°C, and cultured in selective LB media for 12-16 hours. DNA 
was extracted using the QIAGEN Miniprep kit, and subject to restriction 
digestion so as to cut the intended insert out of the vector to verify a 
successful ligation. Successful ligations were subject to DNA sequencing to 
ensure there were no mutations in the insert. Once sequence verified, the 
ligated product was amplified in E.coli, extracted using a QIAGEN Maxiprep 
kit and then used for experiments. 
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CYLD was amplified using a proofreading Taq polymerase, incorporating 
restriction sites SpeI and AgeI, from pOTB7, obtained from the MGC clone 
library (MGC:19923; Geneservice, Cambridge). This product was TA-cloned 
into pCR2.1-TOPO (Invitrogen, UK kit K4500), and cut out using BamHI and 
XhoI. None of these 4 sites were found within the CYLD cDNA. pLEX MCS, a 
lentiviral vector with a multiple cloning site incorporating unique restriction 
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sites BamHI and XhoI was amplified in DH5alpha E.coli cells (Figure 9). 
 
Figure 9 pLEX-MCS vector. 
Both DNA products were cut with the restriction enzymes, before being 
purified on an agarose gel. 
 
Figure 10 Multiple cloning site within pLEX-MCS. 
DNA products were extracted from the agarose gel, and then the two products 
were ligated using a T4 DNA Ligase. To enrich for vectors that contained the 
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CYLD insert, a restriction digest was performed with NotI, which lay between 
the BamHI and XhoI sites on the pLEX-MCS vector (Figure 10). The cut 
product was then transformed in competent cells, plated on selective agar and 
colonies were picked the next day. These colonies were allowed to grow for 6 
hours in 200 µl of LB in a 96 well plate at 37°C on a shaker at 200 rpm. The 
cells were pelleted following centrifugation at 500 rcf for 5 mins at room 
temperature before sterile tips were dipped into the pellets and transferred 
into a 96 well plate for PCR screening. The recipient plate contained a PCR 
mastermix, with 10 µl per well, containing primers that amplified exons 16-18 
of CYLD (5’-3’: CYLD 16F =TCTGTTGTTCTGACTATCCA, CYLD 18R –
TAAACAGAAAAGGCAAAAGC). This plate was then inserted into a 96 well 
thermal cycler, and following the PCR reaction, the products were run on an 
agarose gel. Colonies containing the CYLD insert were selected, and placed 
in selective LB (5mls) overnight. The extracted DNA was then subject to 
digestion with BamHI and XhoI to cut CYLD back out. Once confirmed, the 
pLEX-CYLD product was sequenced to verify the sequence and orientation of 
CYLD. This was then amplified in DH5 alpha cells, and used for lentiviral 
transfection of cylindroma primary cell cultures.  
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The following shRNA constructs were used for lentiviral mediated knockdown 
of the indicated genes in cylindroma primary cells, and were purchased from 
Openbiosystems (Thermo Scientific, UK). DKK2: V2LHS_198410 NM_014421 
shRNAmir Hs Lentiviral pGIPZ RHS4430-98512097,V2LHS_214426 
NM_014421 shRNAmir Hs Lentiviral pGIPZ RHS4430-98853869;  NTRK2: 
V2LHS_63731 NM_001007097 shRNAmir Hs Lentiviral pGIPZ RHS4430-
98842290, V2LHS_63734 NM_001018064 shRNAmir Hs, Lentiviral pGIPZ 
RHS4430-99159070; NTRK3: V2LHS_152393 NM_001012338 shRNAmir Hs 
Lentiviral pGIPZ RHS4430-98911610. For overexpression, pLEX-CYLD, 
generated as described, was used.  
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Figure 11 pGIPZ lentiviral vector. 
Vector Element Function 
CMV Promoter RNA Polymerase II promoter 
cPPT Central Polypurine tract helps translocation into the nucleus of non-
dividing cells 
WRE Enhances the stability and translation of transcript c, 
TurboGFP Marker to track shRNAmir expression 
IRES-puro 
resistance 
Mammalian selectable marker 
Amp resistance Ampicillin (carbenicillin) bacterial selectable marker 
5'LTR 5' long terminal repeat 
pUC ori High copy replication and maintenance of plasmid in E. coli 
SIN-LTR 3' Self inactivating long terminal repeat  
RRE Rev response element 
Zeo resistance Bacterial selectable marker 
Figure 12 Features of the pGIPZ vector. 
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Lentiviral vectors were used to deliver shRNA-targeting genes of interest to 
primary cells. To monitor transfection efficiency and allow for selection, the 
shRNA was linked via a bicistronic internal ribosomal entry site to both GFP 
and puromycin resistance genes. All work with lentiviral vectors and products 
were carried out in a Biosafety level 3 hood, under permission from the Health 
and Safety Executive. Lentiviral vectors were packaged using a mix obtained 
from Openbiosystems, containing the genes required to form the viral 
particles on 5 different vectors. A lipsomal transfection technique was used to 
transfect HEK-293T cells with a specified ratio of packaging mix vectors to the 
lentiviral vector carrying the shRNA. These cells were then grown for 48 
hours, before the supernatant containing the viral particles was extracted. 
Polybrene (SIGMA, UK) was added to the culture medium (final concentration 
4µg/ml) to optimize transfection efficiency and the packaged vectors were 
stored at - 80°C until use. 
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All samples for microarray studies were snap frozen immediately after 
surgery. Tumour blocks were mounted in optimal cutting temperature 
compound and sectioned on a cryostat at 12 µm onto RNAse free Superfrost 
coated slides (VWR). All subsequent steps were performed in RNAse free 
solutions. Tissue sections were fixed in 100% ethanol at -20°C for 2 minutes 
and then washed in 70% DEPC treated ethanol and 50% DEPC treated 
ethanol for 2 further minutes. Sections were stained with crystal violet solution 
(Ambion, UK) for 40 seconds and then dehydrated in increasing 
concentrations of ethanol. Slides were then stored on dry ice until needle 
microdissection was performed. Microdissection was performed at 4°C using 
a Leica dissecting microscope. The dissected samples were placed directly 
into Trizol ® (Invitrogen, UK). Needle homogenisation was performed and the 
sample was frozen at -80°C until RNA and DNA extraction was performed.   
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The 32K BAC re-array collection (CHORI) tiling path aCGH platform was 
constructed at the Breakthrough Breast Cancer Research Centre, as 
described elsewhere (Marchio, Natrajan et al. 2008). This type of BAC array 
platform has been shown to be as robust as and to have comparable 
resolution with high- density oligonucleotide arrays. DNA labelling, array 
hybridisations and image acquisition were performed as described earlier 
(Turner, Lambros et al. 2010). aCGH data were pre-processed and analysed 
using an in-house R script (BACE.R) in R version 2.9.0 as previously 
described (Natrajan, Weigelt et al. 2009). After filtering polymorphic BACs, a 
final data set of 31544 clones with unambiguous mapping information 
according to the August 2009 build (hg19) of the human genome 
(http://www.ensembl.org) was smoothed using the circular binary 
segmentation (cbs) algorithm (Natrajan, Weigelt et al. 2009). A categorical 
analysis was applied to the BACs after classifying them as representing 
amplification (>0.45), gain (>0.08 and <0.44), loss (< -0.08 and >-0.44), 
deletion (<-0.45) or no-change according to their cbs-smoothed Log2 ratio 
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values. aCGH data were deposited at ROCK 
(http://brcabase.icr.ac.uk/index.jsp), at URL: 
http://rock.icr.ac.uk/collaborations/Rajan/Cylindroma. 
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Genomic DNA was extracted from microdissected tissue and assayed on an 
Illumina Sentrix Human Hap550 Genotyping BeadChip according to 
manufacturer’s protocol. SNP array data were deposited at ROCK 
(http://brcabase.icr.ac.uk/index.jsp) , at URL: 
http://rock.icr.ac.uk/collaborations/Rajan/Cylindroma. 
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Polymerase chain reaction (PCR) was performed using primers (5’-3)’ 
CYLD18F –GAGAGCTTAAGCAGATGGAA and CYLD 18R –
TAAACAGAAAAGGCAAAAGC that flanked exon 18, and the PCR product 
was subject to restriction enzyme digestion using HpyCH4V (c.2460delc) and 
Sml I (c.2469+1G>A). Digested products were separated on an agarose gel 
and visualised using ethidium bromide on an ultraviolet transilluminator. LOH 
was determined by the absence of a band that corresponded with loss of the 
wild-type allele in both cases.  
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The Illumina WG-DASL platform was used for each sample that allowed for 
monitoring of gene expression of 24,526 transcripts. This assay was selected 
as it was designed to reliably detect expression levels of partially degraded 
transcripts. Despite attempts to use fresh frozen microdissected tissue, the 
mean RIN of the RNA samples used was 2.3, warranting the use of this 
platform. 50ng of total RNA from each sample was used as per the supplied 
protocol. Briefly, total RNA was converted to cDNA using biotinylated oligo-
dT18 and random nonamer primers. Two assay-specific oligonucleotides 
were designed to interrogate a single contiguous 50 nt sequence on each 
cDNA. Each of these oligonucleotides consisted of two parts: an upstream-
specific oligonucleotide (USO) containing a 3” gene- specific sequence and a 
5” universal PCR primer sequence (P1), while the downstream-specific 
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oligonucleotide (DSO) contained a 5’ gene-specific sequence and a different 
3’ universal PCR primer sequence. The USOs and DSOs were designed with 
an average Tm of 65°C and 58°C, respectively and an average length of 22 
and 20 nucleotides, respectively. Using this approach, a total of 24526 
oligonucleotide pairs (probes) were designed and pooled, which together 
constituted the whole genome DASL assay pool (DAP), corresponding to 
18626 unique genes, based on well-annotated content derived from the 
National Center for Biotechnology Information Reference Sequence Database 
(Build 36.2, Release 22)). The DAP was then annealed to the targeted cDNAs 
during a 16h incubation followed by enzymatic extension and ligation steps. 
Ligated products were PCR-amplified and labeled with a universal Cy3-
coupled primer after which single-stranded labeled products were precipitated 
and then hybridized to whole genome gene expression BeadChips (Illumina 
Human 8 v3 chips). BeadChips were then scanned on a BeadArrayTM 
Reader using BeadScan software (v3.2), during which fluorescence intensities 
were read and images extracted. Scanned data were then extracted using 
Illumina Beadstudio software. Microarray gene expression profiles were 
deposited at Arrayexpress (www.ebi.ac.uk) at accession number E-MTAB-
352. 
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Raw gene expression values were normalised using quantile normalisation. 
Differential expression analysis was performed using Beadstudio software to 
detect significantly different expressed genes. Differences in signal values for 
each gene was scored with a differential score (DS). Bonferroni testing was 
performed to correct for multiple hypothesis testing, and the results were 
ranked in order of differential score with a differential score ranging from +374 
to -374, with +/-65 corresponding to a p value cut off of <0.01. Signal values 
from genes that fulfilled this level of significance were then analysed. 
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Differentially expressed genes between CYLD defective tumours and 
perilesional control skin at a significance threshold of p<0.01 after correction 
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for multiple hypothesis testing using a Bonferroni post test correction were 
used for Ingenuity pathway analysis. 
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Analysis was carried out using gene set expression analysis (GSEA). For this 
analysis, probe values (24526) were collapsed to gene symbols (18630), with 
the max probe value used for replicate probes. All tumours were compared to 
all controls. After filtering, 867 gene sets were used in the analysis. Gene sets 
were permutated 1000 times, before being ranked in order using a “difference 
of classes” metric, with a weighted enrichment statistic applied. 56 gene sets 
were significantly enriched at a nominal p-value of <0.01. 
#">"U J*135,%1&-0(%88%5((
Genomic DNA from the samples used for microarray analysis were assayed 
for methylation of the DKK2 promoter using a quantitative PCR based assay 
(SA Biosciences, Qiagen UK). Samples were divided into 4 equal portions 
that were subject to restriction enzyme digestion with:  a) controls without 
enzymes b) methylation sensitive enzymes c) methylation resistant enzymes 
d) methylation sensitive and resistant enzymes combined. Following a 16 
hour period of digestion at 37°C, the samples were subject to quantitative 
PCR amplification with proprietary primers that amplified the promoter of 
DKK2. SYBR green was used to determine the amount of amplified DNA and 
the reaction was performed on ABI 7900HT machine.  Ct values were 
obtained from all 4 separate reactions for each sample and used in 
accordance with the manufacturers formula to determine promoter 
hypermethylation. 
(http://www.sabiosciences.com/support_manual.php?pfamily=dnamethylation) 
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All cell culture techniques were performed in vertical laminar flow cell culture 
hoods under sterile conditions. Culture media used is indicated in Table 5. 
Defined KSFM eliminated the requirement for bovine pituitary extract by 
inclusion of defined growth promoting additives including insulin, epidermal 
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growth factor and fibroblast growth factor. Cell lines were tested to exclude 
mycoplasma contamination. Standard tissue culture plastic was used (Iwaki 
UK), and this was coated with Type I collagen (Coating Matrix Kit R-011-K; 
Invitrogen, UK) at a concentration of 0.66 µl/cm2 where indicated. 
Table 5 Mammalian cell line cell culture media requirements. 
(All items are from Invitrogen, UK; Product numbers are shown in brackets) 
Tissue transport medium Cylindroma primary cell 
cultures 
293HEK-T cells, Fibroblast 
culture medium 
100ml Ham’s F-10 (22390-
017) 
500ml KSFM with 
supplement (10744-500) 
500ml DMEM 1x High 
Glucose (21969-500)   
25ml FBS (10100-139) 1ml Penicillin/Streptomycin 
(10,000:10,000) (15140-163) 
50ml FBS (10100-139) 
2ml Penicillin/Streptomycin 
(10,000:10,000) (15140-163) 
5ml L-Glutamine (25030-024) 5ml Penicillin/Streptomycin 
(10,000:10,000) (15140-163) 
1ml L-Glutamine (25030-024) 0.2ml Fungizone (15290-
018) 
5ml L-Glutamine (25030-024) 
1ml Fungizone (15290-018)  1ml Fungizone (15290-018)   
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Cell lines were thawed rapidly by placing the vial containing a 1ml aliquot of 
cells, which had been frozen down in FBS and DMSO into a 37˚C water bath. 
The cells were then gently resuspended in appropriate medium, centrifuged, 
and the subsequent pellet resuspended in fresh medium to remove the 
DMSO. Cells were plated onto standard tissue culture flasks. The cells were 
then incubated in a 5% CO2 incubator at 37˚C until almost confluent (usually 2 
-3 days). Media was changed after 72 hours if the cells were not yet 
sufficiently confluent to passage. 
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Cells were passaged every two to three days depending on how rapidly cells 
reached confluency. The existing culture media was aspirated off and the 
cells washed once with sterile PBS (Gibco). 4ml of sterile trypsin 0.5% (Gibco) 
was then added to each 75cm2 cell culture flask, and the cells incubated for 5 
– 15 mins at 37˚C in 5% CO2 or until they had started to detach. The culture 
flask was then tapped sharply to dislodge any adherent cells or cell clumps. 
Cell concentration was determined using a haemocytometer to count the 
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number of cells/cm3. Cells were then seeded into at a concentration 
appropriate to the size of the tissue culture vessel used. Where appropriate, 
an aliquot was frozen and stored in cryotubes at each passage using FBS and 
DMSO (9:1) as freezing medium. 
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Perilesional dermis was dissected under a stereo microscope and cut into 
small pieces, before being cultured in 6 well tissue culture flasks. After 7-14 
days, fibroblast cell cultures were established and passaged . 
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Polystyrene tissue culture scaffolds were obtained from Reinnervate, UK. 
Scaffolds were rehydrated using graded ethanols, and then washed in PBS 
twice. Scaffolds were then coated with Type I collagen (Invitrogen, UK) before 
being washed in KSFM once. 1.5 – 3 million cylindroma primary cells were 
plated onto the scaffold in 250 µl of media, and placed in the incubator for 30 
minutes. After this period media was gently added, and then changed every 
two days.  
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Cells were grown to 40- 60 % confluence in 6 well dishes in a 5% CO2 
incubator at 37˚C for two days. The culture media was then removed, the cells 
washed once with PBS and fixed in 4% PFA for 10minutes at room 
temperature or methanol at –20˚C (20 – 60 minutes). Fixed cells were washed 
twice with PBS and used immediately. 
Fixed cells were washed in PBS and then blocked with 2% Normal Goat 
serum. Cells were incubated in the primary antibody solution for at least 1-2 
hours at room temperature. After three 10 minute washes with TBST at room 
temperature, the cells were incubated with fluorescent secondary antibodies 
mixed with TBST, in the dark for 30 - 60 mins. DAPI was used as a nuclear 
counterstain. 
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Table 6 Antibodies used for immunocytochemistry. 
Primary Antibody Concentration of 
primary Ab 
Secondary antibody Concentration of 
2˚ 
CYLD 
(Ashworth) 
  
1:200 Anti rat FITC 
(Jackson) 
1:200 
CK14 1:200 Anti mouse FITC 
(Jackson) 
1:200 
CK17 1:200 Anti mouse FITC 
(Jackson) 
1:200 
CK6 1:200 Anti mouse FITC 
(Jackson) 
1:200 
SMA 1:200 Anti rabbit FITC 
(Jackson) 
1:200 
No primary antibody was added to negative control cells, and each primary 
antibody was tested with both secondaries to exclude any non-specific cross 
reaction between antibodies. Finally, the cells were washed three times with 
TBST before carefully removing the chamber and seals from the slide. The 
cells were then mounted with a cover slip using Vectashield containing DAPI 
(Vector laboratories, UK). Images were captured with a UV Zeiss Axioimager 
microscope (Zeiss, Germany) 
#"I"I L'&/%'5(4*,,(1'%087*41&-0(
Cells were grown to 50% confluence, and transfected with lentiviral particles 
in culture medium for 24 hours. Lentiviral transfection was performed with 
shRNA against TRKB, TRKC and DKK2 and compared to a non-silencing 
control (Openbiosystems, Thermo Scientific, UK). At this point media was 
replaced with KSFM, and cells grown for a further 48 hours. Transfection 
efficiency was found to be 80-100%, indicated by GFP positivity. Cells were 
then grown in puromycin selective media (4 µg /ml) for a further 72 hours, till 
all cells were GFP positive. Cells were maintained in KSFM for experiments, 
and monitored for maintenance of transfection using a UV microscope for 
GFP positivity.  
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Cell viability was assessed using a luminescent assay that generated a 
luminescent signal in proportion to the amount of ATP present (CellTiter-Glo, 
Promega, UK). The amount of ATP is directly proportional to the number of 
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cells present in culture. 4000 cells were plated out per well in a 96 well format 
in white tissue culture plastic plates with clear bases. After 96 hours, the 
luminescence was read using a Luminoskan plate reader (Thermo Scientific, 
UK). Luminescence was measured as luminescent units (RLU) and was 
tabulated in a spreadsheet. No cell controls were included to determine 
background luminescence. All conditions were performed in triplicate and 
experiments were repeated at least three times. Data was then normalised in 
Prism v5.0 (Graphpad, USA), with the mean value of 3 replicates of the 
control cells representing 100%, and 0 assigned as 0%. To minimize edge 
effects, only the central 60 wells were used, with remaining filled with PBS, as 
well as the inter well spaces. 
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3D tissue culture scaffolds that were 4 weeks old were used. 2mm discs of 
the scaffold were punched out and placed in 96 well plates. Cells were grown 
for two weeks in triplicate in drug dilute in KSFM, with complete exchanges of 
drug and media every 48 hours. CellTiter-Glo was then added and 
luminescence was measured.  
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Cells were grown on 3D tissue culture scaffolds for 28 days, before being 
harvested and transferred to a 96 well format. Cells were grown in the 
following inhibitors, diluted in DMSO, with a final concentration of DMSO at 
0.1%: K252a and Tyrphostin AG879, Salicylic acid (Sigma, UK), Lestaurtinib 
(Toronto Research Chemicals). Cells were maintained for 14 days, with 
exchanges performed every 2 days. The final concentration of DMSO was no 
greater than 0.1%, and this was used in drug free controls. 
#"I"![ <-,-05(7-'/&0=(%88%5(
4000 transfected cells were plated per well in a 6 well tissue culture plate, 
coated with Type I collagen. Cells were grown 10- 14 days for the colony 
formation assay. Cells were fixed in 3.3% tricholoracetic acid, washed once 
and stained with 0.57% sulphorhodamine in 1% acetic acid for 30 mins. Cells 
were then washed in 1% acetic acid, dried and then scanned on a slide 
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scanner at 400% original size at 400 dpi. Images of the 6 well plates were 
then thresholded using Image J software (NIH – v1.64) and then colony 
counts and total cell area was determined. Data was then normalised in Prism 
v5.0 (Graphpad, USA), with the mean value of 3 replicates of the control cells 
representing 100%, and 0 assigned as 0%.  
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Cells were trypsinised, resuspended in PBS and fixed by adding ice cold 
ethanol whilst gently vortexing the tube, until a final concentration of 70% 
ethanol was reached.  Cells were fixed for 1 hour at 4° C. Cells were then 
pelleted and resuspended in Cystain Solution (Partech, UK) which stained the 
nuclear DNA with DAPI. Cells were stained for 1 hour in the dark at 4° C, 
before analysis on a FACS Canto II flow cytometer (Becton Dickson, UK) 
using a UV laser. Cells were analysed for total DNA content and a minimum 
of 10000 events were used for cell cycle data. All cell cycle data was analysed 
using Modfit (Verity Software House, USA) 
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12000 transfected cells were plated in a collagen coated 12 well plate and 
grown to confluence. A linear scratch was made with a P10 pippette tip in the 
centre of the well. Cells were then maintained for 96 hours in media with 2.5% 
serum, to minimise the effects of proliferation on scratch closure. 5 fixed fields 
of view per scratch were photographed using a Nikon Biostation cell culture 
and imaging facility, and each condition was repeated in triplicate. 
Photographs were analysed in Image J (NIH – v1.64) and the size of the 
scratch remaining at 12 hour intervals was made. The experiment was 
repeated three times. 
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A 96 well tissue culture plate with clear-bottomed wells (Nun) was prepared 
such that half the wells were coated with Type I collagen (Invitrogen, UK) and 
the other half with poly-HEMA. Poly-HEMA was dissolved in 95% ethanol to a 
concentration of 50 mg/ml. Poly-HEMA was added to cell culture wells at a 
density of 5 mg/cm2 and allowed to dry overnight, under sterile conditions in a 
laminar flow hood. 4000 transfected cells were plated per well in triplicate in 
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both conditions. After 96 hours, cell viability was measured using a 
luminescent assay (CellTiter-Glo, Promega, UK) in all wells, and the ratio of 
wells where cells were forced to grow in suspension was compared to the 
matched triplicate where they were allowed to grow in adherence. The 
proportion of surviving cells was compared across different gene knockdown 
conditions.  
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4000 cells were plated in a 96 well format. The following day, TNF alpha was 
added at a concentration of 50 ng/ml, and cells were maintained for 4 hours. 
A luminescent assay that served as a readout of cleaved caspase 3 was 
used. This assay lysed cells, and released a luminescent signal in proportion 
to the available amount of cleaved caspase 3 (ApoGLO, Promega UK) 
62H +KKOPQ3AQNN+PE)
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Cells were lysed in order to investigate expression of different receptors 
present on the cell surface or intracellular signalling molecules by western 
blotting. Cells were detached from the flask using Trypsin-EDTA and 
centrifuged in complete media. The pelleted cells were then resuspended in 1 
ml ice cold sterile 1X PBS and centrifuged at 2,000 x g for five minutes at 4°C 
in a table top micro centrifuge. The pelleted cells were then resuspended in 
Lysis buffer ((65mM Tris ph7.5, 50mM NaCl, 5mM EDTA, 2% TritonX, 1% 
NP40, 0.5% Na deoxycholate, 1mM PMSF, 1mM Na Orthovanadate, 0.1% 
SDS), incubated on ice for 15 minutes then recentrifuged at 16 000 x g for 10 
minutes at 4°C. Complete protease and phosphatase inhibitor cocktail tablets 
(Roche, UK) were used when making the lysis buffer. 
The cells were lysed in buffer at a ratio of 40 µl lysis buffer per 50,000 cells. 
The supernatant was then removed and protein concentration determined 
using the BCA protein assay (Pierce, UK).  
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An aliquot of cell lysates were diluted to 1:20 dilution with distilled water, and 
added in a ratio of 1:8 to the prepared BCA assay solution (working reagent), 
made in accordance to the manufacturer’s directions. Typically, 200µl of 
working reagent was added to 25µl of the diluted sample in a 96 well 
microplate. Duplicate wells were used for each sample. An albumin standard 
supplied with the kit was serially diluted with water and a constant proportion 
of lysis buffer and was included on the plate. The samples were then 
incubated at 37°C for 30 minutes, before absorbance at 562nm was 
determined using a plate reader. A standard curve was derived from the mean 
of the duplicate samples, and protein concentrations were interpolated using 
Prism software (v 5.0, Graphpad) , after curve fitting had been applied. The 
values were then corrected for the dilution factor and the protein concentration 
was normalised across samples for comparative analysis using SDS-PAGE 
and Western blotting. 
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Proteins were resolved using 8, 12, 15% acrylamide gels and BioRad 
mini-Protean apparatus. Stacking and resolving gels were made up as 
detailed Table 7. The appropriate percentage resolving gel was prepared, with 
the addition of N,N,N',N’-Tetramethylethylenediamine (Temed) and 
ammonium persulphate facilitating the polymerisation of the acrylamide. 
Before the gel had set it was poured into the apparatus to a level below that at 
which the gel comb sits. It was overlaid with isopropanol until set, which was 
then removed, and the stacking gel added. The gel comb was then inserted 
into the stacking gel so that when set, wells for sample loading were present.  
Table 7 Components of hand-cast polyacrylamide gels. 
Component Stacking gel 8% gel 12% gel 15% gel 
Acrylamide (30%) 4% 8% 12% 15% 
Tris 0.125M pH6.8 0.375M pH8.8 0.375 MpH8.8 0.375M pH8.8 
SDS 1 % (v/v) 1 % (v/v) 1 % (v/v) 1 % (v/v) 
Temed 0.05% (v/v) 0.05% (v/v) 0.05% (v/v) 0.05% (v/v) 
Ammonium Persulphate 0. 1 % (v/v) 0. 1 % (v/v) 0. 1 % (v/v) 0. 1 % (v/v) 
Total volume 10 mls 10 mls 10 mls 10 mls 
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Protein samples were prepared for SDS-PAGE with addition of one quarter 
volume of 5X SDS-PAGE Laemmli buffer (50 mM Tris pH 6.8, 100 mM DTT 
, 2% (v/v) SDS, 10% (v/v) glycerol, 0.1% bromophenol blue, 
beta-mercaptoethanol (BME)) (Laemmli, 1970), boiled for five minutes and 
loaded onto a gel. This buffer and boiling causes the protein to reduce and 
denature as well as becoming coated with SDS, which generates a negative 
charge relative to the size of the protein. The negative charge then allows the 
protein to migrate towards the positive electrode. Molecular weight standards 
(Amersham GE) were run simultaneously to allow molecular weight 
characterisation of samples. Gels were run in SDS running buffer (192 mM 
glycine, 25 mM Tris, 0.1% (v/v) SDS) at 80-120V for approximately 45 
minutes or until the dye reached the bottom of the gel. 
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Western blotting (wet blot method) was performed in order to specifically 
detect and visualise bands of protein using specific antibodies. SDS-PAGE 
gels were run as detailed in section 2.6. 1. Proteins were then blotted onto 
Immobilon P, 0.45 µm transfer membrane (Millipore). This membrane was pre 
washed with 100% methanol for five minutes, rinsed with ddH20 for one 
minute before being equilibrated in transfer buffer (192 mM glycine, 25 mM 
Tris, 20% (v/v) methanol) for five minutes before assembly of the blotting 
apparatus. The transfer buffer was chilled at 4°C for at least one hour before 
use. 
Separated proteins were transferred using a BioRad mini-trans blot apparatus 
for one hour at 100 V. Constant cooling was applied to the blotting system 
throughout the hour through use of ice blocks and wet ice packing around the 
blotting apparatus. Following blotting, the membrane was transferred to 
blocking buffer (Tris buffered saline with Tween-20 (TBST) (50 mM Tris pH 
7.4, 200 mM NACI, 0.1% (v/v) Tween-20 and 5% (w/v) dried non-fat milk 
(Marvel)) and incubated overnight at 4°C. Primary antibody was diluted, 
according to manufacturer's recommendations, in appropriate blocking buffer 
and applied to the blot in a sealed bag with end over end rotation for one hour 
at RT (Table 8). The blot was then washed with wash buffer TBS-T for three, 
10 minute washes. The secondary antibody was then added, once again 
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being appropriately diluted in relevant blocking buffer, and rotated for one 
hour. The blotted membrane was then washed as previously described. 
Bands were visualised using enhanced chemiluminesence plus (ECL-PLUS) 
reagents (Amersham). For western blotting with ECL visualisation, 
horseradish peroxidase (HRP) conjugated secondary antibodies were used.  
Table 8 Antibodies used for immunoblotting. 
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ECL is achieved through the oxidation of luminol by HRP in the presence of 
chemical enhancers. The blotted membrane was submerged in an equal 
volRPN2132) for one minute. The membrane was then covered with Saran 
wrap and exposed to Kodak Biomax MR auto radiographic film. Exposure 
time varied between 10 seconds and 30 minutes depending on signal 
strength, with overnight exposures also performed if the signal was 
particularly weak. 
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Blotted membranes were occasionally stripped for re-probing with different 
antibodies, therefore making use of the same blotted samples more than 
once. Stripping was achieved by three 10 minute washes in stripping buffer, 
(65 mM Tris pH 8.0, 92 mM BME and 2% (v/v) SDS), which was pre warmed 
to 50'C in a water bath. The blot was then thoroughly rinsed with 1x PBS and 
stored in 1x PBS at 4°C until being re-probed. Storage of stripped blots did 
Primary Ab Species primary Ab raised in 
Concentration of 
primary Ab Secondary antibody 
CYLD 
(Ashworth) 
Rat 1:250 Donkey anti-rat HRP 
(Jackson) 1:2000  
B-actin (Santa 
Cruz) 
Mouse 
monoclonal 
1:20000 Sheep anti-mouse HRP 
(Amersham) 1:2000 
BCL2 
(Cell Signalling) 
Rabbit 1:1000 Donkey anti-rabbit HRP 
(Amersham) 1:2000 
TRKB 
(Cell Signalling) 
Rabbit 1:1000 Donkey anti-rabbit HRP 
(Amersham) 1:2000 
TRKC 
(Cell Signalling) 
Rabbit 1:1000 Donkey anti-rabbit HRP 
(Amersham) 1:2000 
DKK2 
(Santa Cruz) 
Rabbit 1:1000 Donkey anti-rabbit HRP 
(Amersham) 1:2000 
phosphoERK 
(Cell Signalling) 
Rabbit 1:1000 Donkey anti-rabbit HRP 
(Amersham) 1:2000 
ERK 
(Cell Signalling) 
Rabbit 1:1000 Donkey anti-rabbit HRP 
(Amersham) 1:2000 
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not exceed two days. Following storage, the membranes were re-blocked 
either overnight at 4°C or for two hours at RT with constant agitation. Probing 
was then carried out as previously described. 
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Heterozygous germline mutations within the CYLD gene locus have been 
identified as the cause of three clinically distinct dermatological phenotypes: 
FC, BSS and MFT (Bignell, Warren et al. 2000; Young, Kellermayer et al. 
2006; Saggar, Chernoff et al. 2008). These conditions are unified by a 
predisposition to develop cylindromas. Although rare in the population, these 
disorders are associated with a high level of morbidity, which can impact 
greatly on the quality of life of the affected individual.  
Cylindromas are purported to arise from hair follicle stem cells (Massoumi, 
Podda et al. 2006), a model supported by the numerous tumours seen on hair 
bearing sites. Ultraviolet radiation (UVR) has been suggested as the major 
predisposing factor for loss of heterozygosity (LOH) and tumour initiation 
(Massoumi 2006), based on the presence of face and scalp tumours. 
However, careful clinical mapping of the distribution of the tumours does not 
exist to support this hypothesis.  
Transgenic CYLD knockout mouse models have been derived, which may 
help inform clinical phenotypes associated with germline CYLD mutations. 
The phenotypes seen in CYLD null mice include: an increased sensitivity to 
cutaneous squamous papilloma formation (Massoumi 2006); immunological 
defects involving T-cell maturation (Reiley, Zhang et al. 2006) and B-cell 
responses (Jin, Reiley et al. 2007); an increased predisposition to inducible 
colitis and colorectal tumour formation (Zhang, Stirling et al. 2006); and a 
protective effect against lethal S. Pneumoniae infections (Lim, Stirling et al. 
2007). Altered immunity and susceptibility to cancer is yet to be clarified in 
humans. 
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Previous work (Table 9) investigating clinical phenotypes across multiple 
families has shown little phenotype-genotype correlation with regard to the 
position of a germline CYLD mutation and the tumours types seen in each 
family (Young, Kellermayer et al. 2006). We were interested in examining 
clinical phenotypes, tumour distribution, and the burden of disease associated 
with the diagnosis of germline CYLD mutations in two large multigenerational 
families. This information is a prerequisite for future accurate genetic 
counselling for individuals from such families.  
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The pedigrees of two families are shown in Figure 13.  They both demonstrate 
an autosomal dominant pattern of inheritance across 7 generations in family A 
with 34 out of 133 individuals being reported as affected, and 5 generations in 
family B with 16 out of 77 individuals being reported as affected. In total, 50 
members of both families out of 210 were reported as clinically affected, 27 
female and 23 male. This result is significantly less than would be expected 
with an autosomal dominant inheritance pattern and could be accounted for 
by either non penetrance of the mutation or a milder presentation of the 
condition which was under reported especially in the earlier generations. In 
particular, female IV-1 and male V-3 in family A, obligate carriers on family 
history for the CYLD mutation, were reported as unaffected. Neither of these 
patients were alive to confirm clinical status. 
To address the possibility of non-penetrance within these families, we 
undertook CYLD mutation analysis in all available living affected individuals 
and contacted non-affected individuals to offer them testing within both 
families. 9 members of family A, in whom a diagnosis of BSS and FC had 
been made, were shown to have the familial mutation by sequencing. 5 
unaffected members (age range 33-64) were shown not to have inherited the 
mutation. Family B were similarly examined, with 3 affected members with an 
FC phenotype, found to have the familial mutation and 3 unaffected members 
(age range 40-54) shown not to have the mutation. 
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Although numbers are small, we found no indication for non penetrance of 
either CYLD mutation. The unaffected obligate individuals present in this 
family most likely indicate a variation in CYLD mutation expression within 
family A. 
 
Figure 13 The pedigrees of family A (7 generations) and family B (5 generations).  
Patients who have had their scalps removed indicated with a star, and the obligate carriers indicated by 
a dot. 
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In our population, 5 female patients and 1 male patient developed severe 
scalp disease which necessitated entire scalp removal and repair with split 
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thickness skin grafts. The mean age for this was 55 (50-60) years. Patients 
who had undergone this procedure were all noted to have multiple tumours on 
the trunk and genital areas. Other markers of severity include use of wigs pre-
operatively (23%) and painful tumours (52%).  
Although there is the suggestion of clustering within the pedigree of 
individuals with a severe tumour burden, relatives of these patients were often 
noted to have only mild disease. These patients had a few tumours, that were 
only apparent on close inspection of the scalp. Conversely, one patient in 
family A (V-14), who had only three tumours on the face, fathered 4 children 
who each presented with more than 30 tumours on the face. In addition, 
unaffected obligate carrier V-3 had 9 affected progeny over three further 
generations, one of whom required total scalp removal. 
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In the course of analysis of another pedigree (Family C), we found a patient 
carrying germline mutations in CYLD that had milia as the only presenting 
feature (Figure 14). Milia are 1-2mm white papules in the skin that are thought 
to represent aborted hair follicles, and are a recognised feature of BSS.  
A 65-year-old woman developed a few 0.5-1 cm diameter scalp cylindromas 
and milia on the forehead from the age of 20. Her 44-year-old son 
demonstrated facial milia only (black arrows). Three other relatives were 
reported to have tumours; two had scalp lesions and one had facial papules, 
but were unavailable for examination (Figure 15). We identified a canonical 
splice acceptor site mutation preceding exon 20 (c.2687-2A>G) in the 
proband and her son, which was absent in unrelated controls. 
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Figure 14 Phenotype of the obligate carrier. 
65-year-old woman developed a few 0.5-1 cm diameter scalp cylindromas and milia on the forehead 
from the age of 20. Her 44-year-old son demonstrated facial milia only (black arrows).  
 
Figure 15 Pedigree with a genotyped obligate carrier. 
The patient with milia is indicated with a red arrow 
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Table 9 Review of series of published pedigrees and correlation with genotype.   
This table indicates: 1) The female preponderance described in the literature is based largely on small pedigrees, 2) 
The reported penetrance can vary between pedigrees 3) Where genotypes are available, there is no correlation with 
phenotype. 
 
)
Author Pedigree 
size 
Proportio
n Affected 
Affected 
Females 
Affected 
Males F:M ratio 
Clinical 
Diagnosis Genotype 
Gerretsen 237 13% 19/119 11/118 1.71 BSS NG 
Rajan 133 26% 18/66 16/67 1.14 FC, BSS, MFT 2460delC 
Welch 115 25% 15/51 14/64 1.34 BSS NG 
Rajan 77 21% 9/42 7/35 1.07 FC, MFT 2469+1G>A 
Welch 67 16% 9/41 2/26 2.85 BSS NG 
Zheng G 36 56% 10/19 10/17 0.89 MFT 2822A>T 
Saunders 32 25% 5/14 3/18  2.14 BSS NG 
Zhang G 29 31% 6/20 3/9 0.90 MFT 2272C>T 
Salhi 
29 45% 6/17 7/12 0.61 MFT 
 2104-
2105 ins 
C 
Young 24 46% 7/14 4/10 1.25 FC, MFT 2806 C>T 
Liang 
23 26% 4/10 2/13 2.60 MFT 
2241_22
42 del 
AG  
Liang 20 30% 2/12 4/8 0.33 MFT 1826+2T>G 
Hu 17 88% 7/8 8/9 0.98 MFT 2240A>G 
Zhang X 
15 60% 6/7 3/8 2.29 MFT 
2355-
2358 del 
CAGA, 
Burrows 14 29% 3/6 1/8 4.00 BSS NG 
Zheng G 14 79% 7/9 4/5 0.97 MFT 1462delA 
Zheng G 11 55% 5/9 1/2 1.11 MFT 2128C>T 
Burrows 9 44% 3/4 1/5 3.75 BSS NG 
Fenske 9 33% 2/5 1/4 1.60 FC, MFT NG 
Bumgardner 8 50% 3/4 1/4 3.00 BSS NG 
Poblitez-
Guirrrez 7 57% 3/4 1/3 2.25 BSS 
2253 del 
G 
Susanne 6 67% 1/3 3/3 0.33 FC NG 
Oiso 4 50% 1/2 1/2 1.00 FC 2272C>T 
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We have summarised the clinical and tumour data in Table 10. The average 
age of onset of tumour formation was 16 years (range 8 - 30), consistent with 
tumour initiation occurring after adrenarche. In both families, the commonest 
site for the presenting tumour was the scalp. The clinically diagnosed tumour 
phenotypes were supported by histology in 10/26 patients.  
 
Family A presented with classical scalp cylindromas, eccrine spiradenomas, 
trichoepitheliomas and milia. This wide variation in tumour type and clinical 
presentation in family A supported a clinical diagnosis of BSS within the 
majority of patients. However, some individuals with exclusively facial 
trichoepitheliomas, if seen in an isolated setting, would have been diagnosed 
with MFT.  
In contrast, family B presented almost exclusively with cylindromas, 
supporting a diagnosis of FC in the majority of these individuals. 
The detailed tumour distribution maps comprising in total 14 female and 12 
male from both families were combined to produce composite maps (Figure 
16).  From these maps, it is clear that the tumours extend beyond the head 
and neck, with the trunk being involved in 69% of patients. The tumour 
distribution forms a “V-shaped” distribution on the trunk with tumours being 
more concentrated in the midline. Noticeably, tumours are highly concentrated 
on the hair bearing pubic and genital areas, with a relative absence on other 
areas of the body such as lower legs and axillary skin. Tumours were not 
seen on hairless areas of the body such as the palms and soles.  
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Table 10 Summary of clinical findings in our patient dataset. 
 
!!!!!!Pt No. Mutation M/F Onset(Yrs) TumourType ClinicalDiag. Scalp Trunk Pubic Ear Wig Use Scalp Removed PainfulTumour
1 2460 F 25 Cy FC + + + + + + +
2 2460 F 12 Cy,Es, 
Te
BSS + + + + + + +
3 2460 F 15 Cy, 
Es, Te
BSS + + + + + + +
4 2460 F 9 Cy,Es, 
Te
BSS + + + + - - +
5 2460 F 8 Cy FC + + - - - - +
6 2460 F 15 Cy FC + + - - - - -
7 2460 F 25 Cy FC + - - - - - +
8 2460 F 12 Cy FC + + - - - - -
9 2460 F 11 Cy, Te, 
Mi
BSS + + + + - - +
10 2460 F 13 Te MFT - - - - - - -
11 2460 F 12 Te MFT - + - - - - -
12 2460 M 15 Te MFT - - - - - - -
13 2460 M 12 Cy, Es BSS + + + - - - +
14 2460 M 30 Cy,Es,
Mi
BSS + - - - - - +
15 2460 M 15 Cy,Te BSS + + - - - - -
16 2460 M NR Cy,Te BSS - - - - - - -
17 2460 M 15 Cy FC + + - - - - NR
18 2469 F 18 Cy FC + + + - + + +
19 2469 F 18 Cy, Es FC + + + - + + +
20 2469 F 23 Cy FC + + + + + - +
21 2469 M NR Cy FC + + + - NR + NR
22 2469 M 17 Cy FC + + - - - - -
23 2469 M 16 Te MFT - - - - - - -
24 2469 M NR Cy,Te FC + - - - - - NR
25 2469 M 18 Cy FC + + + + - - -
26 2469 M 15 Cy FC + - - - - - -
12M
14F
Avg
16
Total 
%
81% 69% 42% 27% 24% 23% 52%
Abbreviations: Cy- Cylindroma, Es - Eccrine Spiradenoma, Te- Trichoepithilioma, Mi - Milia, + Present, - Absent, 
2460 - Family 1 (2460 del C), 2469 - Family 2 ( 2469+1 G>A), NR - Not Recorded
TUMOUR LOCATION! ! MARKERS OF SEVERITY
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Figure 16 Tumor locations in 12 male and 14 female patients in the two families. 
In addition, although not depicted on the tumour maps, patients with 
advanced scalp tumours (Family A: VI-1; Family B: IV-1, IV-2 and IV-3,) 
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showed a higher density of tumours over areas that are predisposed to 
androgenic alopecia (Hamilton, 1951) (Figure 17d). Although in these patients 
tumours did occur on the occipital and temporal scalp, they were smaller and 
not confluent, suggesting this to be a true predisposition, rather than one that 
was biased due to balding. Furthermore this distribution was also seen in 
female patients. Interestingly, one woman with severe disease reported an 
increase in number of tumours during pregnancy and also when hormone 
replacement therapy was started. As this had been previously noted 
anecdotally (Given, Pickrell et al. 1977), the remaining 13 affected females 
were directly questioned. No association was seen between presentation of 
tumours and hormonal exposure, as determined by delineating number of 
pregnancies, hormonal contraception, hormone replacement therapy and 
duration of menarche-menopause in other patients. 
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Pain and disfigurement were commonly reported in individuals from both 
families as major signs and symptoms. Lesion-associated pain was a major 
complaint in over 50% of affected individuals, and attributed by the patient to 
both histologically confirmed cylindromas as well as spiradenomas. Whilst 
eccrine spiradenomas could be distinguished clinically as they were usually 
painful on light pressure and had a deep blue hue (Figure 17a), some painful 
cylindromas were also noted to have blue regions which correlated 
histologically with areas of spiradenomatous differentiation (Figure 18). This 
finding of regions within the same tumour showing spiradenomatous and 
cylindromatous patterns has been previously reported (Crain and Helwig 
1961). 
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Figure 17 Typical CYLD defective tumours at different sites. 
a) Midline distribution of tumors on back (spiradenomas arrowed); b) Pubic eccrine spiradenoma; c) 
Occluded ear canal resulting in conductive deafness; d) Scalp demonstrating larger confluent tumors 
clustering in areas predisposed to androgenetic alopecia. 
 
Apart from pain, tumours on the back which were compressed during sitting or 
sleeping were susceptible to pressure necrosis, which caused problems due 
to ulceration and chronic discharge. Tumours in the pubic area were found in 
42% of affected individuals and resulted in sexual dysfunction (Figure 17b). 
27% of affected individuals were noted to have numerous confluent 
cylindromas in the ear canal resulting in a conductive deafness when 
occlusion of the ear canal occurred (Figure 17c).  
Taken together, the impact on quality of life due to repeated surgery, scalp 
removal, painful tumours, deafness and sexual dysfunction appears to be 
underreported in the literature and a cause of major unaddressed morbidity 
within families. 
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Figure 18 Spiradenocylindroma.  
Haematoxylin and eosin stain displaying the characteristic pattern suggestive of cylinders in cross 
section which gave rise to the term cylindroma (lower left corner; black star), with an adjacent region 
(upper right corner; white star) within the tumor displaying a large ball of basophillic cells with areas of 
ductal differentiation, consistent with an eccrine spiradenoma  (Original magnification 10x). 
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In keeping with a previously reported association (Jungehülsing, Wagner et al. 
1999), one individual was also diagnosed with bilateral parotid gland tumours 
and underwent bilateral parotid surgical excision. (Family B: III-5). 
Unfortunately we were unable to obtain the histology report on these tumours. 
Due to the immunodysregulation observed in CYLD null mouse models, 
affected patients were also questioned as to symptoms associated with either 
an immunodeficiency or autoimmune phenotype. The results revealed no 
evidence of a predisposition to recurrent infections, autoimmune disease, 
colitis, infertility and non-cutaneous cancers. One patient reported vitilligo, 
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whilst other diseases reported included ischaemic heart disease and 
osteoarthritis.  
)
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Here, we provide the most comprehensive study of the clinical features 
associated with germline heterozygous mutations within the CYLD gene 
locus. 
In addition to the well recognised morbidity associated with face and scalp 
cylindromas in these families, we highlight that the tumour predisposition 
associated with this condition extends beyond the face and scalp affecting 
both the trunk and genital areas. These less well recognised sites of tumour 
formation can impact greatly on the quality of life experienced by these 
patients. Unless actively sought these complications may be under-diagnosed 
and not treated. 
In our patient cohort, we found only a slight female preponderance of the 
disease. However, the impact of this disease appears to be more severe in 
females with 5 women, compared to only one male, undergoing entire scalp 
removal. Although clinical photographs support the underlying clinical severity 
that warranted this procedure, it is also feasible that the psychological impact 
and social disability has a greater impact on females.  
Basal cell adenomas and adenocarcinomas of the parotid glands and minor 
salivary glands have been reported in association with this disorder 
(Jungehülsing, Wagner et al. 1999). In our families only one such case was 
reported, suggesting that this is an uncommon event in these families.  
None of our patients developed any of the clinical features associated with the 
CYLD null (CYLDnull ) mouse models (Massoumi 2006; Reiley, Zhang et al. 
2006; Zhang, Stirling et al. 2006; Jin, Reiley et al. 2007; Lim, Stirling et al. 
2007). Conversely, none of the CYLDnull mice developed cutaneous 
cylindromas. This phenotypic difference may be due to the germline 
molecular heterozygosity found in the patients compared to the homozygote 
status of the CYLDnull mouse models, and would suggest that either loss of 
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the second CYLD allele in humans is a rare event outwith the hair follicle or 
that somatic loss of the second CYLD allele in cells from other tissues may be 
non-viable.   However, this explanation does not account for the observation 
that there is over-representation of mutations within the 3’ end of CYLD gene 
in all published human cohorts ascertained on their predisposition to 
cutaneous tumours. 
Thus, an intriguing alternative explanation for the phenotypic difference 
between CYLDnull mice and the patients is that the human mutations 
represent hypomorphic alleles, which could potentially result in the production 
of a truncated protein with the potential for tissue-specific dominant 
negative pathogenic interactions. Evidence underpinning this theoretical 
possibility comes from recent murine models in which truncating mutations 
(CYLDtruncated) were engineered into the mCYLD locus. In direct contrast to the 
viable phenotype seen in the CYLDnull models (Massoumi 2006; Reiley, 
Zhang et al. 2006; Zhang, Stirling et al. 2006; Jin, Reiley et al. 2007; Lim, 
Stirling et al. 2007), the CYLDtruncated mouse models died shortly after birth 
(Ermolaeva, Sebban et al. 2006; Trompouki, Kontoyiannis et al. 2006). 
However, in humans, mechanistic  data is still limited. In cylindroma tissue, a 
truncated form of the CYLD protein has not been visualised on 
immunohistochemistry despite the antibody recognising the N-terminus of the 
CYLD protein (Massoumi, Podda et al. 2006).  In addition, the only 
heterozygous full CYLD gene deletion reported to date is in a 14-year-old girl 
with a large heterozygote chromosome deletion encompassing the CYLD 
locus (DECIPHER 2009). Although the preliminary report does not indicate 
the presence of cutaneous tumours, she is currently too young to exclude this 
as a possible future complication.  Further work is necessary before precise 
mechanisms of the pathogenicity of the mutated CYLD locus can be 
formulated. 
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The pluripotent hair follicle stem cell as the probable cell of origin of 
cylindromas (Massoumi, Podda et al. 2006) is supported by our clinical data. 
The occurrence of multiple, different, rare (Harwood, McGregor et al. 2003) 
skin appendage tumours in these patients suggest tumours may arise from a 
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cell which is not fully committed to a lineage of differentiation. Furthermore, 
sites recognized to have an absence of hair follicles such as the palms and 
soles are spared. As the hair follicle stem cell compartment becomes better 
defined (Ohyama, Terunuma et al. 2006), it is to be hoped that the cell of 
origin of cylindromas will become clearer. 
One key event in familial cancer tumourigenesis is loss of the wildtype allele 
in a previously heterozygous cell (LOH). Due to the high incidence of tumour 
formation on the face and scalp in patients with a CYLD mutation, it has been 
postulated that UVR associated DNA damage may be the main initiating 
factor in the development of cylindromas (Massoumi 2006; Massoumi and 
Paus 2007). Our data supports this hypothesis, as all patients have a tumour 
on the face or scalp, and the highest number of tumours is at these sites. In 
contrast however, we demonstrate a high incidence of genital and trunk 
cylindromas and spiradenomas in more than half of the affected patients. 
Tumours at lifelong light protected sites such as the pubic skin indicate that 
other mechanisms independent of UVR must play a role tumour initiation. 
There is further supportive data from a study of patients with nevoid basal cell 
carcinoma syndrome (NBCCS), where the cutaneous tumours are also 
thought to arise from hair follicles. This study (Goldstein, Bale et al. 1993) 
showed that patients with NBCCS (who carry PTCH mutations) have a 
disproportionately high proportion (59-65%) of tumours on the trunk, 
compared to the general population (9-12%) who present  with basal cell 
carcinoma. There was no correlation to sun exposure behavior, (though 
numbers were small) and tumours were seen at genital sites as well as in 
highly pigmented skin types. Taken together, the distribution of skin tumours 
resulting from germline mutations in 2 known tumour suppressor genes 
suggest alternative, non-UVR mediated mechanisms of tumour induction are 
pertinent. One feature of human hair that may highlight such mechanisms is 
the differential sensitivity of follicles at different body sites to hormonal 
stimulation. Puberty highlights follicles that change from fine vellus hair to 
coarse hair in response to hormonal stimulation in some areas such as the 
beard area, axilla and pubic region. Another follicular response seen is acne, 
where hormonally driven proliferation of the opening of the hair follicle at 
certain sites results in comedones, inflammatory pustules and papules. The 
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detailed mapping of tumour distribution in our patient cohort demonstrates an 
increased incidence of tumours in areas associated with hormonally 
stimulated hair follicles such as the pubic hair and upper trunk. The 
distribution on the torso correlates well with the distribution of hair follicles 
affected by acne at puberty. The converse of this, a relative absence of 
tumours on unstimulated sites such as distal limbs, palms and mucous 
membranes is also seen. Further evidence that the tumours are more likely to 
arise from hair follicles that are hormonally stimulated come from the 
observation that the onset of tumours occurs after adrenarche (Welch, Wells 
et al. 1968), and the larger size and confluency of scalp tumours in areas 
predisposed to androgenic alopecia (male pattern balding is thought to reflect 
follicles that preferentially senesce following androgen stimulation (Bahta, 
Farjo et al. 2007)). Finally, recent preliminary data in mouse follicles has 
shown that CYLD may play a role in hair follicle cycling (K Moriwaki 2007). 
Whilst the precise mechanisms remain undetermined, the clinical data is 
supportive of hormonally sensitive hair follicles being vulnerable to LOH at the 
CYLD locus, leading to tumour induction. 
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The data we present here confirms that even within one family, mutations 
within the CYLD locus give rise to a wide variation of clinical phenotypes. 
More than 75 mutations have now been identified in CYLD, with the majority 
found towards the carboxyl terminus of the protein, the position of the catalytic 
residues of ubiquitin hydrolase (Massoumi and Paus 2007; Saggar, Chernoff 
et al. 2008; Blake and Toro 2009). Clustering around the catalytic residues of 
ubiquitin hydrolase suggests the loss of deubiquitinating activity is important 
for the development of a cutaneous phenotype.  The poor genotype-
phenotype correlation with regard to tumour histology, and wide variation in 
clinical expression that we demonstrate in our families has been noted by 
other authors (Young, Kellermayer et al. 2006; Zhang, Huang et al. 2006). In 
contrast, there have been families in China with up to 4 generations affected 
(Salhi, Bornholdt et al. 2004; Zheng, Hu et al. 2004)with predominantly MFT, 
where the same mutation in other populations have resulted in heterogenous 
phenotypes, highlighting the possibility of population-specific modifier genes.  
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This wide variation in clinical phenotype means that genetic counselling and 
prognostication in families with known CYLD mutations is not straight forward. 
Some mutation carriers may have milia as the only presenting feature, a 
finding that can be missed by professionals unfamiliar with cutaneous 
tumours. Milia are found in other genodermatoses (Berk DR 2010),  and 
hence, can only be taken to be an indicator of CYLD mutation carrier status 
when another relative has either phenotypic features or a confirmed genotype. 
The presence of two obligate carriers in our pedigrees who were reported as 
unaffected by their relatives, but had severely affected children, underlines the 
importance of all ‘at risk’ individuals within a family being offered predictive 
testing if available or examined by a specialist with a prior knowledge of the 
condition. 
A review of the literature places the oldest patient to develop a first tumour at 
42 years (Martins and Bartolo 2000). Taken with our data of unaffected 
patients of the pedigree who were sequenced, this suggests that unaffected 
individuals in families that reach this age are unlikely to be carriers of a 
mutation (Biggs, Wooster et al. 1995). As most couples have children prior of 
this age, predictive testing for a known familial mutation rather than clinical 
examination of the ‘at risk’ individual would be required if reassurance 
concerning future or an ongoing pregnancy was requested. Our results also 
indicate the impact on the lives of future generations of affected individuals 
cannot be gauged by the clinical severity of previously affected individuals. 
Based on the variation seen in our European families, we suggest that the 
clinical diagnosis of BSS, MFT and FC have no prognostic, diagnostic or 
descriptive value and should be abandoned. Individuals found to have a 
germline CYLD mutation should be given the diagnosis of “CYLD cutaneous 
syndrome”, as the eventual clinical phenotype may be uncertain. This 
nomenclature will also avoid confusion with regard to possible genetic 
heterogeneity. 
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The need for non-surgical approaches in the treatment of these families is 
emphasised by the repeated surgical procedures individuals in both families 
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underwent, the frequencies often only being restrained by available clinical 
resources.  
Our current understanding of CYLD’s function as a negative regulator of the 
NF!B pathway (Kovalenko, Chable-Bessia et al. 2003), highlighted a role for 
aspirin in the treatment of these patients (Brummelkamp, Nijman et al. 2003). 
However the clinical efficacy of aspirin in one trial of topical aspirin was 
limited, with only 2 out of 12 tumours showing complete remission after 24 
weeks (Oosterkamp, Neering et al. 2006). This preliminary work however 
does suggest that further studies are required to analyse the dose, timing and 
efficacy of NF!B modifiying drugs, perhaps at an earlier stage of 
tumourigenesis or prophylactically in these patients. Furthermore, detailed 
molecular dissection of these tumours may yield other druggable pathways in 
this tumour syndrome.  
Here, we highlight the wide variation in both clinical severity and tumour type 
present in multigenerational families with CYLD cutaneous syndrome. 
Significantly, the distribution of tumours suggest that hormonally sensitive hair 
follicles may be predisposed to tumour formation. Further understanding of 
the role of CYLD in regulating pathways such as NF!B may help develop non-
surgical treatments of this devastating condition.
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Patients with germline mutations in the tumour suppressor gene CYLD 
develop multiple highly organised cylindromas (Figure 19 a,c). These tumours 
are so called as the tumour cells appear to be arranged in cylinders 
irrespective of which way the specimen is sectioned. Interestingly the same 
patients also develop poorly organised spiradenomas, which are clinically and 
histologically distinct (Figure 19 b,d). Spiradenomas, unlike the pink, painless 
cylindromas, are painful blue nodules and demonstrate poor architectural 
organisation. Occasionally patients develop features of both tumours within 
the same lesion (Figure 19 e). We found that in a study of two large 
pedigrees, that pain was a reported feature in 52% of affected patients, 
suggesting this may be a frequent event (Rajan, Langtry et al. 2009). The 
coexistence of both tumours in the same specimen has been thought to 
reflect a process of tumour maturation from one form to another, however a 
molecular mechanism has not been proposed (Michal, Lamovec et al. 1999). 
Further characterisation of these CYLD defective tumours therefore may 
provide insight into novel mechanisms that may explain the coexistence of 
these distinct tumours. 
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Figure 19 CYLD mutation carriers exhibit distinct clinical and histological tumour phenotypes. 
Patients with germline CYLD mutations develop (a) pink cylindromas on the scalp and trunk as well as 
(b) blue painful eccrine spiradenomas seen here at surgery. (c) Cylindroma tumours are highly 
organised with tumour cells arranged in cylinders, with basophilic cells at the periphery, and larger pale 
cells seen centrally. (d) Spiradenoma tumours are poorly organised, with areas of ductal differentiation 
and a lymphocytic infiltrate. (c-d. 5x original magnification) (e) Both tumour types are often seen 
3D reconstruction of CYLD defective tumours 
 79 
together in the same sample, giving rise to the term “spiradenocylindroma ”. (e. 20x original 
magnification). (Black scale bars indicate 100µm; white scale bars indicate 1cm. 
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Cylindromas are highly organised, with tumour cells arranged in cylinders, 
which inspired the original naming of this tumour. To understand how this 
histological pattern is observed irrespective of how the tumour block is 
sectioned, we reconstructed 12 tumours in silico from serial sections. This 
allowed visualisation of the patterning of tumour cells in three dimensional 
(3D) space. Serial sections were taken at 5 µm thickness through tumour 
specimens, typically covering 750-1000 µm of the block. Standard staining 
was performed and photomicrographs were taken. Alignment of these images 
was performed manually using Amira software (V4.0 – Visage Imaging), 
allowing accurate overlap of serial sections. Artificial colour labels were 
applied to individual cylinders of tumour cells, allowing tracking of cylinders 
through the tumour block. Surface rendering of the ensuing columns of 
tumour cells and virtual flythrough examination was performed within Amira 
software.  
This analysis demonstrated that cylindroma tumour cells grow contiguously, 
and form an interconnected network of cylinders, with branching and budding 
seen (Figure 20, Supplementary video 1 
http://www.youtube.com/watch?v=95biz3YEDhU). Tracking of cylinders 
through the tumour block with different coloured labels demonstrated that all 
cylinders eventually connected to each other at some level in the tumour 
block. This was found to be the case in all twelve specimens examined. This 
finding of contiguous growth had prompted us to include tumours with mixed 
features of both cylindromas and spiradenomas. Spiradenocylindromas, a 
recognised feature in CYLD mutation carriers (Michal, Lamovec et al. 1999), 
have previously been suggested to represent a collision phenomenon, that is 
two adjacent tumours growing into each other (Goette, McConnell et al. 
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1982). However, personal clinical observation of CYLD mutation carriers 
revealed that cylindroma tumours can become painful over time and that this 
is often associated with a change in colour of the tumour from pink to blue, 
suggesting a spiradenoma focus developing within a preexisting cylindroma at 
least in some cases. 3D reconstruction of 4 spiradenocylindromas 
demonstrated that consistent with this clinical observation, they were also 
contiguous structures, with highly organised cylindroma growing in direct 
connection with poorly organised spiradenoma (Figure 21 and Supplementary 
video 2 http://www.youtube.com/watch?v=WcUSHk9NavI). We were able to 
observe a spiradenoma focus that links adjacent areas of cylindroma, 
suggesting an area that has transformed to spiradenoma, displacing the 
surrounding cylindroma columns. Finally, when reconstructed in silico, small 
spiradenomas (two out of twelve specimens) displayed an area that was 
highly organised, which may represent an initial cylindroma that had 
transformed into a spiradenoma (Figure 22 and Supplementary video 3 
http://www.youtube.com/watch?v=NT7USIzcZPo). Methods to access to the 
video material, and the associated legends are detailed in Appendix A. 
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Figure 20 Cylindromas grow in a contiguous manner. 
Paraffin embedded CYLD defective tumours were serially sectioned, typically at 5 µm thickness, stained 
with standard techniques and photographed. Images were aligned and tumour islands were traced 
through the ensuing “virtual block” in silico. Distinct artificial colours were applied when tumour islands 
were traced so that individual columns of tumour cells could be followed.  (a-f) Cylindroma tumours were 
contiguous in growth, and each cylinder seen in cross section ultimately was connected to adjacent 
cylinders, a feature seen in other common hair follicle related tumours such as basal cell carcinoma. 
Here, a single cylinder of tumour cells was labelled in purple, and followed through the block, with all 
directly connecting cells labelled in the same colour. A similar process was performed on a distant 
island of tumour cells in green. The two separate columns of tumour cells are seen to connect higher up 
in the specimen. For clarity only two columns are shown, and only the first section is displayed. A video 
of a virtual flight through the green column via the demonstrated connection to the purple column is 
available (Supplementary video 1). Scale bars where shown indicate 1mm. 
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Figure 21 Spiradenocylindroma: Spiradenomas and cylindromas are part of the same tumour mass.  
(a-h) We also found that areas that were highly organised (cylindroma) were growing in direct 
connection with poorly organised areas (spiradenoma). We found areas in the tumour blocks that were 
disorganised at one level (a) that when followed through were organised further in the block (b), seen 
490um apart in this example. When traced through, and labelled in purple, the two areas were part of 
the same column of tumour cells. Three further organised areas, labelled in red, blue and green were 
also connected to the purple mass. 2 sections are displayed (Original magnification 2.5x). A video of the 
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reconstructed spiradenocylindroma is available (Supplementary video 2). Scale bars where shown 
indicate 1mm. 
 
Figure 22 Spiradenoma with a central focus of cylindroma.  
(a-f) Small spiradenomas sometimes displayed an area that was highly organised, that may represent 
the original organised focus of tumour cells. In this block, the small organised column of cells is shown 
in purple, and the surrounding disorganised mass of cells are shown in light blue. 4 sections are 
displayed. A video of the rotating reconstructed block is available (Supplementary video 3). Scale bars 
where shown indicate 1mm 
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Characterisation of CYLD defective tumours has been previously performed 
highlighting expression of cytokeratins associated with the hair follicle and 
eccrine ducts (Meybehm and Fischer 1997). We validated these findings in 
tumours derived from our pedigrees, which formed the basis of using these 
markers to characterise primary cell cultures from these tumours. These 
findings are shown in Figure 23 below and were largely consistent between 
cylindromas and spiradenomas. 
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Figure 23 Indirect fluorescent immunohistochemical  characterisation of CYLD defective tumours.  
Tissue sections underwent antigen retrieval, were probed with antibodies as indicated in the panels, and 
stained with FITC conjugated secondary fluorescent antibodies. DAPI was used as a nuclear 
counterstain. The outer root sheath of a hair follicle was used as a positive control (CK14), and no 
primary antibody sections were used as a negative control. Scale bar indicates100µm.  
CK17CK14
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Other host-derived cells that may be present in these tumours were 
investigated. CD8 expressing lymphocytes in the tumour cells, were found in 
spiradenomas more than cylindromas (Figure 24a-b). This antibody however 
cross reacted with CK15, and whilst the cells that were CD8 positive had 
small dark nuclei consistent with lymphocytes, further validation with other 
lymphocytic markers are needed.  
We chose to investigate the vascular supply of CYLD defective tumours, as 
the tumour size reached suggested that the tumour cells were likely to require 
a significant blood supply. We found that some cells as well as structures 
were CD31 positive (Figure 24c-d). 
Figure 24 Lymphocyte and vascular markers are expressed in CYLD defective tumours.  
Tissue sections underwent antigen retrieval, were probed with antibodies as indicated in the panels, and 
followed by secondary HRP antibodies. Protein expression was visualized using DAB. Haematoxylin 
was used as a nuclear counter stain. (a) A spiradenoma with multiple lymphocytes arrowed in red, with 
a cylindroma (b) with few lymphocytes seen. (c) CD31 positive channels seen within spiradenoma, and 
(d) occasionally amongst islands of cylindroma tissue. A blood vessel is arrowed ( Scale bar indicates 
100µm).  
We chose to investigate the difference in proliferative index using Ki 67 
staining in CYLD defective tumours. Spiradenomas and cylindromas both 
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demonstrated Ki 67 positivity in central paler cells, rather than peripheral 
basophilic cells (Figure 25a-b).  Spiradenoma had more proliferative cells 
when compared to cylindroma (Figure 25c). 
 
Figure 25 Spiradenoma has a greater proliferative phenotype than cylindroma.  
Tumour sections on a custom-built tissue microarray underwent antigen retrieval, were probed with Ki 
67 antibody and protein expression was visualized with a horseradish peroxidase/DAB system. 
Haematoxylin was used as a nuclear counterstain.(a) Cylindroma, (b) spiradenoma, (c) An increase in 
Ki 67 staining is seen in spiradenoma compared to cylindroma. Statistical significance was tested using 
a t-test (p<0.0001). Error bars indicate standard error of the mean. Scale bar indicates 100µm. 
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CYLD defective tumours represent an intriguing model of cutaneous tumour 
biology. Highly patterned cylindromas and disorganised spiradenomas are 
seen to arise on the same patient and sometimes within individual specimens. 
Here, in keeping with these data, we show that cylindromas and 
spiradenomas represent extremes of a spectrum of tumour organisation.  
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We show that islands of cylindroma cells grow as contiguous structures, a 
finding consistent with the growth pattern found in sporadic hair follicle 
tumours such as basal cell carcinoma (Lang, McKelvey et al. 1987; Scheibe, 
Braumann et al. 2010). An extension of this concept is the finding that 
cylindromas and spiradenomas grow in direct connection with each other, 
which accounts for the recurrent finding that features of both tumours are 
found in the same specimen, termed spiradenocylindroma. Finally, we 
demonstrate that in small spiradenomas, a focus of organised cylindroma can 
be found within, growing in contiguity with the surrounding tumour. These data 
support a model where the default pattern of growth of the tumour cells once 
a "second hit" event such as LOH happens is a to grow in a tubular pattern. 
The tubular structure then buds and branches, and grows in a contiguous 
fashion, giving rise to a cylindroma. As this structure is folded to grow within 
the constraints of the mechanical forces exerted by surrounding tissue in vivo, 
sectioning of this folded structure results in cylinders seen irrespective of 
which way the tumour is sectioned. In spiradenoma, there is loss of patterning 
seen probably at an early stage, before the tumour has grown significantly 
and as we have demonstrated (Figure 22), a preexisting cylindroma can be 
demonstrated in smaller tumours. This loss of patterning is possibly mediated 
by a third molecular event, or “third hit”, giving the cells a proliferative or 
survival advantage. Ki 67 immunostaining supports an increase in proliferation 
in spiradenomas. In spiradenocylindromas, we propose loss of this tubular 
patterning within an established cylindroma happening at a later stage, 
resulting in the coexistence of the two tumour types in the same sample. 
These findings are summarised in this model (Figure 26). 
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Figure 26 Cylindromas and spiradenomas represent extremes of a spectrum of tumour organisation. 
(a) Loss of heterozygosity in a putative pluripotent hair follicle cell results in exclusive expression of 
mutant CYLD, conferring a growth advantage for these cells, (indicated by the red sphere).  The cells 
are restricted to a tubular growth pattern due, giving rise to a structure where growth by extension, 
branching and budding is feasible (indicated by the purple column). This structure when folded gives 
rise to the finding that the tumour cells are seen organised as cylinders irrespective of the way the 
tumour is sectioned. (b) Loss of patterning following a “third hit” (indicated by the yellow triangle), giving 
rise to a disorganised mass of tumour cells (indicated by the green mass), with no restriction to grow in 
a tubular pattern. (c) A late “third hit” event that results a tumour that has already grown as a cylindroma 
to develop a region that is poorly organised, a finding supported by clinical and pathological 
observations of the coexistence of two tumour types in the same specimen. 
 
 
The demonstration of the two tumour types as part of a spectrum fits with the 
immunohistochemical characterisation demonstrating overlapping features 
between cylindromas and spiradenomas. In particular cytokeratin markers 6, 
14 and 17 were seen in both tumour types, a finding corroborated by others 
(Meybehm and Fischer 1997). Interestingly, there was a difference in 
lymphocytic infiltration, seen predominantly in spiradenomas, suggesting the 
tumour milieu was different and may attract these cells. It would be interesting 
to further characterise these cells with other lymphocytic markers. The extent 
of vascular marker expression raises the possibility of extensive vasculature 
that could be targeted with anti angiogenic treatments, however further work 
in in vivo models is needed clarify the feasibility of this approach. 
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These data highlight the spectrum of tumour patterning seen in CYLD 
defective tumours. We demonstrate that cylindroma grows in a contiguous 
fashion. Furthermore we demonstrate coexistence of cylindroma and 
spiradenoma within the same tumour specimen, with areas that are highly 
organised growing in direct connection with areas that are disorganised. In 
keeping with these findings, we propose a model where a third hit may result 
in the loss of organised tubular growth. Mechanisms that may cause in this 
third hit are intriguing, and may be clarified by molecular profiling of these 
different tumour types.  
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CYLD mutant carriers develop hair follicle related tumours, of which cylindromas 
and spiradenomas grow to the largest size and have significant clinical impact. 
The presence of painful spiradenomas and truncal and genital tumours can have 
a significant impact on quality of life, as can the surgery used to remove lesions 
as this may culminate in entire scalp removal. As such, the development of non-
surgical approaches to control tumour burden are required (Rajan, Langtry et al. 
2009). Novel therapeutic approaches with inhibitors of the nuclear factor kappa 
beta (NF!B) pathway such as aspirin were proposed when CYLD was found to 
encode an ubiquitin hydrolase that negatively regulated this pathway 
(Brummelkamp, Nijman et al. 2003; Kovalenko, Chable-Bessia et al. 2003; 
Trompouki, Hatzivassiliou et al. 2003). However, initial clinical studies with topical 
salicylic acid demonstrated a significant response in only a small proportion of 
treated tumours (Oosterkamp, Neering et al. 2006). Therefore, a more detailed 
understanding of the molecular dysregulation caused by loss of functional CYLD 
is warranted and this may inform the development of novel therapeutic 
approaches.  
 Whole genome profiling of tumours, to assess the genetic and transcriptomic 
changes, is widely used in cancer biology to discover new druggable pathways. 
Indeed, the targeting of such pathways, with selected treatment of tumours 
dependent on the presence of specific driver mutations, has been shown to have 
a significant benefit in skin tumours such as melanoma. In this model, patients 
shown to carry a particular activating mutation (V600E) in BRAF, a tyrosine 
kinase, have been shown to have a clinical response to tyrosine kinase inhibitors 
targeting mutant BRAF. This response is not seen in patients with melanoma 
where the tumour does not have this mutation (Bollag, Hirth et al. 2010; Flaherty, 
Puzanov et al. 2010). CYLD defective tumours from patients with germline 
mutations in this tumour suppressor gene are uncommon. As existing 
technologies for transcriptomic profiling requires fresh frozen tissue with high 
quality RNA, this approach is difficult to adopt. I have been able to use this 
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approach with this tumour syndrome as I have access to fresh tumour tissue from 
patients undergoing routine surgery to control tumour burden.  This allows for 
discovery of novel pathways in a human tumour model, independent of 
assumptions based on the previously described functions and ascribed roles 
played by CYLD.  This is particularly important, as CYLD deficient mouse models 
with complete loss of CYLD expression do not develop cylindromas or 
spiradenomas.  Apart from contributing to the discovery of targetable pathways 
for CYLD mutation carriers, such data would inform the pathogenesis of hair 
follicle tumours, as well as other tumours which are CYLD deficient.  
Here, we have performed a detailed molecular analysis of tumours from patients 
with CYLD mutations, and highlight a novel targetable pathway in this cutaneous 
tumour syndrome.  
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Fresh frozen tumours from patients with germline CYLD mutations were 
microdissected to isolate tumour cells and perilesional control cells. Genomic 
analysis of cylindroma and spiradenoma tissue was performed on 12 tumours 
and 7 perilesional skin samples using a 32K bacterial artificial chromosome 
(BAC) tiling path array (Natrajan, Weigelt et al. 2009). This BAC array platform 
has been shown to be as robust as, and to have comparable resolution with high 
density oligonucleotide arrays (Coe, Ylstra et al. 2007; Tan, Lambros et al. 2007; 
Gunnarsson, Staaf et al. 2008). Comparative genomic hybridisation was 
performed using DNA extracted from peripheral blood leukocytes from the same 
patient as the reference. No obvious regional genomic amplification or deletion 
was noted in 12 tumour samples (Figure 27). Moreover, no difference was seen 
between cylindromas (n= 7) and spiradenomas (n=5).  
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Figure 27 32K BAC tiling path array CGH of  perilesional skin and cylindroma tumour. 
Genomic DNA was extracted from microdissected tumours and control perilesional skin and 
competitively hybridised against patient matched peripheral lymphocyte DNA on a 32K BAC tiling 
path array. BACs categorised as displaying genomic gains or amplification are plotted in green 
and those categorised as genomic losses or deletion in red. Circular binary segmentation (cbs)-
smoothed Log2 ratios are plotted on the Y-axis in purple against each bacterial artificial 
chromosome (BAC) clone according to genomic location on the X axis. The threshold for a gain or 
loss is indicated by the blue dashed line (log2 ratio > 0.08 or < -0.08) and the threshold for an 
amplification or deletion is indicated by the black dotted line (log2 ratio > 0.45 or < -0.45). No 
significant copy number change was seen between tumours and perilesional skin; an indicative 
result for perilesional skin and a cylindroma tumour is shown.  
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Given the apparent absence of genomic copy number variation observed using 
BAC arrays, we went on to perform high resolution SNP typing using a 550K SNP 
array platform (Illumina, USA) on four further cylindroma tumours and one control 
sample. This revealed copy number silent LOH for the entire arm of chromosome 
16q in all four tumours but no other significant changes (Figure 28, Figure 29). 
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Figure 28 Perilesional skin SNP microarray analysis showing data from chromosome 16.  
 
 
Figure 29 Cylindroma tumour SNP microarray analysis showing data from chromosome 16.  
To examine for genomic changes at higher resolution, single nucleotide polymorphism (SNP) typing was 
performed using a 550K SNP array in a further 4 cylindromas. LOH was seen across the entire arm of 
chromosome 16q in all 4 samples, indicated by the red arrow. 
 
LOH status at the site of the mutation was assessed in a further 27 tumours used 
in this study, which was possible as the genotype of each patient was known. 
LOH was assessed using genomic DNA from microdissected tumours by using 
restriction enzymes that specifically were unable to cut only the mutated allele in 
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each tumour. Polymerase chain reaction (PCR) amplification was performed 
using primers that flanked exon 18 (CYLD18F and CYLD18R) and the PCR 
product was subject to restriction enzyme digestion using enzymes chosen for 
pedigree specific mutations: HpyCH4V (c.2460delc) and Sml I (c.2469+1G>A). 
This revealed LOH at the site of the mutation in 75% of the 27 tumours, 
suggesting the mechanism resulting in LOH to be similar in the majority of 
tumours (Figure 30).
 
Figure 30 Restriction enzyme digest to determine LOH at c.2460delC. 
 PCR amplification of DNA from microdissected tissue of a region that was 422 bp in size was performed. 
These DNA products were subject to restriction digest and resolved on a 2% agarose gel. a) Restriction 
schematic - The enzyme used for this site (c.2460delc), HpyCH4V, would only cut the normal allele in 3 
places, and the mutant allele in 2 places (lost restriction site following mutation shown as red line). b)  Lane 
1- 100bp ladder; each band is a 100bp increment. Lane 2 and 3 - Control DNA, resulting in 4 cut products 
(Sizes – 163bp, 101bp, 82bp and 76bp). Lane 4 shows presence of the normal allele, indicated by the 163bp 
band, which is digested by HpyCH4V, and the mutant allele (238 bp band), as well as the smaller producte, 
(101, 82 and 76bp) .Lane 5 - LOH resulting in only the mutant allele results the larger 239bp band, and the 
smaller 101 and 82bp bands, but not the 163bp and 76bp band. Resolution of the smaller products was not 
performed as this was not critical to the genotyping.  
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Gene expression profiling was performed on total RNA extracted from 42 
microdissected samples, consisting of 19 cylindromas, 9 spiradenomas, 4 
trichoepitheliomas and 10 perilesional controls. A bead array platform (Illumina, 
USA) that is capable of assaying expression of 24,526 transcripts for each 
sample was used (April, Klotzle et al. 2009). Average signal values from replicate 
beads were summarised, log transformed, and normalised using quantile 
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normalisation across all samples (Workman, Jensen et al. 2002). Unsupervised 
clustering analysis of the individual transcriptomes (24526 probes) by Euclidean 
distance revealed close clustering of the majority of cylindroma and spiradenoma 
tissue, and distinct clustering of the perilesional skin and trichoepithelioma tissue 
(Figure 31). This was corroborated with clustering by an independent technique 
that used multiple bootstrapping to determine the robustness of the clusters. 
Clustering of transcriptomes using individual probes (24526) was employed and 
dissimilarity was measured using the correlation method using a statistical 
package (pvclust) (Suzuki and Shimodaira 2006). Clusters were maintained, 
however due to the small numbers of tumours used, statistical significance was 
seen between tumours and controls (p<0.01), but not between tumour subsets 
(Figure 32). 
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Figure 31 Clustering dendrogram of CYLD defective tumour and control transcriptomes. 
Cylindromas and spiradenomas share similar transcriptomes, and cluster distinctly from 
trichoepitheliomas and perilesional control skin. Total RNA was extracted from 32 microdissected 
tumours and 10 perilesional controls and gene expression levels of 24526 transcripts for each 
sample were assayed. Unsupervised clustering of the 42 transcriptomes was performed, and 
cylindromas and spiradenomas clustered together, with trichoepitheliomas and perilesional skin 
clustering separately. No clustering by gender, genotype or tumour location was seen. 
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Figure 32 Stability of clusters of CYLD defective tumours. 
Clustering analysis of transcriptomic data from CYLD defective tumours and control tissue. Clustering of 
transcriptomes using individual probes (24526) was employed and dissimilarity was measured using the 
correlation method using a statistical package (pvclust) (Suzuki and Shimodaira 2006).  Clusters seen in 
Figure 31 were maintained, however due to the small numbers of tumours used, statistical significance was 
seen between tumours and controls (p<0.01), but not between tumour subsets. pvclust provides two types of 
p-values: AU (Approximately Unbiased – numbers in red) p-value and BP (Bootstrap Probability – numbers 
in green) value. AU p-value, which is computed by multiscale bootstrap resampling, is a better approximation 
to the true unbiased p-value than the BP value computed by normal bootstrap resampling. Numbers in grey 
are edge values.  
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The unsupervised clustering analysis was further corroborated by a supervised 
clustering analysis, allowing class comparison between cylindroma and 
spiradenoma tumours. 19 cylindromas and 9 spiradenomas were subject to 
significance of microarrays analysis (SAM), which showed no significant 
difference between the tumour types when standard criteria were applied (Figure 
33). (Differentially expressed genes between the two groups had to pass a 
significance threshold of p<0.01 and 100 permutations of the data were 
analysed)  
 
Figure 33 Supervised analysis of 19 cylindroma vs. 9 spiradenoma. 
Supervised clustering comparing cylindromas and spiradenomas show no significant difference in 
transcriptomic profiles. Significance of microarrays analysis, a form of supervised clustering analysis was 
performed between 19 cylindroma and 9 spiradenoma samples, and showed no significant difference 
between samples types. 
Given the genomic and transcriptomic similarity seen in cylindromas and 
spiradenomas, and our finding that they were extremes of a spectrum of tumour 
organisation, these were pooled and analysed against pooled controls to provide 
enhanced statistical robustness. Trichoepitheliomas were also included in this 
pool of CYLD defective tumours. 
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Quantitation of differential gene expression was determined using the bead array 
manufacturers’ custom algorithm (Illumina custom method- Illumina Inc, 2009). 
The statistical significance of differential gene expression between tumours and 
samples was calculated as a differential score. This calculation incorporated the 
difference in signal values between the two groups compared, corrected for 
appropriate negative control bead values, and was corrected for multiple 
hypothesis testing using a Bonferroni post test. We used stringent thresholds for 
filtering genes, with only transcripts that were differentially expressed with a p 
value of < 0.01 included for subsequent analysis (n=4492).  
Transcripts of proteins that were previously noted to be overexpressed in 
cylindromas were also present in a subset of 19 cylindroma tumours and 
supported the enrichment of cylindroma tissue following microdissection. These 
included numerous laminins (Table 11) (Tunggal, Ravaux et al. 2002), collagen 4 
and 7 (Timpl, Fujiwara et al. 1984; Bruckner-Tuderman, Pfaltz et al. 1991) and 
cytokeratins (Tellechea, Reis et al. 1995; Meybehm and Fischer 1997) which 
were preferentially expressed in the tumours compared to perilesional epidermis. 
Upregulation of NF!B target genes (http://people.bu.edu/gilmore/nf-
kb/target/index.html) was present as expected and served as an internal positive 
control. 19 cylindroma tumours were compared to all controls, and the NF!B 
target genes that were differentially expressed with a p-value of less than 0.01 
were tabulated in Table 11.  
To detect low level changes in gene expression between all tumours and all 
control tissue, gene set enrichment analysis (GSEA) was performed on data 
filtered at a threshold of p< 0.05 (Subramanian, Tamayo et al. 2005). This 
highlighted multiple gene sets that were involved in apoptosis (Figure 34) and 
genes that were common to these sets were found to be members of or target 
genes of NF!B and JNK signalling pathways (Figure 35). To validate this finding 
at the protein level, we demonstrated expression of p52 and Cyclin D1 in CYLD 
defective tumours (Figure 36) 
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Figure 34  Gene set expression analysis of CYLD defective tumours. 
Gene sets that modulate apoptosis are enriched in the tumour transcriptomes and contain NF!B target 
genes. Expression levels of 24526 genes from 32 microdissected tumours were pooled and compared 
against 10 pooled perilesional controls and subject to gene set expression analysis. Sets of genes 
recognised to modulate apoptosis were found to be enriched in the tumour sample. Leading edge analysis of 
these gene sets revealed NF!B target genes to be frequently present in these samples. A heat map of gene 
set HSA04210_APOPTOSIS is shown in Figure 35.  
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Figure 35 NF!B target genes are overexpressed in CYLD defective tumours.  
Expression levels of 24526 genes from 32 microdissected tumours were pooled and compared against 10 
pooled perilesional controls and subject to gene set expression analysis. Sets of genes recognised to 
modulate apoptosis were found to be overexpressed in the tumour tissue (see also Supplementary figure 1). 
A heat map of the members of one set (HSA04210_APOPTOSIS) is shown here, with overexpressed genes 
shown in red and underexpressed genes in blue. Overexpressed genes included several NF!B target genes. 
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Table 11 Upregulation of NF!B target genes in tumour tissue and markers confirming purity of cylindroma 
tissue following microdissection. 
NF!B target genes that are upregulated in tumour tissue (p<0.01) 
Gene  Fold change Gene name 
SAA1 5.92 Serum amyloid a2 
BCL2A1 5.74 BCL2-related protein a1 
SAA2 4.58 Serum amyloid a2 
BDNF 2.72 Brain-derived neurotrophic factor 
OLR1 4.53 Oxidized low density lipoprotein (lectin-like) receptor 1 
CD83 2.53 Cd83 molecule 
TIFA 2.54 Traf-interacting protein with forkhead-associated domain 
TF 2.77 Transferrin 
CXCL10 2.67 Chemokine (c-x-c motif) ligand 10 
HLA-G 3.44 Major histocompatibility complex, class i, g 
RELB 2.36 V-rel reticuloendotheliosis viral oncogene homolog b 
MYB 2.17 V-myb myeloblastosis viral oncogene homolog (avian) 
Genes that are upregulated in tumour tissue that have been previously 
described to be overexpressed in cylindroma tumours (p<0.01) 
KRT18 1.74 Keratin 18 
KRT13 4.6 Keratin 13 
KRT8 3.71 Keratin 8 pseudogene 9; similar to keratin 8 
KRT7 2.1 Keratin 7 
LAMA1 4.14 Laminin, alpha 1 
LAMA3 3.08 Laminin, alpha 3 
LAMB3 2.79 Laminin, beta 3 
LAMC2 1.86 Laminin, gamma 2 
COL7A1 1.94 Collagen, type vii, alpha 1 
COL4A1 1.5 Collagen, type iv, alpha 1 
COL4A2 1.73 Collagen, type iv, alpha 2 
 
NF!B target genes are overexpressed in 19 cylindroma tumours. Transcripts that were differentially 
expressed between tumours and perilesional controls were filtered with the criteria of a p value of less than 
0.01. Transcripts that fulfilled this criteria were compared against known NF!B target genes and tabulated. 
The purity of tumour microdissection was supported by overexpression of transcripts in cylindroma tissue 
described previously in the literature.
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Figure 36 NF!B target genes, p52 and cyclin D1, are expressed in CYLD defective tumours.  
Cytoplasmic p52 and predominantly cytoplasmic cyclin D1 is seen. Occasional nuclear cyclin D1 is indicated 
with black arrows. Scale bar indicates 100µm. 
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Fold change (FC) analysis (Table 12) revealed overexpression of several 
members of the TRK signalling pathway compared to perilesional tissue, namely, 
TRKC (FC = 4.75x), Neurotrophin 3 (FC=3.00x) and Neurotrophin 4/5  
(FC=3.15x) in the tumour group when compared to perilesional skin.
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Table 12 Fold change analysis of CYLD defective tumours compared against unaffected perilesional 
tissue. 
Altered gene expression in a human CYLD defective model. Transcripts that were differentially 
expressed between tumours and perilesional controls were filtered with the criteria of a  4x fold change 
and p value of less than 0.01. Overexpressed  transcripts are shown in red and underexpressed 
transcripts are shown in green.  
Gene Fold change Gene name 
FGF3 8.38   Fibroblast growth factor 3 (murine mammary tumour virus integration site (v-int-2) oncogene homolog) (FGF3), mrna. 
APIN 6.74   Apin protein (APIN), mrna. 
ABTB2 5.65   Ankyrin repeat and BTB (POZ) domain containing 2 (ABTB2), mrna. 
IQCA 5.53   IQ motif containing with AAA domain (IQCA), mrna. 
SAA1 5.13   Serum amyloid A1 (SAA1), transcript variant 2, mrna. 
RPRM 5.07   Reprimo, TP53 dependent G2 arrest mediator candidate (RPRM), mrna. 
RARB 5.06   Retinoic acid receptor, beta (RARB), transcript variant 1, mrna. 
COL9A2 4.97   Collagen, type IX, alpha 2 (COL9A2), mrna. 
USP6 4.84   Ubiquitin specific peptidase 6 (Tre-2 oncogene) (USP6), mrna. 
IL17RB 4.83   Interleukin 17 receptor B (IL17RB), transcript variant 2, mrna. 
RARB 4.82   Retinoic acid receptor, beta (RARB), transcript variant 2, mrna. 
C1ORF61 4.82   Chromosome 1 open reading frame 61 (c1orf61), mrna. 
BCL2A1 4.81   BCL2-related protein A1 (BCL2A1), mrna. 
REPS2 4.76   RALBP1 associated Eps domain containing 2 (REPS2), mrna. 
CPA6 4.70   Carboxypeptidase A6 (CPA6), mrna. 
NTRK3 4.66   Neurotrophic tyrosine kinase, receptor, type 3 (NTRK3), transcript variant 3, mrna. 
RAB6B 4.64   RAB6B, member RAS oncogene family (RAB6B), mrna. 
LRRN5 4.59   Leucine rich repeat neuronal 2 (LRRN2), transcript variant 1, mrna. 
FLJ45803 4.58   FLJ45803 protein (FLJ45803), mrna. 
ARNT2 4.51   Aryl-hydrocarbon receptor nuclear translocator 2 (ARNT2), mrna. 
EDAR 4.37   Ectodysplasin A receptor (EDAR), mrna. 
KIAA1622 4.34   KIAA1622 (KIAA1622), transcript variant 1, mrna. 
MIA 4.34   Melanoma inhibitory activity (MIA), mrna. 
CLUL1 4.30   Clusterin-like 1 (retinal) (CLUL1), transcript variant 2, mrna. 
DACT2 4.30   Dapper, antagonist of beta-catenin, homolog 2 (Xenopus laevis) (DACT2), mrna. 
ADM2 4.25   Adrenomedullin 2 (ADM2), mrna. 
SNX22 4.15   Sorting nexin 22 (SNX22), mrna. 
ADAMTS18 4.12   ADAM metallopeptidase with thrombospondin type 1 motif, 18 (ADAMTS18), transcript variant 1, mrna. 
LOC130940 4.10   Hypothetical protein BC015395 (LOC130940), mrna. 
COL22A1 4.06   Collagen, type XXII, alpha 1 (COL22A1), mrna. 
MMP7 4.02   Matrix metallopeptidase 7 (matrilysin, uterine) (MMP7), mrna. 
ENPP6 4.00   Ectonucleotide pyrophosphatase/phosphodiesterase 6 (ENPP6), mrna. 
C6ORF85 0.25   Chromosome 6 open reading frame 85 (c6orf85), mrna. 
GRHL3 0.25   Grainyhead-like 3 (Drosophila) (GRHL3), transcript variant 1, mrna. 
KRT10 0.24   Keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris) (KRT10), mrna. 
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ZD52F10 0.24   Dermokine (DMKN), transcript variant 2, mrna. 
ZD52F10 0.24   Dermokine (DMKN), transcript variant 2, mrna. 
TLCD1 0.24   TLC domain containing 1 (TLCD1), mrna. 
MUC15 0.23   Mucin 15, cell surface associated (MUC15), mrna. 
SLC19A3 0.23   Solute carrier family 19, member 3 (SLC19A3), mrna. 
RP11-
19J3.3 0.23   Centromere protein P (CENPP), mrna. 
CPA4 0.23   Carboxypeptidase A4 (CPA4), mrna. 
LGALS7 0.23   Lectin, galactoside-binding, soluble, 7 (galectin 7) (LGALS7), mrna. 
ALDH3A1 0.22   Aldehyde dehydrogenase 3 family, membera1 (ALDH3A1), mrna. 
XKRX 0.22   XK, Kell blood group complex subunit-related, X-linked (XKRX), mrna. 
BNIPL 0.22   BCL2/adenovirus E1B 19kd interacting protein like (BNIPL), transcript variant 1, mrna. 
ALDH3B2 0.21   Aldehyde dehydrogenase 3 family, member B2 (ALDH3B2), transcript variant 2, mrna. 
ANXA8 0.21   Annexin A8-like 2 (ANXA8L2), mrna. 
LOC144501 0.20   Hypothetical protein LOC144501 (LOC144501), mrna. 
CST6 0.20   Cystatin E/M (CST6), mrna. 
MICALCL 0.20   MICAL C-terminal like (MICALCL), mrna. 
HOP 0.20   Homeodomain-only protein (HOP), transcript variant 3, mrna. 
MAP2 0.20   Microtubule-associated protein 2 (MAP2), transcript variant 2, mrna. 
GGT6 0.20   Gamma-glutamyltransferase 6 homolog (rat) (GGT6), mrna. 
PSORS1C2 0.20   Psoriasis susceptibility 1 candidate 2 (PSORS1C2), mrna. 
DCT 0.20   Dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2) (DCT), mrna. 
SERPINB13 0.20   Serpin peptidase inhibitor, clade B (ovalbumin), member 13 (SERPINB13), mrna. 
MAP2 0.20   Microtubule-associated protein 2 (MAP2), transcript variant 1, mrna. 
TMEM79 0.19   Transmembrane protein 79 (TMEM79), mrna. 
FGFR3 0.19   Fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism) (FGFR3), transcript variant 1, mrna. 
C14ORF29 0.19   Abhydrolase domain containing 12B (ABHD12B), transcript variant 2, mrna. 
DSG1 0.19   Desmoglein 1 (DSG1), mrna. 
KRT1 0.19   Keratin 1 (epidermolytic hyperkeratosis) (KRT1), mrna. 
TRIM7 0.19   Tripartite motif-containing 7 (TRIM7), transcript variant 6, mrna. 
SLC39A2 0.18   Solute carrier family 39 (zinc transporter), member 2 (SLC39A2), mrna. 
FLJ10847 0.17   Solute carrier family 47, member 1 (SLC47A1), mrna. 
CST6 0.17   Cystatin E/M (CST6), mrna. 
LOC342897 0.16   Similar to F-box only protein 2 (LOC342897), mrna. 
ATP13A4 0.16   Atpase type 13A4 (ATP13A4), mrna. 
GPR115 0.15   G protein-coupled receptor 115 (GPR115), mrna. 
UNC93A 0.15   Unc-93 homolog A (C. Elegans) (UNC93A), mrna. 
SBSN 0.15   Suprabasin (SBSN), mrna. 
LOC144501 0.14   Hypothetical protein LOC144501 (LOC144501), mrna. 
TYRP1 0.14   Tyrosinase-related protein 1 (TYRP1), mrna. 
GSDM1 0.14   Gasdermin 1 (GSDM1), mrna. 
LOC130576 0.13   Hypothetical protein LOC130576 (LOC130576), mrna. 
FLJ21511 0.13   Hypothetical protein FLJ21511 (FLJ21511), mrna. 
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C3ORF52 0.13   Chromosome 3 open reading frame 52 (c3orf52), mrna. 
WFDC5 0.12   WAP four-disulfide core domain 5 (WFDC5), mrna. 
SLC5A1 0.12   Solute carrier family 5 (sodium/glucose cotransporter), member 1 (SLC5A1), mrna. 
MLANA 0.12   Melan-A (MLANA), mrna. 
TGM5 0.11   Transglutaminase 5 (TGM5), transcript variant 1, mrna. 
CYP3A5 0.10   Cytochrome P450, family 3, subfamily A, polypeptide 5 (CYP3A5), mrna. 
AADACL2 0.10   Arylacetamide deacetylase-like 2 (AADACL2), mrna. 
BPIL2 0.10   Bactericidal/permeability-increasing protein-like 2 (BPIL2), mrna. 
CDSN 0.10   Corneodesmosin (CDSN), mrna. 
K5B 0.10   Keratin 5b (K5B), mrna. 
RDH12 0.09   Retinol dehydrogenase 12 (all-trans/9-cis/11-cis) (RDH12), mrna. 
DSC1 0.08   Desmocollin 1 (DSC1), transcript variant Dsc1b, mrna. 
TGM3 0.07   Transglutaminase 3 (E polypeptide, protein-glutamine-gamma-glutamyltransferase) (TGM3), mrna. 
PPP2R2C 0.07   Protein phosphatase 2 (formerly 2A), regulatory subunit B, gamma isoform (PPP2R2C), transcript variant 2, mrna. 
IL1F10 0.07   Interleukin 1 family, member 10 (theta) (IL1F10), transcript variant 2, mrna. 
CA12 0.07   Carbonic anhydrase XII (CA12), transcript variant 1, mrna. 
CCL27 0.07   Chemokine (C-C motif) ligand 27 (CCL27), mrna. 
PLA2G4F 0.07   Phospholipase A2, group IVF (PLA2G4F), mrna. 
K6IRS3 0.06   Keratin 73 (KRT73), mrna. 
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This finding was corroborated by connectivity mapping analysis (Lamb 2006) 
using Ingenuity Pathways Analysis  (Table 13) (Ingenuity® Systems, 
www.ingenuity.com).  
 
Table 13 Top canonical signalling pathways enriched in 32 CYLD defective tumours. 
Top canonical signalling pathways enriched in 32 CYLD defective tumours when compared to 10 
perilesional skin controls.  The ratio of transcripts of genes seen to be overexpressed to all the 
transcripts in the named pathway are shown in the final column. Thyroid cancer signalling and TRK 
signalling share mutual TRK transcripts. 
Ingenuity canonical pathway P-value Ratio 
Thyroid Cancer Signalling  2.96E-04 10/166 (0.06) 
Wnt/$-catenin Signalling 5.59E-04  8/140 (0.057) 
Human Embryonic Stem Cell Pluripotency 1.26E-03 5/70 (0.071) 
Neurotrophin/TRK 4.02E-03  5/71 (0.07) 
Signalling Tyrosine Metabolism 7.28E-03 5/41 (0.122) 
 
This highlighted the concerted overexpression of multiple members of the 
Neurotrophin/TRK signalling pathway in tumour tissue compared to control 
tissue. This finding was reflected in two pathways, namely, the "Thyroid 
Cancer Signalling" pathway and the" Neurotrophin/TRK " pathway which 
essentially contained transcripts related to the Neurotrophin/TRK signalling 
pathway. In addition to the transcripts detected by FC analysis above, TRKB, 
brain derived neurotrophic factor and PIK3R1, which encodes a regulatory 
subunit of PI3 kinase, a downstream mediator of TRK signalling, were 
elevated in expression (Figure 37).  
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Figure 37 TRK signalling is dysregulated in cylindroma and spiradenoma tissue. 
Expression levels of 24526 genes from 32 microdissected tumours were pooled and compared against 
10 pooled perilesional controls, and genes that were differentially expressed (p value <0.01) were 
analysed using Ingenuity pathway analysis. Overexpressed transcripts are shown in red and 
underexpressed transcripts are shown in green. TRKB (NTRK2) and TRKC (NTRK3), members of the 
TRK signalling pathway, were overexpressed in tumour tissue compared to control samples. Expression 
of TRKA (NTRK1) however was reduced. Downstream members such as PI3K and AKT and BCL2 
were also over expressed.  
 
Moreover, TRKA, a previously described CYLD interacting protein (Geetha, 
Jiang et al. 2005), was found to be downregulated, whilst the cognate ligand 
nerve growth factor (NGF) was upregulated . No obvious changes in copy 
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number were found at the chromosomal location of the different TRK 
receptors and their respective cognate ligands suggesting that genomic 
amplification or deletion was not directly responsible for these changes in 
transcript level. 
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The overexpression of TRKB and TRKC observed at the mRNA level was 
investigated at the protein level in CYLD defective tumours. A tumour tissue 
microarray (TMA) of CYLD defective tumours - cylindromas, spiradenomas, 
trichoepitheliomas and perilesional skin was constructed and protein 
expression assayed using immunohistochemical techniques. Expression of 
TRKB and TRKC was elevated in cylindroma, spiradenoma and to a lesser 
extent in trichoepithelioma tissue compared to perilesional skin (Figure 38). 
Strong membranous staining was apparent in cylindroma cells, whilst diffuse 
cytoplasmic staining was noted in overlying keratinocytes. TRKC expression 
was mainly noted over the basophilic peripheral cells in cylindroma islands, 
whilst TRKB overexpression was non-discriminatory within tumour islands 
(Figure 38). Quantification of membranous TRK expression was performed on 
each core of the TMA. A scoring scale, which assessed the intensity of 
membranous TRK staining and the proportion of tumour cells stained was 
used, (Figure 39), and the difference in expression between tumours and 
perilesional keratinocytes was found to be statistically significant (p<0.05) 
(Figure 39). Perilesional hair follicles were positive for TRKA and acted  as 
positive controls, whilst perilesional epidermis was negative for TRKB and 
TRKC, acting as negative controls. Furthermore, cylindroma cells were 
strongly positive with antibodies against phosphorylated ERK (p44/42), a 
marker of active TRK signalling, mainly at the periphery of each tumour 
island. The antiapoptotic protein BCL2, a downstream target of TRK 
signalling, was also overexpressed in cylindroma tissue, showing strong 
perinuclear staining (Figure 38) 
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Figure 38 TRK immunostaining on a CYLD defective tumour microarray. 
TRKB and TRKC proteins are over expressed in human cylindromas and spiradenomas. (a) Tissue 
microarrays of cylindromas and spiradenomas were probed with antibodies as indicated, and visualised 
using a horseradish peroxidase – diaminobenzene system, with haematoxylin used as a nuclear 
counterstain. Membranous TRKB and TRKC were overexpressed in the tumours, exemplified by the 
cylindroma tumours illustrated here. Patchy perinuclear TRKA staining was seen in some tumour cells. 
Expression of downstream targets phosphoERK and BCL2 was also seen. Perilesional anagen hair 
follicles acted as a positive control (TRKA) and perilesional epidermis was used as a negative control 
(TRKB and TRKC). Scale bars indicate 100µm; insets are shown to demonstrate specific membranous 
staining of TRKB and TRKC (2x enlargement of related image).  
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Figure 39 Membranous TRKB and TRKC scores. 
Membranous TRKB and TRKC is highly expressed in CYLD defective tumours. Membranous TRKC 
expression scores in cylindroma tumours compared to perilesional unaffected tissue.  A custom tumour 
microarray was scored for membranous expression of TRKB and TRKC. Mean scores were grouped by 
tumour type and compared to the scores of unaffected perilesional tissue. Membranous immunostaining 
scores were made on all cores on the array, with p-values of the difference in score (t-test) between 
tumour and control indicated in the adjacent tables. Error bars indicate standard error of the mean. 
 
TrkB Mean score 
and SEM
p value
Normal tissue (N=3) 2.125 ± 0.1250
Cylindroma (N=6) 5.900 ± 0.05571 < 0.0001
Spiradenoma (N=5) 4.800 ± 0.1414 < 0.0001
Cylindrospiradenoma (N=1) 5.800 ± 0.2000 < 0.0001
Trichoepithelioma (N=1) 3.000 ± 0.3162 0.012
TrkC Mean score 
and SEM
p value
Normal tissue (N=2) 0.0005 ± 0.0005
Cylindroma (N=4) 5.350 ± 0.1500 < 0.0001
Spiradenoma (N=4) 3.850 ± 0.1094 < 0.0001
Cylindrospiradenoma (N=1) 4.600 ± 0.2449 < 0.0001
Trichoepithelioma (N=1) 3.400 ± 0.4000 0.0038
Percentage of cells in HPF 63x 
None -0
Less than 50% - 1
50-75% - 2
76-100% -3
Staining
None - 0
Weak - 1
Strong, but not circumfrential -2
Strong and circumfrential - 3
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Cutaneous appendageal tumours seen in CYLD mutation carriers share 
similarities in cytokeratin profiles with sporadic basal cell carcinoma (BCC), 
that in humans are thought to be also derived from the hair follicle (Donovan 
2009). Dysregulation of several mutual oncogenic pathways are seen in 
cylindromas and BCCs. Wnt signalling is thought to play an oncogenic role in 
both, with expression of nuclear $-catenin demonstrated in both cylindromas 
(Tauriello, Haegebarth et al. 2010) and human basal cell carcinoma (Kriegl, 
Horst et al. 2009). Also, the Sonic hedgehog pathway, recognised to depend 
on such canonical Wnt signalling for cutaneous tumour formation (Hoseong 
Yang, Andl et al. 2008), is an important final common pathway in both 
tumours.  In a murine model that overexpresses GLI1 (Nilsson, Undèn et al. 
2000),  tumours that had histological appearances that resembled both 
human basal cell carcinoma and cylindroma were seen. Diffuse light 
expression of TRK receptors has previously been noted in a small series of 
basal cell carcinoma using a pan TRK antibody (Chen-Tsai, Colome-Grimmer 
et al. 2004). Therefore, we went on to investigate if the membranous TRKB 
and TRKC overexpression we observed in CYLD mutant tumours was a 
feature that extended to sporadic skin cancers. We examined expression of 
TRK receptors in a human skin cancer TMA that included samples of 
squamous cell carcinoma (SCC; n=19), melanoma (MM; n=5) and basal cell 
carcinoma (BCC; n=23) using TRKA, TRKB and TRKC specific antibodies. 
Interestingly, membranous TRKC was overexpressed in 70% of BCC tumours 
(Figure 40), 5% of SCC but not melanoma. In some samples, TRKC staining 
was strongest at the invasive front where the tumour cells apposed stroma ( 
Figure 41). No membranous TRKA staining was seen, however some 
perinuclear staining, a feature associated with activated TRKA signalling (Wu, 
Ramirez et al. 2007) and was seen in a 39% of cases of BCC and 16% of 
cases of SCC. TRKB staining was seen in the cytoplasm in 13% of cases of 
BCC only, where it was seen in a few cells, but not at the cell membrane. 
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Figure 40 Membranous TRKC is overexpressed in basal cell carcinoma. 
Membranous TRKC is overexpressed in basal cell carcinoma. A skin cancer tumour microarray with 23 
BCCs, 19 SCCs and 5 malignant melanomas with two cores per case was immunostained with 
antibodies against TRKA, TRKB and TRKC. (a) Strong circumferential membranous immunostaining of 
TRKC is seen in 16 out of 23 cases (70%) of basal cell carcinoma on a tissue microarray, whilst there is 
an absence of membranous TRKA and TRKB staining. (c) One squamous cell carcinoma demonstrated 
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a similar pattern of staining. Malignant melanomas did not display membranous staining. (b,d) 39% of 
BCC and 16% of SCC also demonstrated perinuclear TRKA staining, and 13% of BCCs only  
demonstrated faint cytoplasmic TRKB staining. (e) Percentage of cases with membranous TRKC 
staining. (f) Mean membranous staining scores for TRKC were performed. Membranous TRKC staining 
is seen in 70% of BCC in this series, 5% of SCC, but not in malignant melanoma. Error bars indicate the 
standard error of the mean; Scale bars represent a distance of 100µm. 
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Figure 41 Membranous TRKC is seen in basal cell carcinoma predominantly at the invasive front 
adjacent to stroma.  
Membranous TRKC is seen in basal cell carcinoma predominantly at the invasive front adjacent to 
stroma. A skin cancer tissue microarray containing 23 BCCs, 19 SCCs and 5 malignant melanomas with 
two cores per case was immunostained with antibodies against TRKA, TRKB and TRKC. (a-j) TRKA 
and TRKC staining varied across basal cell carcinoma tumour samples, with membranous TRKC seen 
at the invasive edge adjacent to stroma, indicated with white arrows (a,c,f and h) are enlarged in (d,e,i 
and j).  TRKA staining was cytoplasmic, but predominantly perinuclear at the invasive front, indicated 
with black arrows. (a-c, f-h) were taken at 5x original magnification and (d-e, i-j) were taken at 20x 
original magnification. Scale bars represent a distance of 100µm. 
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We were intrigued by the finding that Wnt/Beta-catenin signalling pathway 
was dysregulated in CYLD defective tumours and characterised this finding 
further (Table 13). We used Ingenuity Pathways Analysis  (Ingenuity® 
Systems, www.ingenuity.com) to compare 24526 transcripts from 32 pooled 
CYLD defective tumours to 10 pooled perilesional tissue controls; differentially 
expressed transcripts with a significance level of <0.01 were included for 
analysis. Enrichment for transcripts that were components of the Wnt/Beta-
catenin signalling pathway was seen (p=5.59E-04). 
Fold change analysis was then carried out to highlight over and 
underexpressed transcripts associated with the Wnt/Beta-catenin signalling 
pathway in the tumour tissue (Table 14)
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Table 14 Dysregulated Wnt/Beta-catenin pathway members and target genes in CYLD defective 
tumours. 
Wnt/Beta-catenin pathway members and target genes that are overexpressed (Fold change>2) or 
underexpressed (fold change<0.5) in 32 CYLD defective tumours when compared to 10 perilesional 
skin controls. Only differentially expressed transcripts that attained a level of statistical significance of 
p<0.05 were included.  
 
Gene FC Gene name 
RARB 6.03 Retinoic acid receptor, beta 
SOX10 4.48 SRY (sex determining region Y)-box 10 
UBD 4.00 Ubiquitin D 
MMP7 3.92 Matrix metallopeptidase 7 (matrilysin, uterine) 
SOX8 3.66 SRY (sex determining region Y)-box 8 
KREMEN2 3.49 Kringle containing transmembrane protein 2 
CDKN2A 3.15 
Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits 
CDK4) 
DKK1 2.72 Dickkopf homolog 1 
CTNNB1 2.59 Beta-catenin (cadherin-associated protein), beta 1, 88kda 
SOX13 2.56 SRY (sex determining region Y)-box 13 
SFRP1 2.47 Secreted frizzled-related protein 1 
SOX11 2.23 SRY (sex determining region Y)-box 11 
TCF3 2.20 
Transcription factor 3 (E2A immunoglobulin enhancer binding 
factors E12/E47) 
GSK3B 0.48 Glycogen synthase kinase 3 beta 
WNT16 0.48 Wingless-type MMTV integration site family, member 16 
PPP2R1B 0.43 
Protein phosphatase 2 (formerly 2A), regulatory subunit A, beta 
isoform 
CDH12 0.40 Cadherin 12, type 2 (N-cadherin 2) 
GNAO1 0.38 
Guanine nucleotide binding protein (G protein), alpha activating 
activity polypeptide O 
CDH5 0.38 Cadherin 5, type 2 (vascular endothelium) 
DKK2 0.38 Dickkopf homolog 2  
SOX6 0.33 SRY (sex determining region Y)-box 6 
WNT2B 0.32 Wingless-type MMTV integration site family, member 2B 
WNT11 0.32 Wingless-type MMTV integration site family, member 11 
SOX5 0.31 SRY (sex determining region Y)-box 5 
WNT3 0.18 Wingless-type MMTV integration site family, member 3 
WNT7B 0.14 Wingless-type MMTV integration site family, member 7B 
PPP2R2C 0.05 
Protein phosphatase 2 (formerly 2A), regulatory subunit B, 
gamma isoform 
A network with transcripts related to the Wnt/Beta-catenin signalling pathway 
was developed to visually represent this data, with overexpressed transcripts 
indicated in red and underexpressed in green (Figure 42). 
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Figure 42 Members of the Wnt signalling pathway are overexpressed in CYLD defective tumours. 
Enrichment of Wnt/Beta-catenin signalling in CYLD defective tumours. 24526 transcripts from 32 pooled 
CYLD defective tumours were compared against 10 pooled perilesional tissue controls and a 
differentially expressed transcripts that attained a significance level of <0.01 were included for analysis. 
5006 transcripts were subject to pathway analysis and transcripts related to the Wnt/Beta-catenin 
signalling pathway are visually represented here as overexpressed (red) and underexpressed (green). 
Groups of transcripts (eg; members of Frizzled) that had both under and overexpressed members are 
shaded as half red and half green. 
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To validate the finding of dysregulated Wnt/Beta-catenin signalling at the 
protein level, we examined nuclear beta-catenin expression in CYLD defective 
tumours. Nuclear beta-catenin was seen in cells at the periphery of islands, 
adjacent to stroma in cylindromas, affecting a minority of cells (Figure 43 a-b - 
indicated with black arrows). Other tumour cells predominantly displayed 
membranous beta-catenin at higher levels than perilesional epidermis. 
Trichoepitheliomas demonstrated a similar pattern to cylindromas (Figure 
43c). Spiradenomas demonstrated nuclear beta-catenin both at the interface 
with stroma but also throughout the disorganised mass of tumour cells (Figure 
43d) indicated with black arrows). This difference in nuclear beta-catenin 
suggested differential Wnt/Beta-catenin signalling in the two tumour types, 
prompting us to compare the two tumour type transcriptomes. 
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Figure 43 Nuclear beta-catenin and LEF1 expression in CYLD defective tumours.  
Tumour sections on a custom-built tissue microarray underwent antigen retrieval, were probed with 
beta-catenin (a-d) and LEF1 (e) antibodies and protein expression was visualized with a horseradish 
peroxidase/DAB system. Haematoxylin was used as a nuclear counterstain. (a) Nuclear beta-catenin 
was seen in cells at the periphery of islands, adjacent to stroma in cylindromas, affecting a minority of 
cells (indicated with black arrows). Other tumour cells predominantly displayed membranous beta-
catenin at higher levels than perilesional epidermis. (b) A cylindroma with sparse stromal tissue seen 
between islands demonstrated similar findings as the stromal rich sample seen in  (a) (indicated with 
black arrows). (c) A trichoepithelioma demonstrating nuclear beta-catenin in the stromal cells (indicated 
with white arrows), with predominant overexpression of membranous beta-catenin in the tumour cells. 
(d) A spiradenoma demonstrating nuclear beta-catenin both at the interface with stroma but also 
through ought the disorganised mass of tumour cells (indicated with black arrows). (e) Nuclear LEF 1 is 
seen predominantly over peripheral cells in this cylindroma. Scale bar indicates 100µm. 
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To analyse genes that may be important in loss of tumour organisation in the 
transition of cylindromas to spiradenomas, we reanalysed transcriptomic data 
from 32 microdissected fresh frozen tumours. Our initial categorisation of 
tumours as cylindroma or spiradenoma was based on clinical and histological 
features of the tumour. However, detailed review of the histology revealed 
different levels of tumour organisation even within a cylindroma, making 
precise categorisation of organisation a challenge. To address this, we 
developed a novel method to quantify tumour organisation of each sample 
used for transcriptomic analysis. The first and last sections enclosing the 
microdissected sections used for profiling were stained using standard 
techniques. They were found to be similar over the 80-100 micron thickness 
of tumour they enclosed. A photomicrograph (Figure 44a) was taken and each 
tumour island of cells on each sample was traced out and a cartoon was 
developed (Figure 44b).  The area of each island was measured, using an 
imaging programme (Image J v1.64, NIH - (Rasband)). A threshold size that 
correlated with loss of organisation was determined, and this was used to 
determine the proportion of each sample that was organized and disorganised 
(Figure 44c). 3000 selected transcripts associated with developmental 
patterning and cancer were correlated with level of organisation of 25 
technically adequate samples. Of the 77 transcripts that had statistically 
significant correlations, the highest level of correlation was seen with DKK2 
expression. DKK2 expression correlated inversely with disorganisation 
(Spearman’s R value: -0.7612, 95% confidence interval (-0.8890 to -0.5234), 
p-value 0.000001) (Figure 44d). DKK2 was of interest given our previously 
noted finding of dysregulated Wnt/Beta-catenin signalling in CYLD defective 
tumours.  
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Figure 44 Reduced expression of DKK2 transcripts is associated with increasing disorganisation. 
32 fresh frozen tumours were sectioned, microdissected and used for whole genome expression 
profiling. The first and last sections enclosing the sections used for profiling were stained and used to 
quantify level of tumour organisation. (a-b) A cartoon was developed by (a) tracing out each tumour 
island on each sample and the (b) area of each island was measured. Scale bar indicates 1mm. (c) A 
threshold size that correlated with loss of organisation was determined, and this was used to determine 
the proportion of each sample that was organised and disorganised. 25 samples were technically 
suitable for such quantification. (d) The gene expression profiles of 3000 selected genes were 
correlated with level of organisation and levels of DKK2 expression correlated inversely with 
organisation.  
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Recently, methylation of the DKK2 promoter has been described as a 
candidate mechanism to account for reduced expression of DKK2 in human 
renal cell and colorectal carcinoma (Sato, Suzuki et al. 2007; Hirata, Hinoda 
et al. 2009). Therefore we assessed DKK2 promoter methylation status in this 
cutaneous tumour model. Promoter hypermethylation was assessed using a 
DKK2 targeted quantitative PCR based assay. Equal amounts of tumour DNA 
from each sample was subject to restriction digestion with methylation 
sensitive and methylation insensitive enzymes. Comparison of the ratio of 
amplification of the DKK2 promoter between these amounts allowed for 
assessment of extent of promoter hypermethylation. Genomic DNA from 13 
microdissected tumours was included in the analysis. Percentage of promoter 
expression was found to inversely correlate with transcript levels (r=-0.833, 
p=0.0041), once 4 outliers were excluded (Figure 45), suggesting that this 
mechanism was not exclusive in altering DKK2 expression. 
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Figure 45 Methylation status of the promoter of DKK2 in 9 tumours correlated with expression of DKK2 
transcript.  
Percentage of promoter hypermethylation was assessed using a DKK2 targeted quantitative PCR based 
assay that compared amplification between equal amounts of starting tumour DNA that was subject to 
restriction digestion with methylation sensitive and methylation insensitive enzymes. Percentage of 
promoter expression was found to inversely correlate with transcript levels (Spearman’s R coefficient = -
0.833, p=0.0041). 
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The alteration in DKK2 levels associated with tumour organisation in CYLD 
defective tumours prompted us to conceptually reframe the cylindromas and 
spiradenomas as “DKK2 high” and “DKK2 low” tumours. We compared the 
pooled transcriptomes of 4 DKK2 “low” tumours against the transcriptomes of 
4 DKK2 “high” tumours to characterise transcripts associated with reduction in 
DKK2 expression. We used Ingenuity pathway analysis, including genes that 
were differentially expressed with a fold change of 2 or greater and a level of 
statistical significance of p<0.05.  Gene ontology analysis of these transcripts 
demonstrated that the highest scoring categories were associated with 
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“Cancer” (p value 2.43E-04 - 4.88E-02; 521 transcripts) and “Cellular Growth 
and Proliferation” (p value 3.59E-04 - 4.71E-02; 335 transcripts). The 
transcripts that were differentially expressed are listed in Table 15.  
Table 15 Top ten over- and underexpressed transcripts in DKK2 “low” tumours (spiradenomas). 
 
Gene FC Gene name 
XRN2 19.25 5'-3' exoribonuclease 2 
ID3 6.92 Inhibitor of DNA binding 3, dominant negative helix- loop-helix 
protein 
MGC29506 5.40 Hypothetical protein MGC29506 
PI3 5.33 Peptidase inhibitor 3, skin-derived 
NOD1 5.22 Nucleotide-binding oligomerization domain containing 1 
TNFAIP2 5.16 Tumour necrosis factor, alpha-induced protein 2 
CYP4F12 5.06 Similar to cytochrome P450, family 4, subfamily F, polypeptide 
12; 
JAG2 4.93 Jagged 2 
MS4A1 4.76 Membrane-spanning 4-domains, subfamily A, member 1 
ELF3 4.75 E74-like factor 3 (ets domain transcription factor, epithelial-
specific ) 
FLG  0.04 Filaggrin 
SCGB2A2  0.06 Secretoglobin, family 2A, member 2 
USP9Y 0.07 Ubiquitin specific peptidase 9, Y-linked 
SPRR2E 0.08 Small proline-rich protein 2E 
PIP  0.08 Prolactin-induced protein 
RPS4Y1  0.08 Ribosomal protein S4, Y-linked 1 
LAMC3  0.09 Laminin, gamma 3 
SPRR1A  0.09 Small proline-rich protein 1A 
ZFY  0.10 Zinc finger protein, Y-linked 
GGCT 0.11 Gamma-glutamyl cyclotransferase 
Network analysis of differentially expressed genes suggested that DKK2 low 
tumours had upregulated transcripts that included antiapoptotic BCL2. (Figure 
46a). Notably Wnt/Beta-catenin pathway transcripts including APC were 
expressed at lower levels in DKK2 low tumours (Figure 46b). 
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Figure 46 Reduction in DKK2 expression is associated with overexpression of transcripts associated 
with cancer and cell proliferation. 
Comparison of the pooled transcriptomes of 4 DKK2 “low” tumours (spiradenomas) against the 
transcriptomes of 4 DKK2 “high” tumours (cylindromas) to characterise transcripts associated with 
reduction in DKK2 expression. (a) Network analysis of differentially expressed genes suggested that 
DKK2 low tumours had upregulated transcripts that included antiapoptotic BCL2, a TRK target gene 
highlighted previously by our group in CYLD defective tumours. (b) Notably Wnt/Beta-catenin pathway 
transcripts including APC were expressed at lower levels in DKK2 low tumours. 
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CYLD mutation carriers face repeated, disfiguring surgery to control tumour 
burden, and in our study of two large pedigrees, up to one in four affected 
patients underwent total scalp removal (Rajan, Langtry et al. 2009). Painful 
eccrine spiradenomas, the development of conductive deafness caused by 
occlusive tumours in the ear canal and the risk of malignant transformation 
(Gerretsen, van der Putte et al. 1993) justify the development of non-surgical 
alternatives for this patient group. Here, we performed an unbiased approach 
using genomic and transcriptomic analysis of CYLD defective tumours.  
We demonstrated that cylindroma and spiradenoma tumours were 
genomically similar and stable, with LOH at 16q found in the majority of 
tumours in this study. A level of LOH at 75% was demonstrable, in keeping 
with previous studies that performed assays using techniques capable of 
lower resolution analysis (Biggs, Wooster et al. 1995) (Biggs, Chapman et al. 
1996) (Bignell, Warren et al. 2000).   
We sought to clarify the genomic changes using high-resolution array CGH 
and confirmed that there were no significant changes seen in copy number 
between CYLD defective tumours (n=12) and perilesional skin (n=7). We also 
performed SNP genotyping of 4 cylindroma tumours and found that loss of 
heterozygosity was reserved to 16q. Interestingly, LOH analysis at the 
mutation site demonstrated the presence of the mutant allelle only in 75% of 
tumours. Taken together, the copy number neutral aCGH data, the presence 
of the mutant allelle only in the majority of tumours assayed by restriction 
enzyme analysis and the extent of LOH demonstrated in the SNP data 
support previous suggestions (Biggs, Chapman et al. 1996) that loss of 16q is 
key event in tumourigenesis and the lost arm is reduplicated by homologous 
recombination in the majority of tumours in this study. The genomic stability of 
cylindroma tumours we demonstrate may explain the benign, non-invasive 
nature of the tumours and the rare occurrence of transformation to malignancy 
(Gerretsen, van der Putte et al. 1993). Moreover, it raises the attractive 
possibility that genomically stable tumours may be less liable to the 
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acquisition of resistance mechanisms to novel therapeutics that arise through 
genomic diversity.  
We detected upregulation of transcripts of TRKB and TRKC and their cognate 
ligands BDNF and NT3/NT4 in cylindroma and spiradenoma samples. This 
was of particular interest as CYLD, a deubiquitinase with K63 linked ubiquitin 
specificity, has previously been shown to deubiquitinate TRKA and inhibit its 
internalisation from the cell membrane and subsequent downstream signalling 
via the phosphatidylinositol-3-kinase (PI3K) pathway (Geetha, Jiang et al. 
2005). Furthermore, recent studies have shown that BDNF is a NF!B target 
gene that may afford a neuroprotective role in astrocytes, supporting the 
finding that this TRK ligand is overexpressed by the cylindroma cells resulting 
in an autocrine loop (Saha, Liu et al. 2006). Validation of protein expression 
using TRK specific antibodies demonstrated strong membranous expression 
of TRKB and TRKC in cylindromas and spiradenomas, when compared to 
perilesional epidermis and hair follicles. Finally, downstream targets of TRK 
signalling such as phosphorylated ERK and BCL2 were overexpressed in the 
tumours.  
TRK receptors have received considerable attention as mediators of neuronal 
growth, survival and maintenance (Huang and Reichardt 2001), and have 
been shown to be expressed in hair follicles (Adly, Assaf et al. 2005; Blasing, 
Hendrix et al. 2005). Their role in cancer was initially shown by uncommon 
oncogenic fusions involving C-terminal sequences of the NTRK1/NGF 
receptor gene with 5% terminal sequences of various activating genes, such as 
TPM3, TPR and TFG in colon and papillary thyroid carcinoma (Martin-Zanca, 
Hughes et al. 1986; Butti, Bongarzone et al. 1995). Exploitation of the 
constitutively active prosurvival signalling that is usually restricted to neurons 
was thought to confer an advantage for the cancer cells. Recent advances in 
the understanding of complex signalling pathways involved in cancer (Luo, 
Solimini et al. 2009) has suggested that some neural derived cancer cells, 
such as neuroblastoma, may become dependent on TRK signalling for 
survival, independent of mutations in TRK (Matsumoto, Wada et al. 1995; 
Scala, Wosikowski et al. 1996). Subsequent demonstration of TRK expression 
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associated with a survival advantage in epithelial tumours including breast 
(Lagadec, Meignan et al. 2009), prostate (Weeraratna, Arnold et al. 2000), 
lung (Ricci, Greco et al. 2001),  extended the role of TRK signalling to non-
neural derived tumours. At a genomic level, we established that neither TRKB 
and TRKC amplification, nor that of BDNF and NT3/4 was demonstrated to 
account for the overexpression seen in cylindroma tumours, suggesting that 
CYLD dysfunction perturbs normal TRK homeostasis.  
The differential expression of TRKA, TRKB and TRKC in these tumours is 
intriguing. Whilst TRKA is regulated by CYLD, the interaction of CYLD with 
TRKB and TRKC remains to be clarified. The low perinuclear expression of 
TRKA, but conversely the high membranous expression of TRKB and C 
suggests that not all TRKs are regulated by CYLD in the same manner.  This 
has been shown to be true with other forms of ubiquitin modification including 
monoubiquitunation (Arévalo, Waite et al. 2006) or Lys48 polyubiquitination 
(Geetha, Jiang et al. 2005). Arévalo et al. demonstrated that an E3 ubiquitin 
ligase, Nedd4-2, associated with the TRKA receptor and was phosphorylated 
upon NGF binding whilst Nedd4-2 did not bind or ubiquitinate related TRKB 
receptors, due to the lack of a consensus PPXY motif. These results suggest 
that TRK receptors are differentially regulated by ubiquitination to modulate 
the survival of neurons (Arévalo, Waite et al. 2006). Interestingly, Geetha et 
al. have demonstrated that the scaffold protein p62 which facilitates the 
interaction between CYLD and TRKA, is able to bind to specific lysine 
residues on TRKB (Lys 811) and TRKC (Lys 602 and 815) and mutation of 
these sites disrupted downstream signalling (Geetha, Seibenhener et al. 
2008). This suggests the possibility that CYLD could interact with TRKB and 
TRKC, but the precise mechanism of TRK specific homeostasis remains to be 
clarified. 
 
We chose to investigate the expression of TRK in other human skin cancer 
models. The over expression of membranous TRKC in a high proportion of 
basal cell carcinoma is interesting. In sporadic BCC, LOH at 9p, the locus for 
PTCH1, has been found in the majority (93%) of basal cell carcinoma (Teh, 
Blaydon et al. 2005), whilst 16q, the locus for CYLD, appears rarely affected. 
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TRKC signalling in non melanoma skin cancer has not been characterised, 
but there are data from other models to support that TRK signalling could 
confer a proliferative advantage to cells where constitutively active SHH 
signalling following loss of functional PTCH could occur.  Synergy between 
NT3, the cognate ligand for TRKC, and SHH has already been demonstrated 
in murine motorneurons where both are important for growth, and use of NT3 
antibodies in this system reduces growth of these neurons (Dutton, Yamada 
et al. 1999) . TRKC also directly interacts with bone morphogenetic signalling 
receptors (BMPRI) in murine epithelial cells, and inhibits the tumour 
suppressor effects of BMP signalling (Jin, Yun et al. 2007) in a mouse colon 
cancer model. BMP and SHH signalling are tightly balanced, and BMP2, the 
ligand of BMPRI has been shown to oppose SHH mediated proliferation in 
murine cerebellar granular precursor cells via regulation of N-myc (Alvarez-
Rodríguez, Barzi et al. 2007). Furthermore, BMP signalling is protective in 
cutaneous carcinoma, and a SMAD 4 conditional knockout expressed in 
murine keratinocytes has indeed shown to result in spontaneous squamous 
and basal cell carcinomas (Qiao, Li et al. 2006). It is hence conceivable that 
TRKC mediated inhibition of BMP signalling, on a mutated PTCH background 
in basal cell carcinoma may play a pathogenic role. The localisation of TRKC 
at the invasive margin of basal cell carcinoma tumour islands suggests that 
this role may be in invasion (Figure 41). The mechanism that results in TRKC 
overexpression in basal cell carcinoma however remains to be explored. 
However, TRK receptors may represent a novel therapeutic target both in 
tumours with loss of CYLD function but also for basal cell carcinoma, the 
commonest cancer in humans. 
Beyond the use of this rare tumour syndrome to highlight targetable pathways 
in basal cell carcinoma, CYLD defective tumours represent an intriguing 
model of cutaneous tumour patterning. Highly patterned cylindromas and 
disorganised spiradenomas arise on the same genomic background and 
demonstrate homogeneity at the molecular level. We have shown that these 
two tumours are genomically similar, and share similar transcriptomic profiles, 
despite their histological and clinical differences. In keeping with these data, 
we show that cylindromas and spiradenomas represent extremes of a 
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spectrum of tumour organisation. Firstly, we show that islands of cylindroma 
cells grow as contiguous structures, a finding consistent with the growth 
pattern found in sporadic hair follicle tumours such as basal cell carcinoma 
(Lang, McKelvey et al. 1987; Scheibe, Braumann et al. 2010). Also, 
spiradenomas are shown to arise within and grow contiguously from 
preexisting cylindromas, accounting for the recurrent finding that features of 
both tumours are found in the same specimen, termed spiradenocylindroma. 
Finally foci of organised cylindroma are demonstrated within small 
spiradenomas.  
The molecular changes that account for this variation of organisation may be 
explained by a model proposed below that incorporates the recent finding that 
loss of CYLD results in constitutively active Wnt/Beta-catenin signalling, via 
lack of regulation of Dishevelled (Tauriello, Haegebarth et al. 2010).  CYLD 
defective tumours represent a cutaneous tumour model that has arisen on a 
background of abnormal Wnt/Beta-catenin signalling. We demonstrate 
nuclear beta-catenin in cells adjacent to stroma in cylindromas, and 
throughought the tumour mass in spiradenomas, suggestive of active 
signalling. By using morphometric analysis of tumour specimens, we were 
able to quantify the level of organisation of 25 CYLD defective tumours. 
Correlation analysis highlighted that reduced expression of DKK2, a negative 
regulator of Wnt/Beta catenin signalling, correlated with increasing 
disorganisation. DKK2 is one of four members of the DKK family, thought to 
negatively regulate Wnt/Beta-catenin signalling by binding to LRP (Katoh and 
Katoh 2007). Modulation of regulators of Wnt/Beta-catenin signalling has 
been shown to be associated with higher grades of malignancy in human 
tumours. Loss of expression of DKK family members has been described in 
cancers where Wnt/Beta-catenin signalling has been shown to be pathogenic, 
such as colorectal cancer, cervical cancer and breast cancer where such loss 
is mediated by epigenetic inactivation (Aguilera, Fraga et al. 2006; Lee, Yoon 
et al. 2008; Suzuki, Toyota et al. 2008). In renal cell carcinoma, epigenetic 
modification by methylation of DKK2 has been recently shown to be 
associated with advanced tumour stages and reduced survival (Hirata, Hinoda 
et al. 2009). We demonstrate that DKK2 promoter methylation positively 
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correlated with reduced DKK2 expression in the majority of tumour samples 
assayed. Epigenetic inactivation has an established pathogenic role in non 
melanoma skin cancer. Methylation of genes including FOXE1 and 14-3-3 
sigma having been shown to play a pathogenic role in squamous cell 
carcinoma (Zhu, Xia et al. 2007; Venza, Visalli et al. 2010) and basal cell 
carcinoma (Lodygin, Yazdi et al. 2003). Methylation of Wnt inhibitors, whilst 
demonstrated in other tumours, has not been previously described in non-
melanoma skin cancer. Our data extends the role of DKK2 beyond playing a 
role in hair follicle morphogenesis (Sick, Reinker et al. 2006), to potentially 
influencing the phenotype of skin tumours where Wnt signalling is pathogenic. 
When we compared DKK2 high tumours (cylindromas) against DKK2 low 
tumours (spiradenomas), we found that the signalling networks that were 
overexpressed in spiradenomas were principally involved in cellular 
proliferation. Changes in Wnt/Beta-catenin signalling were seen in DKK2 low 
tumours. Recent characterisation of transcript changes over time of Wnt/Beta-
catenin signalling pathway members in HEK-293 cells following stimulation of 
with Wnt3a also demonstrate the downregulation of APC transcripts in active 
Wnt/Beta-catenin signalling as seen in our model (Gujral and MacBeath 
2010). Increased Wnt/Beta-catenin signalling has been shown to result in 
increased NF!B signalling, an effect mediated via increased transcription of 
beta transducing repeat-containing protein ($TrCP). This has been shown to 
reduce levels of I!B by ubiquitination (Spiegelman, Slaga et al. 2000) and 
may account for the increased expression of NF!B target genes seen in 
DKK2 low tumours such as TNFAIP2. DKK2 low tumours may thus have a 
proliferative advantage due to synergistic effects of oncogenic Wnt and NF!B 
signalling in a CYLD defective cellular context. Finally, it is interesting to 
speculate that the tissue tropism seen with CYLD defective tumours may be 
related to the dysregulation of pathways recognised to be important in 
embryological hair development. 
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Here we demonstrate dysregulated TRK and Wnt signalling in CYLD defective 
tumour following transcriptomic profiling. Validation of the TRK 
overexpression at the protein level confirmed overexpression of TRKB and 
TRKC in CYLD defective tumours. Furthermore, we examined sporadic skin 
cancers, and found that TRKC is overexpressed in 70% of BCC, making this a 
potential therapeutic target beyond CYLD mutation carriers.  
By correlating the transcriptomic data against the level of organisation of 
tumours, we show that increasing disorganisation is associated with a 
reduction of expression of the Wnt signalling pathway inhibitor DKK2.  
These data warrant further investigation in a cell culture model. In the next 
chapters, the derivation of primary cell cultures from CYLD defective tumours 
is used to investigate the functional consequences of targeting these 
pathways.
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Primary cell culture of CYLD defective tumours (CPCC) serve as an in vitro 
model to perform functional analysis of dysregulated pathways identified from the 
transcriptomic analysis of these tumours. They are also important for the 
screening of potential therapeutic targets. Derivation of primary cell culture has 
been described previously, and we chose to optimise the method of developing 
primary cell cultures from fresh tumour specimens (Weber, Wick et al. 1984; 
Bruckner-Tuderman, Pfaltz et al. 1991). 
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Tumour tissue obtained following surgery was stored in transport medium, and 
processed within 2 hours. Cylindroma tumours that had a homogenous 
macroscopic appearance were used for primary cell cultures. Spiradenoma 
tumours with cystic or necrotic changes, or specimens with mixed features were 
excluded. Tumours were examined under a dissecting stereo microscope within a 
laminar flow hood, and microdissected, to ensure only tumour tissue and not 
perilesional tissue was used for primary cell culture (Figure 47). These pieces of 
tissue were maintained in the transport medium until dissection was complete. 
Tissue pieces were then cut using a scalpel till they were uniformly 1-2 mm in 
their longest dimension. Tissue pieces were then subject to enzymatic digestion 
with collagenase (Sigma, UK) for 90 minutes at 37 °C in a sterile centrifuge tube. 
Following this, the cells were spun down, and resuspended in trypsin (Invitrogen, 
UK) at 37 °C for 60 minutes. Cells were then resuspended in transport medium, 
to inhibit further enzymatic digestion, before being resuspended in KSFM for 
plating out, or in freezing medium for storage. Aliquots of tumour cells that were 
frozen down were placed in a cryogenic vessel that contained propranolol, that 
allowed the gradual cooling of cells at a rate of 1 °C per minute (Nalgene, UK). 
For cells that were used immediately for experiments, cell viability was assessed 
using Trypan Blue (Sigma, UK) and viable cells were counted and plated out at a 
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density of 600-25,000 cells per cm2 depending on the application. Cells were 
plated on collagen coated (Type I Collagen- Invitrogen UK) tissue culture 
plasticware and grown in keratinocyte serum free medium (Invitrogen UK). Cells 
were maintained at 37°C at 5% CO2 and 21% O2 unless otherwise specified. 
Cultures were fed every 48 hours. Confluent cultures were passaged and 
replated at an appropriate density. The cells were washed in PBS, followed by a 
wash in Versene, before being incubated with Trypsin 0.5% with EDTA. Once 
cells had detached, the Trypsin was neutralised with soya bean Trypsin inhibitor 
(Sigma, UK). Cells were then pelleted and resuspended in KSFM, before viable 
cells were counted for plating. Cells that were grown on 3D polystyrene tissue 
culture scaffolds were prepared as above, before being plated onto scaffolds 
prepared in accordance with manufacturer's instructions. This involved 
rehydrating the scaffold with graded ethanols, washing with PBS, and finally 
coating with collagen (Type I Collagen - Invitrogen UK). Cells were plated at a 
density of 250,000-750,000 cells per cm2 of scaffold material. Cells were grown 
as described above. 
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Figure 47 Microdissection technique and cellular disassociation. 
 (a) A fresh tumour specimen, demonstrating the external surface with overlying surface, and shave excision 
margins drawn in purple ink. (b) The reverse side of the same specimen, exposing the tumour tissue. (c-e) 
Microdissection with fine surgical instruments, and subsequent extraction of a piece of tumour tissue. (f) The 
sample after microdissection of the tissue. The 6 tumour samples are seen on the right and are used for 
enzymatic digestion, while the remaining tissue (on the left) is not used. (g) Before enzymatic digestion, and 
(h) after, when a single cell suspension is obtained. (i) Cells shown at 48 hrs after being plated on collagen 
coated tissue culture plastic; Scale bar indicates 100 µm. 
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CPCC were derived from CYLD defective tumours obtained from patients with 
germline mutations undergoing surgical procedures to control tumour burden. 
Following a period of optimisation of protocols described in the literature, viable 
cell cultures were achieved. Cylindroma cells formed colonies of different sizes, 
and features of holoclones and meroclones were seen (Figure 48 a-b) 
(Barrandon and Green 1987). Cells that had grown to confluence demonstrated a 
classic cobblestone appearance (Figure 48 c-d), as seen by others (Weber, Wick 
et al. 1984). Two morphologies were seen; small cells typical of keratinocytes in 
culture were the predominant type, and large flat cells with increased nuclear size 
were occasionally seen. 
 
Figure 48 Primary cell culture of CYLD defective tumours (CPCC). 
 (a) Small tight colonies (meroclones), as well as cells that formed larger colonies (b) of widely distributed 
cells (holoclones) were both seen. (c) Cells at the edge of colonies were mobile and typically had a small 
cytoplasmic volume. (d) When cells became confluent, a classic cobblestone appearance was seen. Scale 
bar indicates 100 µm. 
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In the development of primary keratinocyte cultures without feeder layers, low 
calcium (<0.08mM) conditions have been shown to be important (Boyce and 
Ham 1983). We attempted culture in different media, which allowed for growth in 
different concentrations of calcium, as well as additives such as bovine pituitary 
extract, fibroblast growth factor, epidermal growth factor and insulin.
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Figure 49 CYLD defective tumour CPCC maintained in different media, seen at 2 days after plating. 
(a) Keratinocyte differentiation medium (Low calcium, low BPE - Cnt-02), (b) Fully defined keratinocyte 
medium (Low calcium, No BPE - Cnt-07 PCT), (c) Keratinocyte non-defined medium (Low BPE, low 
calcium - Cnt-57 PCT) , (d) Keratinocyte fully defined medium (High calcium (1.2mM), serum and BPE 
free - Cnt-02 3D Prime), (e) Keratinocyte serum free medium, (Low calcium, no BPE), (Invitrogen 
KSFM). Scale bar indicates 100 µm.  
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Figure 50 CPCC maintained in different media, seen at 1 week after plating. 
(a) Keratinocyte differentiation medium (Low calcium, low BPE - Cnt-02), (b) Fully defined keratinocyte 
medium (Low calcium, No BPE - Cnt-07 PCT), (c) Keratinocyte non-defined medium (Low BPE, low 
calcium - Cnt-57 PCT), (d) Keratinocyte fully defined medium (High calcium (1.2mM), serum and BPE 
free - Cnt-02 3D Prime), (e) Keratinocyte serum free medium, (Low calcium, no BPE), (Invitrogen 
KSFM). Scale bar indicates 100 µm.  
Following this period of optimisation, KSFM was selected as the medium for 
the subsequent experiments, as the cells appeared to proliferate, with few or 
no fibroblasts seen. This media was serum free, and had low calcium 
(0.08mM), and did not contain bovine pituitary extract. This was used for 
further characterisation of cells in different conditions.  
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Cells were grown in hypoxic conditions (pO2 =5%) and normal oxygen tension 
(pO2=21%) and colony sizes were monitored on a daily basis using 
photographs. Cells in each colony were then counted, and charted below 
(Figure 51).  
 
Figure 51 Growth of CPCC in normoxia and hypoxia.  
Cell counts per colony was measured daily at 5% pO2 (white bars, prefixed "B") and 21% pO2 (black 
bars, prefixed "A") on uncoated plasticware. Photographs were taken of colonies and counted daily. 
Error bars indicate the standard error of the mean, Experiments were done in triplicate on one CPCC.   
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Cells were then grown at 21% pO2 thereafter, and growth was compared 
between uncoated plasticware and Type I collagen coated plastic ware. 
Collagen coating resulted in increased colony sizes, and also loss of plateau 
of cell proliferation at day 7 (Figure 52). 
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Figure 52 CPCC growth on coated vs. uncoated plasticware. 
Comparison of growth profile on Type I collagen coated plasticware (black bars, prefixed "C") and 
uncoated plastic ware (white bars, prefixed "B") at 21% pO2. Bars indicate cell counts per colony. The 
vertical axis has a logarithmic scale. Experiments were done in triplicate on one CPCC. Error bars 
indicate standard error of the mean. 
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Figure 53 Colony forming assay.  
CPCC were plated at a density of 1400 cells per well on Type I collagen coated plasticware and grown 
for 14 days. Cells were then fixed and stained with SRB, before colonies were counted. One plate, 
indicative of the triplicate is shown. 
CPCC were grown on collagen coated plastic ware and passaged up to ten 
times. To clarify the longevity of these cultures, clonal cultures were 
established (Figure 53). In this CPCC, a mean colony forming rate of 71.67 
cells (standard error of the mean - 9.77) per 1400 (5.2%) plated was seen 
when grown under standard culture conditions on collagen coated 
plasticware.  Colonies were principally of two morphologies as previously 
seen in confluent cultures: the majority were smaller cells forming a variety of 
clones with some larger flatter cells with increased nuclear volume typically 
forming small clones. The predominant cell type was subject to serial 
subcloning. Serial subcloning was feasible for up to 5 times before cells did 
not proliferate in culture despite being maintained for two weeks presumably 
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having reached Hayflick’s limit (HAYFLICK 1965). 
 
Figure 54 Colony forming assay with serial dilutions of plated CPCC. 
 CPCC were serially diluted 5 times and plated, and then grown for 2 weeks, before cells were fixed, 
stained and colonies counted. Each CPCC was plated in triplicate. Two CPCC are shown here, with 
different rates of colony formation, varying from 4-8%. Error bars indicate standard error of the mean. 
CPCC appeared to display different rates of colony formation that varied 
between tumour samples. To clarify this, we performed a colony forming 
assay with serial dilutions of cells and found that cells formed colonies at a 
rate that varied between 4-8%.  
When CPCC was grown in KSFM, there were rare clones of cells (<1 in a 
1000) in some CPCC that were of a different morphology, consistent with the 
appearance of fibroblasts. These cells matched the appearance of cells grown 
from fibroblast cultures of perilesional dermis (Figure 55). Fibroblast cultures, 
developed to be used as a control cell culture, were grown in fibroblast culture 
medium, that contained 10% FBS. These cells had a linear shape, with 
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dendritic processes seen when subconfluent, and had a whorled, storiform 
appearance when confluent.  
 
 
Figure 55 Fibroblast culture of perilesional dermis  
Scale bar indicates 100 µm 
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To confirm the purity of CPCC when grown in KSFM, we assayed expression 
of full length CYLD. We determined CYLD protein expression as a marker of 
purity of CPCC. CPCC lacked full length CYLD, whilst control HeLa and 
perilesional fibroblast cultures demonstrated CYLD expression (Figure 56). 
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Figure 56 Expression of CYLD as a marker of purity in CPCC.  
Total cell lysates were separated using SDS-PAGE, and subject to immunoblotting with anti CYLD 
antibody. Actin was used as a loading control.  
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CPCC were characterised using immunocytochemical techniques to confirm 
the presence of proteins seen in vivo (Figure 57).  Cytokeratins 6, 14, 17 and 
smooth muscle actin were seen. 
 
Figure 57 CPCC express markers that are seen in vivo.  
CPCC were subject to fluorescent indirect immunocytochemistry, using the antibodies as labelled in the 
panels above. Cells in culture (4 left panels) expressed cytokeratins and smooth muscle actin as seen in 
tumour sections (4 right panels). Scale bars indicate 100 µm. 
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CPCC were transfected with a lentiviral vector expressing CYLD under the 
control of the cytomegalovirus promoter. This resulted in reduced cell viability, 
with counts of cells reducing each day compared to cells transfected with 
empty vector. 
 
Figure 58 Reintroduction of wild type CYLD results in reduced cell viability.  
Cells were plated in equal numbers and transfected with empty vector, wild type CYLD and red 
fluorescent protein, and selected with puromycin. At Day 5 post selection, cells were trypsinised and 
viable cells counted. (a) Expression of CYLD was assessed using immunoblotting, demonstrating full 
length CYLD (107kd) and a shorter natural splice variant (86kd) (Hövelmeyer, Wunderlich et al. 2007). 
(b) Small numbers of viable cells were seen with CYLD reintroduction. (c) FACS analysis was 
performed to determine changes in cell cycle and highlighted a sub G0/G1 peak suggestive of 
apoptosis. The experiments were performed in three different primary cell cultures derived from 
separate tumours. 
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Cell cycle analysis was performed using FACS, and this demonstrated a sub 
G0/G1 peak, suggestive of apoptosis. The reduced cell viability precluded 
further work with CPCC with reintroduced wild type CYLD. 
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CPCC were plated and grown on 3D polystyrene tissue culture scaffolds to 
determine whether this would influence protein expression of TRK receptors.  
This was done as expression of TRKB and TRKC was high in tissue sections, 
but low in standard 2D culture. We hypothesised that the increased cell-cell 
interaction facilitated by 3D culture may influence the expression of 
membrane bound receptors. Cells were shown to maintain the same 
cytokeratin profiles seen in 2D culture (Figure 59). We found that expression 
of TRKB and TRKC were increased following 3D culture (Figure 60). The 
amount of TRKB and TRKC in vivo was significantly higher, and hence to 
allow for comparison with the 3D CPCC, only 5ug of tumour lysate was 
loaded versus the 20ug of lysate from 3D CPCC. Consistent with this, 
immunocytochemistry to demonstrate expression of TRKB and TRKC on  3D 
scaffolds gave poor results on preliminary attempts (data not shown). 
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Figure 59 Immunocytochemistry demonstrates maintenance of expression of cytokeratins seen in 2D 
and in vivo in 3D CPCC. 
Scale bars indicate 100 µm. 
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Figure 60 TRKB and TRKC expression in vivo compared with 3D and 2D culture. 
Total cell lysates from fresh tumours, 3D and 2D cell cultures were separated using SDS-PAGE, and 
immunoblots were probed using TRKB and TRKC antibodies as indicated. Lanes 1 and 2 were loaded 
with 5µg of cell lysate from fresh tumours as TRK expression levels were significantly higher in tumour 
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tissue than the primary cultures, labelled “Cylindroma 1 and 2”, rest 20µg of lysate from primary cell 
cultures in 3D (CPCC 2,4 3D) and cultures in 2D (CPCC 2,4 2D). TRKB and TRKC were expressed at 
higher levels in 3D cell cultures (Lanes 3 and 5) compared to matched 2D cultures (Lanes 4 and 6). 
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Having developed a model where we were able to demonstrate increased 
expression of TRK, optimisation of a technique to determine cell viability was 
performed, with a view to determine the effect of inhibiting TRK. 3D cultures at 
28 days were used. 2mm discs were punched out of the scaffold as shown in 
the sequence in Figure 61. These discs were placed individually in wells in a 
96 well tissue culture plate, and maintained for two further weeks.  
 
Figure 61 2mm disc 3D CPCC harvesting. 
Cellular viability was assessed using an assay that lysed the cells, and 
produced a luminescent signal in direct proportion to the amount of available 
ATP (CellTiter GLO, Promega UK). This served as a readout of cell viability. 
CPCC grown on 2mm scaffold discs assayed in this manner at 2 weeks 
demonstrated a strong luminescent signal above background when read on a 
luminometer. Readings for each 2mm 3D CPCC disc were taken across three 
replicates (Figure 62). This demonstrated consistency in viable cells across 
triplicate discs, with a small standard error demonstrated.  
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Figure 62 Assay of 3D CPCC cell viability using an ATP dependent luminescent assay.  
2mm 3D CPCCs were assayed in triplicate, and error bars indicate standard error of the mean. 
Readings were taken in 96 well clear bottom plates, at the time points indicated after lysis of cells, with 
and without the bottom of the plate taped over with white tape. This optimization resulted in increased 
luminescence and was used subsequently.  
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CPCC are an attractive model to study dysregulated pathways highlighted 
following transcriptomic profiling of CYLD defective tumours. By using CPCC 
from tumours derived from the same pedigrees, the genomic background is 
likely to be similar and homogeneous. Furthermore, by using primary cell 
cultures that are typically in the first passage for experiments, the likelihood 
for genomic change in the cells are minimised. Therapeutic targets discovered 
in this context are likely to remain pertinent to the in vivo context.  
Primary cell cultures of aggressive skin tumours with a variety of genomic 
changes such as seen in melanoma or squamous cell carcinoma is well 
established, as are the development of cell lines from these tumours (Giard, 
Aaronson et al. 1973; Kondo and Aso 1981). Less aggressive but common 
tumours such as basal cell carcinoma, where mutations in the SHH pathway 
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appear to be sufficient to cause the tumour phenotype in vivo are difficult to 
establish in culture in vitro. Typically further mutations in other tumour 
suppressors such as p53 are needed to establish an in vitro line (So, 
Langston et al. 2006). Recent advances in the understanding of the 
dependence of such tumours on SHH signalling from peritumoural stroma 
may explain the difference seen in vitro vs. in vivo (Yauch, Gould et al. 2008). 
In keeping with this, sporadic basal cell carcinoma in humans is often 
intersposed with stroma.  
As CPCCs are quickly established within hours of plating, it is likely that low 
passage tumours have a similar genomic profile to that demonstrated in 
tumours previously, i.e., LOH at 16q, rather than acquiring further genomic 
changes to allow in vitro proliferation. In humans, the tumours show 
remarkable growth, with lesions reaching up to 10 cm across in vivo, with little 
peritumoural stroma interspersed between tumour cells. It is interesting to 
speculate that it is this low dependence on stroma that allows development of 
in vitro CPCC.  
CPCC are able to proliferate in vitro and are hence useful for investigating 
functional consequences of targeting pathways highlighted in the previous 
chapter. Whilst these cells are noted to stop proliferating typically after 5 serial 
subclones, preventing the development of cell lines, the tumours are of a 
sufficient size to generate significant amounts of CPCC. Characterisation of 
CPCC demonstrates consistent expression of cytokeratins seen in the hair 
follicle and related structures such as eccrine ducts. Theses features are 
retained in 2D as well as 3D culture. CPCC also do not express full length 
CYLD, indicating their purity. We attempted to reintroduce wild type CYLD into 
CPCC to develop an isogenic control, but found that this reduced cell viability. 
This suggests that the loss of functional CYLD in this cellular context is 
important to initiate the tumour phenotype and maybe the key driver mutation. 
Cell cycle analysis demonstrated a sub G0/G1 peak that is suggestive of 
apoptosis. Further characterisation was not pursued given the rarity of these 
samples.  
CPCC were grown on 3D tissue culture scaffolds as to determine of this 
would alter the expression of TRK proteins. Lagadec et al. have found in that 
TRKA expression whilst high in breast cancer, was low in cell lines derived 
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from breast cancers (Lagadec, Meignan et al. 2009). Instead of 
overexpressing TRK artificially in the cell line, 3D growth alone was able to 
restore TRK expression, making this a model that was suitable to test the 
effects of TRK inhibition. The level of TRK expression however was not as 
high as seen in the tumours, and hence this model also has its own 
limitations.  
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Primary cell cultures are useful to investigate the functional consequences of 
gene knockdown. Furthermore they are useful for determining the utility of 
targeting dysregulated pathways with therapeutic agents. Here, CPCC are 
derived from fresh tumours and are characterised. In the following chapter, 
these cells are utilised for functional assays and drug testing, offering 
interesting insight into the biology of CYLD defective tumours.  
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CYLD transgenic murine models do not develop cylindroma tumours, precluding 
functional analysis in vivo. Using CPCC, we explore the role of targeting 
dysregulated TRK signalling using short hairpin RNA (shRNA) to silence TRKB 
and TRKC in altering cell viability. Furthermore, we can explore the functional 
effect of DKK2 knockdown.  Given the precious nature of these CPCC, a variety 
of functional assays were performed to give insight into various biological aspects 
of this cell model. Here we describe the preliminary investigation of the effect of 
knockdown of TRK and DKK proteins in the assays described below. 
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To demonstrate functional TRK signalling in 3D CPCCs, we stimulated the 
cultures with recombinant human cognate ligands of TRK receptors. 3D CPCCs 
were stimulated with NGF (100ng/ml), BDNF (100ng/ml) and NT3 (50ng/ml) for 
up to 24 hours, and cells were assayed for levels of phosphorylated ERK and 
BCL2. Changes in phosphorylated ERK were seen within an hour (Figure 63), 
whilst BCL2 levels typically altered after 6 hours (Figure 64). The loading control 
used to compare the phosphorylated ERK was obtained by stripping and 
reprobing the membrane with total ERK. This suggested unequal loading of 
protein between lanes. 
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Figure 63 Stimulation of 3D CPCC with NGF, BDNF and NT3, with effect on phosphorylated ERK protein 
levels. 
Cylindroma cells grown on 3D scaffolds and stimulated with NGF, BDNF and NT3 for the periods indicated, 
and then transferred to ice cold PBS, and cell lysates were extracted for immunoblotting. Membranes were 
probed with antibodies to phosphorylated ERK. All experiments were repeated at least three times. 
 
Figure 64 Stimulation of 3D CPCC  with NGF, BDNF and NT3, with effect on BCL2 protein levels. 
Cylindroma cells grown on 3D scaffolds and stimulated with NGF, BDNF and NT3 for the periods indicated, 
and then transferred to ice cold PBS, and cell lysates were extracted for immunoblotting. Membranes were 
probed with antibodies to BCL2. All experiments were repeated at least three times. 
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To assess the functional significance of TRKB and TRKC in cylindromas, primary 
cell cultures were established from fresh tumour samples from the patients that 
contributed samples used for the molecular profiling and used for functional 
studies . These primary cells were transduced with lentiviruses expressing short 
hairpin (sh) RNAs targeting TRKB and TRKC. The shRNA vectors carried a GFP 
reporter allowing monitoring of delivery and a puromycin gene allowing selection - 
cells were grown in media containing puromycin for 48 hours post transfection 
resulting in cultures that were approximately 100% GFP positive when analysed 
(Figure 65).  
 
Figure 65 Lentiviral transfection of CPCC.  
Cells seen after 3 days of puromycin selection. Transfection efficiency was monitored by GFP expression, 
and was between 90-100% following selection. 
 
TRKB and TRKC knockdown was assayed using immunoblotting and 
corroborated with quantitative PCR, as the differences in protein expression 
particularly with TRKB were subtle (Figure 66,  
Figure 67). After 10-14 days in culture, cells were fixed, stained and colonies 
were counted. Primary cells with knockdown of TRKB and TRKC demonstrated a 
modest reduction (20-40%; p<0.05) in colony formation (Figure 68). 
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Figure 66 TRKB shRNA mediated silencing assessed by protein expression and transcript expression. 
CPCC cells were subject to lentiviral mediated short hairpin RNA knockdown of TRKB and these were 
compared against a control hairpin. (a) Knockdown was assessed at the protein level using immunoblotting, 
and (b) at the transcript level using quantitative PCR. 
 
Figure 67 TRKC shRNA mediated silencing assessed by protein expression and transcript expression.. 
CPCC cells were subject to lentiviral mediated short hairpin RNA knockdown of TRKC and these were 
compared against a control hairpin. (a) Knockdown was assessed at the protein level using immunoblotting, 
and (b) at the transcript level using quantitative PCR. 
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Figure 68 Lentiviral knockdown of TRKB and TRKC results in reduced viability. 
Following puromycin selection, GFP positive cells were plated and grown over 12 days. TRKB and TRKC 
knockdown resulted in reduced colony formation. All experiments were repeated at least three times. Error 
bars indicate standard error of the mean 
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To determine if these cultures were dependent on TRK signalling for survival, 
they were treated with small molecule TRK kinase inhibitors. These molecules 
inhibit all TRK receptors and feasibly cause a greater effect on cell viability than 
inhibition of individual TRKs by shRNA. As a control, CPCC were also exposed to 
salicylic acid which has previously been shown to effect survival in CYLD 
deficient cells (Brummelkamp, Nijman et al. 2003).  Cells were only modestly 
sensitive to salicylic acid (surviving fraction (SF50) 1.5mM), but were much more 
so to the panTRK inhibitors, lestaurtinib (CEP-701) (SF50, 4.57µM), AG879 (SF50, 
4.21 µM) and K252a (SF50, 366 nM) (Figure 69).  
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Figure 69 3D CPCC demonstrate an increased sensitivity to TRK inhibitors relative to aspirin. 
Cylindroma 3D cell cultures were grown for two weeks in the presence of salicylic acid, K252a, Tyrphostin 
AG879 and lestaurtinib (CEP-701) in triplicate in a 96 well format. This was repeated using at least three 
different tumours, from different body sites in three patients. Cell viability was assessed using a luminescent 
cell viability assay at the end of this period and dose response curves were generated. Cylindroma cells 
were sensitive to lestaurtinib at micromolar levels, whilst salicylic acid had a similar effect at milimolar levels. 
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To better understand how DKK2 expression contributes to tumourigenesis, we 
investigated the functional consequence of DKK2 silencing in cylindroma tumour 
derived cells. Cells were grown both in adherent conditions (Figure 65) and in 
suspension (Figure 70). A GFP reporter linked by an internal ribosomal entry site 
to the targeting hairpins, allowed for monitoring of transfection efficiency and for 
puromycin selection. DKK2 silencing was assayed by immunoblotting (Figure 71). 
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One hairpin used (DKK2-1) had no effect on DKK2 protein expression levels. 
Cylindroma cells with silenced DKK2 demonstrated increased survival after 
growth for 96 hours on collagen coated tissue cultured plastic compared to 
controls (Figure 72). In addition to an increase in short term viability, DKK2 
knockdown resulted in increased colony formation (Figure 73). In keeping with 
the differing efficiency of knockdown seen with the two shRNAs used, this effect 
was more convincing in shRNA DKK2-2. As the spiradenoma cells were highly 
disorganised and had fewer intercellular connections, we investigated if DKK2 
knockdown was associated with anchorage independent growth. DKK2 
knockdown resulted in increased trend towards anchorage independent growth 
when grown in suspension and compared to matched cells grown in adherent 
conditions, but this difference was not statistically significant (Figure 74). In 
addition, DKK2 knockdown resulted in increased migration when assayed using a 
scratch assay (Figure 75). Finally, we investigated if DKK2 knockdown resulted in 
an increased resistance to apoptosis when exposed to TNF; DKK2 knockdown 
resulted in a trend towards increased sensitivity to TNF induced apoptosis, 
though this was not statistically significant (Figure 76). 
 
Figure 70 Transfected cylindroma primary cells growing in suspension. 
Growth in suspension following treatment of tissue culture plastic with poly-HEMA coating (20x original 
magnification; scale bar indicates 100µm). 
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Figure 71 DKK2 shRNA mediated silencing assessed by protein expression. 
Total cell lysate from GFP positive cells were separated by SDS-PAGE, immunoblotted and probed with 
antibodies against DKK2. 
 
Figure 72 DKK2 silencing results in increased short term viability  
Transfected cylindroma primary cells were plated in triplicate in a 96-well format, grown for 96 hours and the 
surviving fraction was assayed using a luminescent cell viability assay. All error bars indicate standard error 
of the mean.  
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Figure 73 DKK2 silencing results in increased colony formation. 
Transfected cylindroma primary cells were plated onto collagen coated tissue culture plastic and grown for 
10-14 days. Colonies were fixed, stained and colonies were counted. All error bars indicate standard error of 
the mean.  
 
Figure 74 DKK2 silencing results in increased anchorage independent growth.  
Transfected cylindroma primary cells were plated in triplicate in a 96 well format, in matched poly-HEMA and 
collagen coated wells, allowing for growth in suspension and in adherence to be compared. The percentage 
of surviving cells was then calculated as a ratio at 96 hours using a luminescent cell viability assay as a 
readout. All error bars indicate standard error of the mean.  
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Figure 75 DKK2 knockdown results in increased migration. 
Cylindroma primary cells were plated and grown to confluence, and the reduction in size of a scratch made 
in the centre of the tissue culture well monitored every 12 hours. Error bars indicate standard error of the 
mean. 
 
Figure 76 DKK2 knockdown results in an increased sensitivity to TNF induced apoptosis. 
Cells were plated in 96 well format, grown for 48 hours, and TNF (50ng/ml) was added. Cleaved caspase 3 
was assayed using a luminescent assay that served as a readout for apoptosis, and the fold increase was 
compared to control treated cells in triplicate. All error bars indicate standard error of the mean.  
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We established TRK signalling was effective in cylindroma primary cell culture 
using recombinant human BDNF and NT3 for TRKB and TRKC respectively, and 
demonstrated increased expression of phosphorylated ERK and BCL2. These 
experiments are preliminary, and ideally could be optimised further to allow for 
more consistent loading across lanes. To delineate the advantage conferred by 
TRKB and TRKC expression, we used a lentiviral mediated knockdown system. 
This demonstrated reduced colony formation in TRKB and TRKC deficient cells 
supporting the pathogenic role of these receptors. Protein expression as a means 
to assess knockdown of TRKB suggested a small level of knockdown seen, 
which was supported by quantitative PCR at the transcript level. Further 
optimization of shRNA design in future work to target TRKB in particular would 
allow for greater level of knockdown and potentially clarify the consequence of 
more effective TRKB knockdown. 
To investigate whether dysregulated TRK signalling in patients with truncating 
CYLD mutations represented a druggable pathway, we employed a 3D primary 
cell culture model. As seen in breast cancer (Lagadec, Meignan et al. 2009), TRK 
expression in vitro was low when 2D cylindroma cell culture was compared to 
tumours. 3D culture was associated with an increase in expression of TRKB and 
TRKC, allowing us to use this as an in vitro model to assay cell viability in the 
presence of TRK inhibitors.  The reduction in viability at micromolar 
concentrations of TRK inhibitors is encouraging, particularly as these tumours are 
amenable to transcutaneous or intralesional drug delivery. We attempted to 
determine whether the mechanism of action of TRK inhibition in our primary cell 
culture model was mediated by ERK or BCL2. This analysis proved not to be 
possible because of the high sensitivity of the primary cells to TRK inhibitors, 
resulting in only very few live cells after TRK inhibitor exposure. The result seen 
with lestaurtinib is particularly interesting as this agent was recently found in a 
screen of 2800 compounds to be a potent inhibitor of NF!B, suggesting it may 
target two key pathways in CYLD mutant tumours (Miller, Huang et al. 2010). 
Lestaurtinib is currently in phase 3 clinical trials (Shabbir and Stuart 2010), and 
serum levels in patients on a 80 mg oral dose twice a day was 17- 25 µm after 
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taking the drug for 28 days (Marshall, Kindler et al. 2005), suggesting that the 
sensitivity of CYLD deficient tumours suggested by our model may be achievable 
in patients. This is in contrast to aspirin, where millimolar amounts appear to be 
necessary to obtain an equivalent effect, whilst patients typically achieve peak 
serum levels of 0.36mM after high doses of 800mg orally (Cerletti, Bonati et al. 
1984). As novel agents with increased pan TRK specificity such as AZ-23 
become available (Thress, Macintyre et al. 2009), patients with truncating CYLD 
mutations may be another step closer to non-surgical alternatives for this 
disfiguring disease. 
 
We then went on to determine if reduced DKK2 expression in CYLD defective 
tumour primary cell cultures conferred a survival advantage to tumour cells. We 
demonstrated trends towards increased cellular proliferation, anchorage 
independent growth and cellular migration. We found a slight increased sensitivity 
to apoptosis in these cells, suggesting DKK2 loss may result in increased tumour 
volume predominantly via an increased proliferative drive. Further work, 
potentially with optimized shRNA targetting DKK2 may yield more conclusive 
results.This data corroborated the transcriptome analysis of DKK2 low tumours, 
where signalling networks that were overexpressed in spiradenomas were 
principally involved in cellular proliferation, and the increased Ki 67 positivity seen 
in spiradenomas.  
Increased Wnt/Beta-catenin signalling has been shown to result in increased 
NF!B signalling, an effect mediated via increased transcription of beta 
transducing repeat-containing protein ($TrCP). This has been shown to reduce 
levels of I!B by ubiquitination (Spiegelman, Slaga et al. 2000) and may account 
for the increased expression of NF!B target genes seen in DKK2 low tumours 
such as TNFAIP2. DKK2 low tumours may thus have a proliferative advantage 
due to synergistic effects of oncogenic Wnt and NF!B signalling in a CYLD 
defective cellular context. 
These data support a model where epigenetic changes influencing Wnt/Beta-
catenin signalling may be a key player in specification of cutaneous tumour 
organisation in CYLD defective tumours. Contiguous growth in CYLD defective 
tumours, DKK2 modulation by methylation and the resulting proliferative 
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phenotype seen in DKK2 low models in vivo and in vitro led us to refine the 
model described in Chapter 3, that may account for the different histological 
phenotypes seen in CYLD defective tumours (Figure 77). 
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Figure 77 A model of epigenetic specification of tumours.  
Given the contiguous growth of cylindromas and spiradenomas, and the finding the DKK2 expression was 
altered with change of organisation, we propose a model where perturbation of patterning by altered Wnt 
signalling may specify tumour phenotype in CYLD mutation carriers. (a) Loss of heterozygosity in a putative 
pluripotent hair follicle cell results in exclusive expression of mutant CYLD, conferring a growth advantage 
for these cells, (indicated by the red sphere).  The cells are restricted to a tubular growth pattern due, giving 
rise to a structure where growth by extension, branching and budding is feasible (indicated by the purple 
column). This structure when folded gives rise to the finding that the tumour cells are seen organised as 
cylinders irrespective of the way the tumour is sectioned. (b) Loss of patterning associated with reduced 
expression of DKK2 may arise due to an epigenetic event (indicated by the yellow triangle) such as 
methylation, giving rise to a disorganised mass of tumour cells (indicated by the green mass), with no 
restriction to grow in a tubular pattern. (c) A late event that results in loss of DKK2 may result in a tumour 
that has already grown as a cylindroma to develop a region that is poorly organised, a finding supported by 
clinical and pathological observations of the coexistence of two tumour types in the same specimen. 
 
This model is one where the timing of an epigenetic event such as DKK2 
methylation accounts for the different histological patterns seen in CYLD 
defective tumours. Whilst this remains to be validated in an in vivo model, it 
raises the possibility that the prevention of progression of cylindromas to painful 
spiradenomas may be feasible with methylation inhibitors such as azacitadine. A 
further intriguing prospect that is yet to be explored is the role of epigenetic 
silencing of Wnt inhibitors in other sporadic skin tumours where Wnt signalling is 
pathogenic, such as basal cell carcinoma (Hoseong Yang, Andl et al. 2008; 
Kriegl, Horst et al. 2009). 
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Here we demonstrate in CPCC, functional consequences of targeting two 
pathways highlighted from transcriptomic analysis of CYLD defective tumours. 
Firstly, dysregulated TRK is amenable to targeting with in human TRK inhibitors 
such as lestaurtinib, and use of such an agent may have the added benefit of 
activity against NF!B . Secondly, modulation of dysregulated Wnt signalling by 
DKK2 is supported by these data, and in some cases, this may be mediated by 
an epigenetic mechanism.   
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Herein we describe exciting data of direct translational relevance. CYLD 
cutaneous syndrome is a disease with severe impact on quality of life. Using a 
genomic approach, we characterised the genomic and transcriptomic changes in 
CYLD defective tumours. Dysregulated TRK and Wnt signalling are 
demonstrated, consequent to LOH at 16q, and functional effects are 
characterised in a primary cell culture model derived from CYLD defective 
tumours. Importantly, TRK inhibitors, which are currently in use in humans with 
demonstrated safety profiles, have an effect in this in vitro model. In addition to 
the translational implications of the TRK data, this model also offers insight into 
cutaneous tumour patterning via modulation of Wnt/Beta-catenin signalling. 
The implications of both these findings may bear relevance for sporadic skin 
cancer such as basal cell carcinoma, the commonest human cancer. TRKC, a 
target highlighted by this work in CYLD defective tumours, is shown to be 
overexpressed in 70% of BCC. This finding is intriguing and warrants further 
investigation. BCC is also dependent on pathogenic Wnt signalling, and the 
epigenetic influences on the different histological patterns seen in BCC remain to 
be explored.  These data from the characterisation of CYLD defective tumours 
may hence be important in improving the understanding of common skin cancer. 
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Online video supporting information 
To access the videos, please enter the URL addresses indicated in blue below 
into a web browser. 
 
Supplementary video 1 Cylindroma tumours are contiguous. A video of a 
virtual flight through one column of tumour cells (green) to a distinctly formed 
column (purple) via a connecting bridge of tumour cells found further in the block. 
(http://www.youtube.com/watch?v=95biz3YEDhU). 
 
Supplementary video 2 Cylindromas and spiradenomas are part of the same 
tumour mass. An organised region of tumour shown in purple was followed 
490µm and was shown to be connected to a disorganised region of tumour. 
Three organised areas (highlighted in red, blue and green) are also shown 
extending from the disorganised structure. 
(http://www.youtube.com/watch?v=WcUSHk9NavI). 
 
Supplementary video 3 A spiradenoma with a central focus of cylindroma. A 
spiradenoma (light blue) with a central organised column of cells indicated in 
purple. http://www.youtube.com/watch?v=NT7USIzcZPo)  
 
